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ABSTRACT 
 
REGULATION OF TISSUE HOMEOSTASIS BY INNATE LYMPHOID CELLS 
 
Laurel Anne Monticelli 
 
David Artis, PhD 
 
The barrier surfaces of the lung, intestine and skin are continually exposed to 
environmental insults, which can result in infection, inflammation and tissue injury when 
the barriers become disrupted. Epithelial barrier repair requires a balance between 
promoting beneficial remodeling responses that drive cell proliferation while also acting 
to limit these responses once homeostasis has been achieved. Failure to either initiate 
or resolve these reparative responses has detrimental effects, resulting in either loss of 
tissue integrity and function or promotion of chronic inflammation and fibrosis, as 
observed in multiple inflammatory diseases of the respiratory and intestinal tracts. While 
the immune system is integral to maintaining barrier integrity at these mucosal surfaces, 
the precise cellular and molecular factors that orchestrate restoration of homeostasis 
following tissue injury are poorly understood. 
 Over the past several years a novel family of immune cells have emerged called 
innate lymphoid cells (ILCs) that are crucial regulators of immunity and inflammation at 
barrier sites. However, whether ILCs exist in the respiratory tract and how they may 
influence immunity, inflammation or tissue homeostasis in the lung was unknown. The 
data presented in Chapter 2 identify a population of Group 2 ILCs (ILC2s) constitutively 
present in the respiratory tract of humans and mice and demonstrate a novel function for 
	   vi	  
ILC2s in regulating airway epithelial barrier integrity and tissue homeostasis following 
influenza virus-induced pulmonary damage. Further, studies in Chapter 3 investigate the 
nature of the crosstalk between the damaged tissue and ILC2 function, revealing that 
ILC2s possess a wound healing transcriptional signature and identifying the 
amphiregulin (AREG)-epidermal growth factor receptor (EGFR) pathway as an essential 
regulator of airway epithelial repair and host recovery from influenza virus infection. 
Lastly, Chapter 4 explores the relevance of this pathway in sites outside the lung, 
uncovering an interleukin (IL)-33-dependent innate immune mechanism of intestinal 
tissue repair dependent on AREG-EGFR interactions. Collectively, the data presented in 
this thesis identify an evolutionarily conserved feedback loop in which cytokine cues 
from damaged epithelia activate innate immune cells to express growth factors essential 
for the restoration of epithelial function and maintenance of tissue homeostasis at 
multiple barrier surfaces. 
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Chapter 1 
Introduction 
 
The mucosal surfaces of the mammalian respiratory and intestinal tracts are continually 
exposed to commensal microbes, pathogens and environmental insults, all of which can 
result in infection, inflammation and tissue injury if the epithelial barrier is breached. 
Restoration of tissue homeostasis and barrier integrity requires a delicate balance 
between promoting beneficial remodeling responses that drive cell proliferation while 
also acting to limit these responses once homeostasis has been achieved. The failure to 
either initiate or resolve these reparative responses can have detrimental effects on the 
host, resulting in either loss of tissue integrity and function or promotion of chronic 
inflammation and fibrosis, as observed in multiple inflammatory diseases of the 
respiratory and intestinal tracts (Barker, 2014; Crosby and Waters, 2010; Gorski et al., 
2012; Peterson and Artis, 2014; Rock et al., 2010).  
The aim of this thesis is to interrogate the cellular and molecular factors that 
orchestrate restoration of epithelial barrier integrity and tissue homeostasis following 
injury in the respiratory and intestinal tracts. Chapter 2 will characterize a novel 
population of Group 2 innate lymphoid cells (ILC2s) constitutively present in the 
respiratory tract of humans and mice and test whether these cells influence restoration 
of airway epithelial barrier integrity and tissue homeostasis following influenza virus-
induced pulmonary damage. Further, studies in Chapter 3 will investigate the nature of 
the crosstalk between the damaged tissue and ILC2 function, specifically examining how 
the amphiregulin (AREG)-epidermal growth factor receptor (EGFR) pathway regulates 
airway epithelial repair and host recovery from influenza virus infection. Lastly, Chapter 
4 will explore the relevance of this pathway in sites outside the lung, uncovering an 
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interleukin (IL)-33-dependent innate immune mechanism of intestinal tissue repair 
dependent on AREG-EGFR interactions. 
Chapter 1 of this thesis will serve as an introduction into the architecture of the 
epithelial barriers in the lung and intestine, the cytokine and growth factor signals that 
reciprocally regulate epithelial and innate immune cell function, the family of innate 
lymphoid cells and murine models of lung and intestinal tissue injury. 
 
1.1 Barrier function in the lung and intestine 
At mucosal surfaces of the mammalian lung and intestine, only a single layer of epithelial 
cells separates the host from the dangers of the external environment. As discussed 
below, the specialized cellular architecture and production of anti-microbial factors helps 
maintain epithelial barrier integrity to preserve tissue homeostasis. 
 
1.1.1 Architecture and defense of the intestinal epithelial barrier 
In the intestine, maintenance of intestinal barrier integrity is essential not only to prevent 
infection with pathogens, but also to preserve anatomical containment of the trillions of 
commensal microbes that inhabit the gut microenvironment (Maloy and Powrie, 2011; 
Peterson and Artis, 2014; Rescigno, 2011). While the symbiotic relationship between 
commensal bacteria and the mammalian host is essential for normal digestion and 
proper nutrition, unrestrained microbial dissemination has severe consequences for the 
host, resulting in systemic immune activation that has been associated with progression 
of multiple chronic inflammatory diseases, such as HIV, hepatitis infections and cancer 
(Brenchley et al., 2006; d'Ettorre et al., 2011; Douek, 2007; Marchetti et al., 2011; Page 
et al., 2011; Paiardini et al., 2008; Sandler et al., 2011). Therefore, homeostatic 
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maintenance and effective repair of the epithelial barrier is critical for preservation of 
human health.  
In mammals, the intestinal epithelial barrier is protected by multiple layers of 
physical and immuno-regulatory protection. First, a thick layer of mucus secreted by 
goblet cells covers surface of the epithelium, thereby thwarting invasion by commensal 
microbes, pathogens and environmental agents that attempt to enter from the lumen 
(Barker, 2014; Maloy and Powrie, 2011; Peterson and Artis, 2014; Rescigno, 2011). The 
single layer of epithelial cells serves as the second line of host defense in the intestine, 
with tight junction proteins and adhesion molecules providing an additional mechanism 
to prevent microbes or noxious environmental agents from crossing the barrier. 
Secretion of anti-microbial peptides such as defensins, cathelicidins, and C-type lectins 
produced by specialized paneth cells also provide an effective defense against infection 
and injury of the epithelial barrier (Barker, 2014; Peterson and Artis, 2014; Rescigno, 
2011).  
The small and large intestinal epithelium must undergo rapid renewal to maintain 
optimal function of the cells in the crypts and villi. More than 300 million new epithelial 
cells are estimated to be generated daily in the small intestine alone as part of normal 
homeostatic turnover and an even greater amount during tissue injury (Barker, 2014; 
Peterson and Artis, 2014; Rescigno, 2011). Regeneration begins at the crypt base, 
where stem cells regularly divide to first generate transit-amplifying (TA) cells and then 
differentiate to the absorptive versus secretory cell lineages while migrating upwards. 
Cytokines and growth factors expressed by innate and adaptive immune cells can 
influence intestinal epithelial cell proliferation and differentiation (Peterson and Artis, 
2014; Sato et al., 2011; Sato et al., 2009) (and discussed in greater detail below). 
Studies performed in Chapters 3 and 4 of this thesis will specifically explore the ability 
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of Group 2 innate lymphoid cells (ILC2s) to produce growth factors that regulate 
restoration of epithelial barrier function following acute tissue injury. 
 
1.1.2 Architecture and defense of the lung epithelial barrier 
The mammalian lung is a dynamic organ that takes in approximately 10,000 liters of air 
every day for efficient gas exchange, providing ample opportunity for circulating 
pathogens, allergens or other environmental particulates to invade the airways and 
cause disruption of the epithelial barrier leading to tissue damage and inflammation 
(Gorski et al., 2012; Hallstrand et al., 2014; Lambrecht and Hammad, 2014; Rock et al., 
2010). The lung barrier consists of a psuedostratified epithelium that contains basal cell 
(BCs), ciliated cells, multiple secretory cell lineages (goblet cells, Clara cells and serous 
cells) and neuroendocrine cells (Borok et al., 2011; Chen et al., 2009; Morrisey and 
Hogan, 2010; Rackley and Stripp, 2012; Rock et al., 2010). At the interface of the lung 
epithelium and the circulating air, secretion of mucus by goblet cells and surfactants by 
Clara cells form the first line of defense to prevent invasion from noxious environmental 
agents and pathogens. Any pathogens or particulate matter caught in the mucus layer 
are swept away from the barrier by ciliated cells. Under homeostatic conditions, the 
structural integrity of the lung barrier is maintained by tight junction proteins, claudins 
and other adhesion molecules while dysregulation of these structural molecules is 
associated with development of airway inflammation and tissue damage (Gorski et al., 
2012; Hallstrand et al., 2014; Morrisey and Hogan, 2010; Rackley and Stripp, 2012; 
Rock et al., 2010).  
Despite intense investigation, it is still controversial whether a single 
bronchioalveolar stem cell (BASC) population exists that can give rise to all the different 
lineages of the lung or whether there are lineage-restricted facultative precursors that 
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only regenerate distinct epithelial subsets (Borok et al., 2011; Crosby and Waters, 2010; 
Morrisey and Hogan, 2010; Rawlins et al., 2009; Rock et al., 2010). Further, the majority 
of lung epithelial stem cell work has been restricted to studies of prenatal development 
and postnatal homeostatic turnover, while the epithelial lineages involved in airway 
remodeling and restoration of barrier integrity following pathogen-induced tissue damage 
are virtually unexplored.  
Similar to the intestinal tract, there is extensive immunoregulation of the lung 
epithelia, consisting of cytokines, growth factors and enzymes produced by innate and 
adaptive immune cells to maintain integrity of the barrier under steady-state conditions 
and coordinate tissue repair if the epithelium is damaged (discussed in further detail 
below). Studies undertaken in this thesis investigate how populations of ILCs respond to 
cues from the damaged mucosal barrier to orchestrate epithelial repair and promote 
restoration of tissue homeostasis in the lung and intestine through production of growth 
factors. 
 
1.2 Epithelial cell-derived cytokines regulate the innate immune system 
At the epithelial barrier, secretion of the cytokines interleukin(IL)-25, IL-33 and thymic 
stromal lymphopoietin (TSLP) are prominent inducers of the type 2 inflammatory 
response (Oboki et al., 2011; Saenz et al., 2010a; Smith, 2011) (Fig 1). In particular, IL-
33 acts an “alarmin” danger signal, releasing rapidly upon epithelial cell damage to 
activate resident immune cell populations of the lung and intestine (Le et al., 2013; 
Lopetuso et al., 2012; Oboki et al., 2011; Saenz et al., 2010a; Smith, 2011). The ability 
of the IL-33-IL-33R signaling pathway to regulate innate cell function and tissue repair 
will be investigated in this thesis; therefore the sections below will specifically focus on 
the induction, sources and cellular targets of IL-33 in detail. 
	   6	  
1.2.1 Cellular distribution of IL-33 and ST2 
IL-33 is a member of the IL-1 cytokine family and is widely expressed in epithelial and 
endothelial stromal cell lineages of the central nervous system, lung and intestine under 
steady state conditions (Le et al., 2013; Lopetuso et al., 2012; Oboki et al., 2011; Smith, 
2011). Upon infection, inflammation or tissue injury, IL-33 can also be upregulated in 
dendritic cells, macrophages and fibroblasts. Inside the cell, IL-33 is localized to the 
nucleus and can be released in bioactive form from necrotic cells in injured tissue 
without any caspase processing (Le et al., 2013; Pastorelli et al., 2011; Smith, 2011). As 
such, IL-33 is commonly referred to as an “alarmin” or a damage-associated molecular 
pattern (DAMP). The receptor for IL-33 is termed ST2 and can exist in a bioactive 
transmembrane form (also called ST2L) or a soluble form (sST2) that acts as a decoy 
receptor. Binding of IL-33 to ST2 and recruitment of MyD88 triggers a signaling cascade 
involving NF-κB and AP-1 through IRAK, TRAF6 and MAP kinases (Le et al., 2013; 
Pastorelli et al., 2011; Smith, 2011).  
ST2 can be expressed on virtually every member of the innate and adaptive 
immune systems that serve to regulate the balance of immunity, inflammation and tissue 
repair at barrier surfaces (Fig 1). The innate cell targets of IL-33 signaling consist 
primarily of the classical type 2 immune response: mast cells, basophils, eosinophils, 
dendritic cells, macrophages, neutrophils and the newly described Group 2 innate 
lymphoid cells (ILC2s) (Le et al., 2013; Lloyd, 2010; Mirchandani et al., 2012; Smith, 
2011). Additionally, adaptive immune cells such as CD8 T cells, B cells and Th2 CD4 
helper T cells can also express ST2 during ongoing inflammatory or infectious disease 
settings. Lastly, ST2 expression is not restricted to hematopoietic lineages, as stromal 
cell populations such as fibroblasts, epithelial cells, endothelial cells and osteoclasts 
have all been implicated as direct targets of IL-33 signaling (Le et al., 2013; Lloyd, 
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2010). The extensive and diverse array of cell types responsive to IL-33-IL-33R 
stimulation illustrates the critical importance of this alarmin in regulating immune function 
at barrier surfaces.   
 
1.2.2 Role of IL-33 during immune responses in the lung and intestine 
 
In the lung, IL-33 has been shown to be a primary activator of the cell types involved in 
initiating airway inflammation and hyper-reactivity (Barlow et al., 2012; Barlow et al., 
2013; Bartemes et al., 2012; Kim et al., 2012; Le et al., 2013; Mirchandani et al., 2012). 
Further, GWAS studies in asthma patients have identified IL-33 and ST2 (Ho et al., 
2013), suggesting that therapeutic manipulation of this pathway may result in improved 
clinical disease outcomes. Particularly in the case of ILC2s, previous studies have 
indicated that IL-33 is a more potent signal than IL-25 or TSLP for eliciting ILC2 
proliferation and expression of the type 2 cytokines IL-5 and IL-13 that drive airway 
inflammation (Barlow et al., 2013; Saenz et al., 2013). In the context of respiratory viral 
infection, IL-33 has been shown to be released by influenza virus-infected epithelial cells 
and macrophages (Chang et al., 2011; Le Goffic et al., 2011a), although the functional 
role of the IL-33-IL-33R signaling pathway in influencing viral clearance, tissue 
inflammation or restoration of epithelial barrier integrity is unknown. Studies in Chapter 2 
and 3 will directly test the contribution of the IL-33-IL-33R pathway to immunity and 
tissue repair following influenza virus-induced lung damage.  
 In the intestinal tract, IL-33 along with IL-25 signaling has been shown to be 
essential for generating optimal anti-parasitic immune responses to helminth parasites 
via activation of IL-13-producing ILC2s (Moro et al., 2010; Neill et al., 2010; Price et al., 
2010). In the context of non-infectious tissue injury such as models of intestinal colitis, 
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whether IL-33-IL-33R interactions play a tissue-protective or pathologic role during 
disease progression is highly controversial (Duan et al., 2012; Garcia-Miguel et al., 
2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso et al., 2012; Pastorelli et al., 
2011; Pushparaj et al., 2013; Sedhom et al., 2013), and the cellular and molecular 
mechanisms which act downstream of IL-33 to regulate disease severity are not well 
understood. In Chapter 4, we will employ the dextran sodium sulfate model of intestinal 
injury to assess whether ILC2s and IL-33 signaling are involved in promoting 
inflammation versus tissue repair.  
 
1.3 Role of amphiregulin and the epidermal growth factor receptor at barrier sites 
In addition to the cytokine-mediated regulation of innate immunity and barrier function 
discussed above, the epithelium is also responsive to growth factor pathways that 
promote proliferation, differentiation and survival of distinct stromal cell lineages. In the 
lung and intestine, the amphiregulin-epidermal growth factor receptor pathway is a key 
regulator of both epithelial and hematopoietic cell function in the steady state and during 
tissue injury.  
 
1.3.1 Role of AREG-EGFR signaling in non-hematopoietic stromal cells 
The growth factor Amphiregulin (AREG) was originally discovered in a human breast 
cancer cell line culture and named “amphi-“ for its dual ability to either promote or to limit 
proliferation and differentiation of normal and cancerous epithelial cells (Berasain and 
Avila, 2014; Busser et al., 2011b). Amphiregulin is remarkably widespread in its 
expression pattern, ranging throughout mammalian tissues to include the reproductive, 
urinary, respiratory, and intestinal tracts as well as the circulatory system and bone 
structure (Berasain and Avila, 2014; Busser et al., 2011b). As such, AREG is reported to 
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regulate diverse physiological processes, most critically mammary gland development, 
stromal cell proliferation and differentiation, bone formation and keratinocyte proliferation 
(Berasain and Avila, 2014; Busser et al., 2011b).  
 AREG is a ligand of the epidermal growth factor receptor (EGFR), a 
transmembrane tyrosine kinase receptor belonging to the ErbB/human epidermoid 
receptor (HER) family (Berasain and Avila, 2014; Busser et al., 2011b). Compared to the 
other EGFR ligands (epidermal growth factor (EGF), tumor growth factor-alpha (TGFα), 
heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EREG) and betacellulin 
(BTC)), AREG binds to EGFR with low affinity yet still exhibits remarkably strong 
biological activity at low concentrations (Berasain and Avila, 2014; Busser et al., 2011b; 
Kataoka, 2009). Binding of AREG to EGFR leads to receptor dimerization and activation 
of multiple downstream signaling pathways including the Ras/MAPK, PI3K/AKT, PLCγ 
and STAT pathways. Importantly, EGFR signaling is absolutely required for normal 
development of multiple organ systems, as genetically modified mice lacking EGFR 
activity die in utero and mice heterozygous for mutations reducing EGFR activity still 
exhibit profound defects in sites where EGFR expression is highest, notably 
keratinocytes and mammary tissue (Busser et al., 2011b; Du et al., 2004; Kataoka, 
2009; Lee and Threadgill, 2009; Luetteke et al., 1999). However, the importance of 
EGFR signaling in regulating postnatal tissue function after injury, particularly in the lung, 
is not well understood. Chapters 3 and 4 will interrogate the potential role of 
endogenous AREG-EGFR interactions in epithelial cell repair and restoration of tissue 
homeostasis in response to lung damage or intestinal injury. 
Cleavage of the AREG precursor protein (pro-AREG) to generate the mature 
active form is accomplished by the tumor-necrosis factor-alpha converting enzyme 
(TACE), a member of the disintegrin and metalloproteinase (ADAM) family (also called 
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ADAM-17). After cleavage, AREG can act in a paracrine or autocrine fashion on many 
stromal cell types that also express EGFR (Burgel and Nadel, 2004, 2008; Busser et al., 
2011b; Kataoka, 2009). Diverse endogenous and exogenous signals induce AREG 
production depending on the tissue site; however, the signals that promote AREG in the 
stromal cells of the lung and intestinal tracts are virtually unknown except for TGFβ and 
cigarette smoke (lung) and prostaglandins (intestine) (Berasain and Avila, 2014; 
Kataoka, 2009; Nadel, 2001; Takeyama et al., 2001). Whether cytokine alarmins such as 
IL-33 can induce AREG expression and EGFR activity will be examined in Chapter 3 of 
this thesis.  
 
1.3.2 Role of AREG-EGFR signaling in hematopoietic cells 
EGFR expression was thought to be exclusively restricted to non-hematopoietic 
cells, although recent evidence has emerged challenging this dogma and revealing 
functional EGFR expression on hematopoietic stem cells (HSCs) (Doan et al., 2013), 
regulatory T cells (Tregs) (Zaiss et al., 2013) and macrophages (Lu et al., 2014). 
Whether other immune cell populations may express EGFR and respond to AREG 
signaling is not yet known.  
Until recently, AREG was primarily known for its involvement in human cancers 
(most notably lung, intestine, breast and pancreas), where it serves as a prognostic 
marker of poor clinical outcome (Berasain and Avila, 2014; Busser et al., 2011b). 
However, within the past several years it has become increasingly clear that AREG can 
also serve as an important regulator of hematopoietic cell function in context of infection 
and tissue injury. Interestingly, the source of AREG in these settings is also 
hematopoietic in origin, although it acts in a paracrine, not autocrine, fashion unlike what 
has generally been reported for stromal cells (Berasain and Avila, 2014; Burgel and 
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Nadel, 2008; Busser et al., 2011b; Kataoka, 2009). First reported as a new component 
of the type 2 cytokine franchise produced by Th2 CD4 T cells to expel parasites from the 
intestine (Zaiss et al., 2006), AREG is now considered to be an effector molecule of 
multiple cells types associated with type 2 immunity, including basophils, eosinophils, 
mast cells and Tregs (Burgel et al., 2001; Burzyn et al., 2013; Meulenbroeks et al., 2014; 
Qi et al., 2010). Human basophils express AREG in response to IL-3 stimulation while a 
functional role for basophil-derived AREG was recently revealed in a murine model of 
Ultraviolet-B (UVB) irradiation-induced immunosuppression (Meulenbroeks et al., 2014; 
Qi et al., 2010). Human blood eosinophils have been reported to express AREG upon 
stimulation with GM-CSF (Burgel et al., 2001; Matsumoto et al., 2009), although the 
functional relevance of eosinophil-intrinsic AREG has not been examined. Mast cells 
have also been reported to be a critical source of AREG, capable of enhancing 
suppressive function of EGFR+ Tregs in culture and in vivo (Zaiss et al., 2013). Lastly, 
Tregs themselves have recently been shown to express AREG to promote muscle tissue 
repair (Burzyn et al., 2013). Studies in Chapter 3 and 4 will expand upon these findings 
to test the signals that induce AREG expression in populations of Group 2 innate 
lymphoid cells (ILC2s) and what role ILC2-intrinsic may play in tissue repair responses 
of the injured lung and intestine. 
 
1.4 Innate lymphoid cells 
Emerging studies over the past several years have revealed the existence of a 
previously unrecognized population of immune cells that appear to represent the innate 
counterpart to the T cell lineage of the adaptive immune system. Located at multiple 
anatomical sites, these heterogeneous populations of innate lymphoid cells (ILCs) serve 
as crucial regulators of immunity and inflammation at barrier surfaces such as the skin, 
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intestine and respiratory tract (Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al., 
2011; Spits and Cupedo, 2011). The following sections will discuss the phenotypic, 
transcription and functional characteristics of the ILC subsets.  
 
1.4.1 The ILC family 
ILC populations share morphological, developmental and functional similarities with 
CD4+ T helper cells, but lack antigen receptors. Specifically, members of the ILC family 
lack expression of cell surface makers associated with granulocytes, dendritic cells (DC), 
macrophages and conventional B and T lymphocytes but can be positively identified by 
expression of CD90 (Thy1), CD25 (IL-2Rα), CD127 (IL-7Rα) and c-Kit among others 
(Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al., 2011; Spits and Cupedo, 2011). 
While the cell lineage relationships between heterogeneous ILC populations are still 
being elucidated, it has been demonstrated that ILCs develop from the classical 
common lymphoid progenitor cell (CLP) and require common gamma chain cytokine 
signaling for development (Spits and Cupedo, 2011; Wong et al., 2012; Yang et al., 
2011). All ILCs are thought to develop from a common bone marrow-derived lymphoid 
precursor that is dependent on the transcription factor inhibitor of DNA-binding 2 (Id2) 
(Monticelli et al., 2011; Moro et al., 2010; Spits and Cupedo, 2011), and recent work has 
identified high expression of the transcription repressor promyelocytic leukaemia zinc 
finger (PLZF) as a defining feature of an ILC precursor that differentiates into all known 
ILC subsets but notably not NK cells (Constantinides et al., 2014) (Fig 2). Heterogeneity 
in cell surface marker expression, transcriptional regulation and effector molecule 
expression allow mature ILCs to be broadly classified into 3 main population subsets, 
referred to as Group 1 ILC (ILC1), Group 2 ILC (ILC2) or Group 3 ILC (ILC3) (Fig. 2 and 
(Spits et al., 2013))  
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The Group 1 ILC population is the most recently described subset and includes 
cells dependent on the Th1 cell-associated transcription factor T-bet that are capable of 
responding to IL-12 and IL-15 signaling to produce IFNγ (Bernink et al., 2013; Klose et 
al., 2014) (Fig 2). Although the distinctions between ILC1s and classical NK cells are not 
fully defined, true ILC1s are thought to be distinguished from NK cells by their absence 
of many NK cytotoxicity receptors and by their dependence on the common ILC 
precursor transcription factor PLZF (Bernink et al., 2013; Klose et al., 2014). 
ILC populations found in Group 2 are composed of cells that express the T 
helper type 2-associated cytokines IL-5, IL-9 and IL-13 but do not express much IL-4 
(Koyasu et al., 2010; Monticelli et al., 2012; Saenz et al., 2010a). These cell populations, 
that were originally termed Natural Helper cells, Nuocytes or Innate Helper Type 2 cells 
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010), also express the Th2 cell-
associated transcription factor GATA3, as well RORα, TCF-1 and Gfi1 (Furusawa et al., 
2013; Hoyler et al., 2012; Klein Wolterink et al., 2013; Mjosberg et al., 2012; Spooner et 
al., 2013; Wong et al., 2012; Yang et al., 2013) (Fig. 2). ILC2s are activated primarily by 
the epithelial-derived cytokine IL-33 and to a lesser extent, IL-25. Additional epithelial 
cell-derived factors, such as thymic stromal lymphopoetin (TSLP), can augment ILC2 
responses (Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al., 2011; Spits and 
Cupedo, 2011). 
The third ILC subset (ILC3) is comprised of several distinct cell populations that 
share a common developmental requirement for RORγt and a cytokine expression 
profile reminiscent of CD4+ Th17 cells. A variety of names have been used to describe 
IL-17A/IL-22-producing ILCs, including adult lymphoid tissue inducer (LTi)-like cells, 
ILC22 and ILC17 (Cella et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 2008; 
Sonnenberg et al., 2011; Spits and Cupedo, 2011; Takatori et al., 2009). Similar to fetal 
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LTi cells, these RORγt+ adult LTi-like ILC3s are also capable of producing lymphotoxin 
(LT)  for lymphoid organ development (Lochner et al., 2011; Marchesi et al., 2009). 
Additionally, all ILC3 populations have the ability to produce high amounts of IL-22 or IL-
17A in response to stimulation with IL-23, IL-1β and dietary AhR ligands (Fig 2).  
The focus of this thesis will be to explore the regulation and effector function of 
ILC2s in the respiratory and intestinal tracts in response to tissue injury. Therefore, the 
following sections will discuss the phenotypic, transcriptional and functional 
characteristics of ILC2s at barrier sites in more detail.   
 
1.4.2 Identification of murine ILC2s 
Expression of the Th2-cell associated cytokines IL-5 and IL-13 is a classic hallmark of 
both pathologic allergic inflammation and host-protective anti-parasitic immune 
responses at mucosal sites (Allen and Maizels, 2011; Doherty and Broide, 2007; 
Oliphant et al., 2011; Saenz et al., 2010a). Group 2 ILCs provide a critical, early innate 
source of these cytokines before the onset of adaptive CD4+ Th2 cell-dependent 
immune responses. A non-T cell, non-B cell source of type 2 cytokines critical for anti-
helminth immunity in the intestine was originally reported a decade ago (Fallon et al., 
2006), although it would be several more years until flow cytometric advances allowed 
for the characterization and formal identification of this novel innate cell type. These 
RORγt-independent, ILCs were first described by Moro and colleagues as Natural Helper 
(NH) cells located in fat-associated lymphoid clusters (FALC) surrounding the gut 
mesentery that provide aid to B1 cells and promote expulsion of intestinal helminth 
parasites (Moro et al., 2010). Subsequent studies by two independent laboratories 
further identified populations at multiple tissue sites (termed Nuocytes or Innate Helper 
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Type 2 cells (Ih2)) that were critical for optimal protective type 2 immunity against 
intestinal helminth parasites (Neill et al., 2010; Price et al., 2010).  
Now collectively referred to as Group 2 ILCs (ILC2s), these cells express the 
receptors for the epithelial cell-derived cytokines IL-25 (IL-17Rb) and IL-33 (T1/ST2) and 
produce IL-5 and IL-13 upon stimulation with IL-25 and/or IL-33 in combination with IL-2 
and IL-7 (Koyasu et al., 2010; Neill et al., 2010; Price et al., 2010; Spits et al., 2013). In 
parallel with these studies, a separate report identified a population of IL-25-elicited, 
multi-potent progenitor type 2 cells (MPPtype2 cells) that also augment anti-helminth 
immunity, but are functionally distinct from ILCs by their ability to differentiate into 
myeloid cells and their preferential responsiveness to IL-25, but not IL-33, signaling 
(Saenz et al., 2010b). Extensive comparison of the phenotypic, functional and 
transcriptional profiles of ILC2s and MPPtype2 cells revealed that MPPtype2 cells more 
closely resemble common myeloid progenitors than fully differentiated ILC2s (Saenz et 
al., 2013). 
The discovery of ILC2s at the intestinal barrier surface prompted us to ask 
whether ILC populations exist at extra-intestinal barrier sites such as the respiratory 
tract. Studies in Chapter 2 will examine the phenotypic, developmental and functional 
characteristics of ILC2 populations in the lung and test whether these cells may regulate 
immunity, inflammation or tissue repair following infection with Influenza A virus. Notably, 
since the completion of these studies in Chapter 2, multiple groups have reported 
similar ILC2 populations in murine lung parenchyma (Barlow et al., 2012; Bartemes et 
al., 2012; Chang et al., 2011; Halim et al., 2012; Kim et al., 2012; Yang et al., 2011; 
Yasuda et al., 2012) that are involved in promoting airway inflammation upon exposure 
to environmental allergens or lung pathogens (discussed in detail in section 1.5.1) 
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1.4.3 Identification of ILC2s in human tissue 
Several studies have identified ILCs in human blood, lymphoid organs, skin and 
intestinal tissue that share the phenotypic and cytokine profile reminiscent of murine 
ILC1s, ILC2s and ILC3s (Bartemes et al., 2014; Bernink et al., 2013; Cella et al., 2009; 
Cella et al., 2010; Crellin et al., 2010a; Crellin et al., 2010b; Cupedo et al., 2009; Hughes 
et al., 2010; Kim et al., 2013a; Sonnenberg et al., 2012; Teunissen et al., 2014). 
However, the existence and functional characterization of ILCs within the human 
respiratory tract was unknown. In Chapter 2, we performed the first interrogation of the 
ILC population in healthy human lung tissue and bronchioalveolar lavage (BAL) fluid of 
lung transplant patients, discovering an ILC2-like population expressing CD25, CD127 
and ST2 (IL-33R) analogous to murine ILC2s. In a parallel study, Mjosberg et al. 
identified ILC2 populations at multiple tissue sites, including fetal and adult intestine and 
lung that were characterized by expression of CD161 and the chemoattractant receptor 
CRTH2 (Mjosberg et al., 2011). CRTH2+ ILC2s expressed high levels of GATA3 and 
responded to IL-33 and IL-25 to produce IL-13, similar to their murine counterparts 
(Mjosberg et al., 2012; Mjosberg et al., 2011). Notably, CRTH2+ ILCs were also 
detectable in human blood and displayed some level of plasticity not observed in tissue-
resident ILC populations. Blood CRTH2+ ILCs could produce IL-22 and IL-13 (Mjosberg 
et al., 2011), suggesting that the blood may contain a progenitor ILC population capable 
of differentiating into either IL-22-producing ILCs or IL-13-producing ILCs depending 
upon the cytokine signals present in the tissue microenvironment. Since these initial 
reports of ILC2s in the respiratory tract, subsequent studies have now identified ILC2 
populations in a wide variety of human tissues and disease states, including in BAL from 
patients with Idiopathic Pulmonary Fibrosis (IPF) (Hams et al., 2014), polyps from 
patients with allergic rhinosinustiis (Mjosberg et al., 2012), skin from patients with atopic 
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dermatitis (Kim et al., 2013a), and blood from asthmatic patients (Bartemes et al., 2014). 
Collectively these studies indicate that ILC2s populate diverse lymphoid and barrier sites 
within the human body, suggesting they may serve crucial roles in balancing immunity, 
inflammation and tissue homeostasis during disease. 
 
1.4.4 Transcriptional control of ILC2 development 
The molecular cues that direct differentiation of the three ILC lineages are an ongoing       
area of investigation. Recent reports have demonstrated striking similarities between the 
transcriptional program that instructs ILC and CD4 T cell lineage specification. Mirroring 
their Th2 CD4 T cell counterparts, ILC2s express high levels of GATA3 but lack 
expression of RORγt and T-bet (Furusawa et al., 2013; Hoyler et al., 2012; Klein 
Wolterink et al., 2013; Mjosberg et al., 2012). Interestingly, GATA3 has been shown to 
be critical for the early development of both Group 2 and Group 3 ILCs (Serafini et al., 
2014; Yagi et al., 2014). However, temporal deletion of GATA3 only in mature cells 
results in a loss of ILC2s while leaving ILC3s unaffected (Hoyler et al., 2012), suggesting 
that only ILC2s require continual expression of GATA3 for long-term maintenance. 
Additionally, the T cell master regulator TCF-1 (Tcf7), a target of Notch signaling, 
instructs ILC2 development via GATA3-dependent and GATA3-independent 
mechanisms (Yang et al., 2013). Intriguingly, a second report demonstrated TCF-1 
regulates ILC3s in addition to ILC2s (Mielke et al., 2013a), suggesting TCF-1 may be 
acting on a common ILC2/ILC3 precursor at an early developmental checkpoint. 
Whether TCF-1 regulates ILC1s in a similar fashion is currently unclear. ILC2s are 
critically dependent on the transcriptional regulator RORα for development although the 
developmental stage at which RORα acts remains unknown. (Spits and Cupedo, 2011; 
Wong et al., 2012). IL-33R expression is a hallmark of the ILC2 lineage although the 
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molecular factors regulating its expression are not well understood. Recent evidence 
indicates that the transcription factor Gfi1 controls ILC2 development and activation by 
directly regulating IL-33R and GATA3 (Spooner et al., 2013). Collectively these studies 
provide insight into the transcriptional network controlling ILC2 development although 
further investigation is required to more thoroughly delineate the factors controlling 
specification of the ILC1/2/3 lineages. 
 
1.4.5 Cytokine regulation of ILC2 responses  
Consistent with their enrichment at epithelial barrier surfaces, ILC2s are characterized 
by their responsiveness to the predominately epithelial cell-derived cytokines IL-25, IL-
33 and TSLP (Barlow and McKenzie, 2014; Kim et al., 2013b; Monticelli et al., 2012; 
Spits and Cupedo, 2011). In vivo and in vitro evidence suggests that IL-33 and/or IL-25 
are the primary signals for ILC2 activation at most tissue sites, with TSLP playing a more 
minor role in amplifying ILC2 effector function by promoting cell survival (Barlow et al., 
2013; Halim et al., 2012; Salimi et al., 2013). 
While the initial reports describing the role of intestinal ILC2s in anti-helminth 
immunity implicated involvement of both IL-33 and IL-25 signaling (Moro et al., 2010; 
Neill et al., 2010; Price et al., 2010), subsequent characterization of ILC2s in the lung 
and lymphoid organs has indicated that IL-33, not IL-25, is the dominant signal for 
inducing ILC2 proliferation and cytokine effector function (IL-5 and IL-13) (Barlow et al., 
2013; Saenz et al., 2013). These studies suggest that cues from the local tissue 
microenvironment may instruct the cytokine-responsiveness of ILC2 populations. In 
addition, the relative ability of these cytokines to promote ILC2 responses may also 
depend upon mouse strain genetics. Supporting this, recent work by two groups 
examining skin ILC2 responses during atopic dermatitis revealed that the role of TSLP 
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versus IL-33/IL-25 signaling in eliciting ILC2 responses and regulating disease 
progression was influenced by the genetic background of the mouse strain used 
(C57BL/6 versus Balb/c) (Kim et al., 2013a; Salimi et al., 2013). Interestingly, 
examination of genetically modified mice lacking all three cytokines IL-33, IL-25 and 
TSLP demonstrated that development of ILC2s was largely unaffected although their 
functional cytokine capacity was severely impaired (Van Dyken et al., 2014), indicating 
that these epithelial cell-derived cytokines primarily serve as activation signals but are 
not essential for cell development and maintenance.   
While these studies collectively shed light on the cytokine regulation of ILC2 
function at multiple tissue sites, examination of ILC2 functionality has largely been 
restricted to measuring their production of the classic type 2 cytokines IL-5 and IL-13. 
How IL-33 versus IL-25 signaling may influence other aspects of ILC2 effector function, 
such as expression of growth factors, remains unknown. Furthermore, it is unclear 
whether these cytokines elicit homogenous populations of cytokine-expressing ILC2s or 
whether there is heterogeneity in the cytokine profile of ILC2s that may reflect their pro-
inflammatory versus tissue-protective functions. Studies in Chapter 3 and 4 of this 
thesis will examine the relative ability of these cytokines to elicit production of the growth 
factor AREG in ILC2s and influence tissue repair in the lung and intestine. 
 
1.5 ILC2s regulate immunity, inflammation and tissue homeostasis in the lung and 
intestine 
The presence of a population of ILCs that is constitutive in human and murine 
respiratory tissue raises questions about their potential involvement in regulation of 
immunity, inflammation or tissue homeostasis in the lung. The following sections will 
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discuss the emerging evidence that ILC2s serve as crucial mediators of inflammatory 
airway disease primarily through their production of the classical type 2 cytokines. 
 
1.5.1 ILC2s promote development of airway hyper-reactivity 
 Airway inflammation is commonly triggered by a wide variety of allergic stimuli, 
such as pollen or animal dander, and is characterized by high levels of IgE, type 2 
cytokines, mucus production and eosinophilia (Broide, 2008; Corren, 2011; Crosby and 
Waters, 2010; Doherty and Broide, 2007). Additionally, a second type of non-allergic 
inflammation can arise following respiratory viral infection (Broide, 2008; Doherty and 
Broide, 2007), but the cellular and molecular mechanisms underlying this type of airway 
hyper-reactivity (AHR) response are much less understood. Recently lung ILC2s were 
implicated in playing a pathologic role in promoting AHR following viral infection. In this 
model, infection with influenza A virus subtype H3N1 induced acute airway inflammation 
independently of adaptive immunity but dependent on the IL-33-IL-33R pathway and 
ILC2s. (Chang et al., 2011). IL-13 has been shown to promote epithelial cell proliferation 
in multiple settings of airway injury or inflammation (Broide, 2008; Crosby and Waters, 
2010; Doherty and Broide, 2007; Rock and Hogan, 2011) and IL-13 expression by ILC2s 
appeared to be essential for infection induced-AHR responses, as adoptive transfer of 
wildtype, but not IL-13-deficient ILC2s, was sufficient to drive AHR responses in IL-13-
deficient hosts (Chang et al., 2011).   
 In addition to regulating virus-induced airway hyper-reactivity, further studies 
have now defined roles for ILC2s in promoting allergic inflammation in response to a 
wide variety of allergens. Intranasal challenge with either OVA antigen, recombinant IL-
25 or IL-33 protein resulted in the accumulation of IL-13-expressing ILC2s in the lung 
and the development of AHR was dependent upon ILC2-intrinsic IL-13 (Barlow et al., 
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2012). A similar dependence on ILC2-derived IL-13 was also observed in an AHR model 
using NKT glycolipid antigen (Kim et al., 2012). Exposure to the protease allergen 
papain similarly induced ILC2s, eosinophilic infiltration and mucus production in the 
airways (Halim et al., 2012), providing further evidence that ILC2-derived cytokines are 
central to the promotion of chronic airway inflammation in multiple models (Fig. 3). 
Expression of IL-13 in cooperation with IL-4 drives alternative activation of macrophages 
(termed AAMacs) that have been implicated as important regulators of lung tissue 
fibrosis in settings of allergic airway inflammation and chronic pulmonary fibrosis 
disorders like COPD (Byers and Holtzman, 2011; Moreira and Hogaboam, 2011). Using 
intranasal administration of chitin, lung ILC2s were recently shown to be required for 
optimal polarization of AAMacs (Van Dyken et al., 2014), illustrating another mechanism 
by which ILC2s can modulate development of airway inflammation. In addition to IL-5 
and IL-13, IL-9 has been linked to a wide array of allergic disorders, although the cellular 
sources and regulation of IL-9 expression remains controversial (Noelle and Nowak, 
2010; Wilhelm et al., 2012). In response to papain exposure, ILC2s became a 
predominant early source of IL-9 (Wilhelm et al., 2011). Although IL-9 production by 
ILC2s was transient and dissipated soon after allergen challenge, antibody-mediated 
blockade of IL-9 activity demonstrated a crucial role for autocrine IL-9 in promoting 
optimal IL-5 and IL-13 expression (Fig 3). While collectively these studies implicate 
ILC2s as important initiators of airway inflammation and hyper-reactivity to a broad array 
of environmental insults, further investigation is required to define the differential 
contributions of IL-5, IL-13 and IL-9 in ILC2-dependent regulation of allergic and non-
allergic virally-induced airway inflammation.  
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1.5.2 ILC2s regulate pulmonary immunity 
The lung circulates over 10,000 liters of air every day, thereby being exposed to a 
multitude of pathogens with the potential to invade the epithelium and cause disease 
(Hallstrand et al., 2014; Holgate, 2011; Lambrecht and Hammad, 2014). Breach of the 
epithelial barrier by viral, bacterial or parasitic pathogens requires coordinated efforts by 
the innate and adaptive immune systems to contain the infection, clear the infected cells 
and eliminate pathogen replication (Gorski et al., 2012; Hallstrand et al., 2014; Rackley 
and Stripp, 2012). Currently there is no evidence to suggest that ILC2s directly regulate 
anti-bacterial immunity in the lungs although this area merits further investigation. The 
respiratory epithelium is also a frequent target of viral infections and the question of 
whether ILC2s can influence anti-viral immunity will be addressed in Chapter 2 
employing infection with influenza A virus. Lastly, there is some indication that ILC2s 
may modulate anti-parasitic immunity during the transient pulmonary phase of infection. 
Although adult helminth worms reside in the gut, the larvae must first migrate through 
the lung parenchyma before being coughed up and swallowed to complete maturation 
within the intestine (Allen and Maizels, 2011; Anthony et al., 2007). The cells and 
effector mechanisms involved in regulating expulsion of the parasites from the lung 
remain poorly defined. In two studies, Liang et al. and Yasuda et al. observed that IL-5 
and IL-13-producing ILCs accumulated in the lung in response to two helminth parasites, 
Nippostrongylus brasiliensis or Strongyloides venezuelensis (Liang et al., 2012; Yasuda 
et al., 2012). Given the known role of IL-5-elicited eosinophils in parasite killing and 
expulsion, it conceivable that IL-5 produced by the activated ILCs may aid in parasite 
clearance (Yasuda et al., 2012) (Fig 3).  
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1.5.3 ILC2s promote restoration of lung tissue homeostasis 
The ability of ILC2s to regulate restoration of airway tissue homeostasis in response to 
influenza virus-induced damage will be a central focus of Chapters 2 and 3 of this 
thesis. Since the completion of these thesis studies, however, additional evidence has 
emerged implicating ILCs in another model of pathogen-induced lung damage. During 
infection with the helminth parasite Nippostrongylus brasiliensis, larval passage through 
the lung results in severe acute tissue damage and triggers development of chronic type 
inflammation and emphysematous pathology that persists for weeks after the parasite 
leaves the respiratory tract (Allen and Maizels, 2011; Anthony et al., 2007). The cellular 
and molecular factors that promote repair of the damaged lung and ultimately become 
dysregulated to cause chronic inflammation are largely unknown. Since both IL-13 and 
AREG are potent inducer of epithelial hyperplasia characteristic of both injury repair 
responses and chronic pulmonary fibrosis (Crosby and Waters, 2010; Doherty and 
Broide, 2007; Rock and Hogan, 2011), it is conceivable that ILC-derived IL-13 and/or 
AREG may regulate remodeling and chronic inflammation of the injured lung. Supporting 
this, depletion of ILC2s during N. brasiliensis resulted in reduced IL-13 and AREG levels 
that correlated with impaired lung function and increased severity of the emphysematous 
pathology (Turner et al., 2013). Further studies are needed to dissect the relative 
contribution of IL-13+ and AREG+ ILC2s in regulating restoration of tissue homeostasis in 
response to diverse patterns of injury. 
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1.5.4 Role of ILC2s in regulating intestinal immunity, inflammation and tissue 
repair 
 
ILC2s were originally described as crucial early innate sources of the type 2 cytokines 
IL-5 and IL-13 during infection with the intestinal helminth parasite Nippostrongylus 
brasiliensis (Moro et al., 2010; Neill et al., 2010; Price et al., 2010). Employing immuno-
deficient mice or mice with disruptions in IL-25 or IL-33 cytokine signaling, these studies 
demonstrated conclusively that ILC2s were both necessary and sufficient to mediate 
parasite expulsion from the intestine. However, whether or not ILC2s play a role in 
immunity against intestinal bacterial or viral infections remains an unanswered question. 
Further, in comparison to the multitude of studies demonstrating the role of lung ILC2s in 
promoting inflammation (reviewed in section 1.5.1), there is currently little evidence 
supporting involvement of ILC2s in the development or progression of inflammatory 
intestinal diseases such as IBD. One study utilizing an oxazolone-induced intestinal 
injury model where type 2 cytokines are known to be pathologic observed that IL-25 
elicited IL-13+ ILC2s correlated with disease severity (Camelo et al., 2012), although the 
precise requirement for these cells in development of disease was not directly tested. 
Finally, there is no information on whether ILC2s may play a beneficial, tissue-protective 
role during inflammatory disease to regulate repair of the damaged tissue. Chapter 4 of 
this thesis will explore the potential role of ILC2s and the IL-33-AREG-EGFR pathway in 
tissue repair following acute intestinal injury. 
 
1.5.5 Crosstalk between ILC2s and the adaptive immune system 
ILCs are remarkably rare immune cells, vastly outnumbered by their conventional T cell 
counterparts at barrier surfaces and lymphoid organs of both mice and man (Barlow and 
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McKenzie, 2014; Kim et al., 2013b; Monticelli et al., 2012; Spits and Cupedo, 2011). 
Since the ILC family shares many transcriptional and phenotypic characteristics with 
CD4 T cell subsets, currently there are limited techniques available to selectively 
manipulate ILC function without affecting conventional T cells. As a result, the majority of 
studies investigating ILC function have been limited to utilizing immuno-deficient Rag-/- 
mice that lack an adaptive immune system. While these studies have yielded useful 
information on the innate role of ILCs, the critical question of how ILCs may interact with 
the adaptive immune system to regulate immunity, inflammation and/or tissue repair 
remains relatively unexplored. Understanding the cross-regulation between ILCs and the 
adaptive immune system is essential for translating the mechanistic insights gained in 
the murine studies to potential therapeutic targets in human disease. 
 Interplay between ILCs and adaptive T and B cells can potentially occur via direct 
cell-cell contact mechanisms or indirectly through secretion of cytokine and chemokine 
effector molecules that act on secondary cell types. In the case of ILC2s, reports have 
provided evidence for both direct and indirect cross-regulation with T and B cells of the 
lung and intestine. In the setting of intestinal anti-helminth immunity, adipose tissue-
associated ILC2s were originally described as sources of IL-6 that promote B1 cell 
proliferation and antibody responses in the intestine during helminth infection (Moro et 
al., 2010). More recently, direct interactions between MHCII-expressing ILC2s and CD4 
T cells have been shown to be essential for expulsion of the parasites from the intestine 
while production of IL-2 from T cells reciprocally augments proliferation of MHCII+ ILC2s 
(Oliphant et al., 2014). In the context of airway inflammation, T cell-derived IL-2 was also 
shown to be important for ILC2 cytokine effector function, as ILC2-intrinsic IL-9 during 
papain allergen exposure was reduced in the absence of IL-2 from T cells (Wilhelm et 
al., 2011). Conversely, ILC2s have been proposed to indirectly augment CD4 T cell 
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responses during airway inflammation by secreting IL-13 that enhances dendritic cell 
migration to the lymph node to promote Th2 cell differentiation (Halim et al., 2014). 
These initial studies provide evidence of critical crosstalk between ILC2s and the 
adaptive immune system that influences the function of these cells during immunity and 
inflammation. Continued examination and greater understanding of the extent of the 
interplay between these cell types may aid in predicting the clinical implications of 
targeting these cells during human health and disease. 
 
1.5.6 Role of ILC2s in human disease 
Allergic airway diseases affect over 300 million people worldwide (Broide, 2008; Corren, 
2011), representing a significant global public health burden. While there is some clinical 
evidence showing an association between elevated levels of IL-5 and IL-13 and 
incidence of allergic airway disorders in human patients (Broide, 2008; Corren, 2011; 
Doherty and Broide, 2007; Wilson and Wynn, 2009), the potential contribution of ILCs to 
the development and/or progression of allergic inflammation in humans remains poorly 
defined. The ability of ILC2s to secret high levels of Th2 cell-associated cytokines, and 
their role in murine models of AHR indicate that ILC2s could be an attractive potential 
target for improved immuno-therapies. Supporting a role for ILC2s in human allergic 
airway disorders, Mjosberg and colleagues found elevated numbers of CRTH2+ ILC2s in 
the nasal polyps of patients with chronic rhinosinusitis, an allergic type 2 inflammatory 
disease characterized by high levels of circulating IgE and eosinophilia (Mjosberg et al., 
2011). Based on these observations, it is possible that high amounts of IL-5 produced by 
CRTH2+ ILC2s within the nasal polyps can contribute to the characteristic eosinophilia 
observed in this disease. Consistent with this hypothesis, patients with rhinosinusitis 
polyps have higher levels of IL-5 and IL-13 transcripts than patients without polyps 
	   27	  
(Mjosberg et al., 2011), suggesting that CRTH2+ ILC2s may be an important target in the 
development of new therapeutic strategies to ameliorate allergic airway inflammation. In 
the setting of chronic lung inflammation and fibrosis, little is known about whether ILC2s 
are dysregulated. One recent study has reported elevated CRTH2+ ILC2s in the BAL 
fluid of patients with Idiopathic Pulmonary Fibrosis (IPF) (Hams et al., 2014), although 
the functional potential of these cells was not examined. Importantly, the potential 
influence of ILC2s on development or progression of human inflammatory diseases is 
not limited to the airways. Dysregulated ILC2 responses have also been observed in 
patients suffering from inflammatory conditions at other barrier surfaces, including skin 
from patients with atopic dermatitis (Kim et al., 2013a), although the potential role of 
ILC2s in intestinal inflammatory disease is unknown.  
 
1.6 Murine models of tissue damage at barrier surfaces 
In this thesis, two models of epithelial tissue damage will be employed to test the 
potential contribution of ILC2s, IL-33-IL-33R signaling and AREG-EGFR interactions. 
 
1.6.1 Influenza A virus infection of the respiratory tract 
Infection with influenza A virus is a significant public health burden, with seasonal 
outbreaks causing at least 36,000 deaths and more than 200,000 hospitalizations every 
year in the United States (Clark and Lynch, 2011; Medina and Garcia-Sastre, 2011; 
Molinari et al., 2007). As a member of the enveloped single stranded (ss)RNA family 
Orthomyxoviridae, influenza A virus targets the epithelial cells of the respiratory tract for 
replication and eventually spreads to infect dendritic cells and macrophages in the lung 
(Iwasaki and Pillai, 2014; Jamieson et al., 2013; Peiris et al., 2010). Sensing of virus 
infection by the epithelia and innate immune system involves recognition by TLR7, RIG-I 
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and the NLRP3 inflammasome, resulting in a cascade of pro-inflammatory cytokines and 
chemokines to recruit and activate the host innate and adaptive immune systems 
(Iwasaki and Pillai, 2014; Peiris et al., 2010; Ranjan et al., 2009; Ueki et al., 2013). In 
particular, generating a production type 1 interferon response is crucial for host recovery. 
During this robust immune response, the airway epithelium becomes severely damaged 
due to direct necrosis from the viral replication as well as secretion of inflammatory 
mediators like IFNγ, TNFα and MIP-1α that elicit strong immune cell infiltration (Iwasaki 
and Pillai, 2014; Peiris et al., 2010; Ueki et al., 2013). 
While generation of CD8 T cell memory and long-lived antibody responses is 
critical for protection against secondary infection, it has become increasingly clear that 
successful repair of the damaged epithelia is equally important for ensuring host 
recovery. As such, recovery from respiratory infections such as Influenza A virus 
consists of three main phases: clearance of the virus, elimination of virus-induced 
inflammation and initiation of epithelial remodeling responses to restore lung tissue 
homeostasis and barrier integrity. Failure to adequately repair the damaged lung tissue 
has been associated with elevated risk of secondary bacterial infections, particularly in 
pandemic outbreaks such as the H1N1 strain in 2009 where loss of epithelial repair 
mechanisms was shown to be a primary determinant of the severity of disease 
pathogenesis (Peiris et al., 2010). 
 Despite the importance of tissue repair in host recovery, relatively little is known 
about the cellular and molecular factors that regulate these processes in the context of 
virus infection. Released by infected epithelial cells, TGFβ can induce proliferation of 
fibroblasts to release collagen and matrix proteins to build a new foundation for epithelial 
progenitor cells to expand upon (Iwasaki and Pillai, 2014; Peiris et al., 2010). 
Additionally, production of IL-22 by NK cells was reported to promote regeneration of 
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tracheal epithelial cells, although IL-22 appears not to affect repair of the epithelial cells 
in the lower airways and parenchyma (Guo and Topham, 2010; Monticelli et al., 2011). 
Whether cytokines and growth factors produced by type 2 innate immune cells, such as 
IL-13 and AREG, can modulate epithelial repair following influenza virus infection-
induced damage is unknown and will be explored in Chapters 2 and 3 of this thesis. 
 
1.6.2 Dextran sodium sulfate-induced intestinal inflammation 
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the intestinal 
mucosa that results in impaired epithelial barrier integrity and a failure to regulate 
mucosal wound healing (Hisamatsu et al., 2013; Kaser et al., 2010; Krishnan et al., 
2011; Neurath, 2014; Strober et al., 2007). There are multiple genetic and inducible 
models of intestinal injury that are designed to mimic some of the features of human IBD 
(Melgar et al., 2008; te Velde et al., 2007; Wirtz et al., 2007), although no model can 
completely recapitulate the complexity of this multi-factorial human disease. Studies in 
this thesis will utilize the dextran sodium sulfate (DSS)-induced model of acute intestinal 
damage and inflammation. Oral administration of DSS in the drinking water is toxic to 
epithelial cells at the base of the colon crypts, leading to barrier leakage and subsequent 
exposure to commensal bacteria that results in epithelial damage and increased 
expression of pro-inflammatory cytokines that activate immune cell populations (Melgar 
et al., 2008; Perse and Cerar, 2012; te Velde et al., 2007). Symptoms of DSS-induced 
intestinal injury include lethargy, weight loss and bloody stool that can eventually result 
in death. Depending upon the dose, molecular weight and duration of DSS 
administration, the mice can develop acute or chronic inflammation with varying degrees 
of mucosal lesions and immune infiltrate, making DSS an attractive model to examine 
multiple stages of disease severity (Melgar et al., 2005; Melgar et al., 2008; te Velde et 
	   30	  
al., 2007; Wirtz et al., 2007). Tissue injury specifically during acute DSS exposure, as 
employed in Chapter 4, is characterized by goblet cell depletion with accompanying loss 
of mucins, epithelial degeneration and necrosis, loss of crypt architecture and extensive 
immune cell infiltration consisting primarily of neutrophilia (Melgar et al., 2005; Melgar et 
al., 2008; te Velde et al., 2007; Wirtz et al., 2007). Importantly, unlike other intestinal 
injury models such as T cell transfers into immuno-deficient mice, the progression of 
DSS-induced intestinal inflammation does not require the adaptive immune response 
(Perse and Cerar, 2012). 
 Notably, expression of IL-33 and its receptor ST2 has been shown to be 
dysregulated in patients diagnosed with IBD (Kobori et al., 2010; Lopetuso et al., 2012; 
Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a tissue-
protective or pathologic role in the colonic intestinal mucosa during disease is 
controversial (Duan et al., 2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda 
et al., 2011; Lopetuso et al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013; 
Sedhom et al., 2013) and the mechanisms which act downstream of IL-33 to regulate 
disease severity are poorly understood. Additionally, the etiology of IBD has been linked 
to multiple growth factor pathways, including EGFR-associated family members 
(Hisamatsu et al., 2013; Lu et al., 2014; Neurath, 2014; Sipos et al., 2010; Yan et al., 
2011). Collectively, these attributes make DSS a useful model to assess the contribution 
of ILC2s to intestinal inflammation and tissue repair. In Chapter 4 of this thesis, I will 
employ oral administration of 3% DSS to induce acute intestinal injury over a one week 
period and assess the role of the IL-33-ILC2-AREG pathway in regulating intestinal 
inflammation and repair of the barrier. 
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1.7 Outline of the thesis 
The focus of this thesis will be to explore how populations of innate lymphoid cells 
orchestrate restoration of tissue homeostasis at epithelial barrier surfaces of the lung 
and intestine in response to acute tissue damage. Chapter 2 will characterize the 
population of ILCs constitutively present in the respiratory tract of humans and mice and 
examine whether lung ILC2s can influence airway epithelial barrier integrity and tissue 
homeostasis following influenza virus-induced pulmonary damage. The mechanism of 
ILC-mediated tissue repair will be examined in Chapter 3 through interrogation of the 
role of the AREG-EGFR growth factor pathway in host recovery from influenza virus 
infection. Lastly, data presented in Chapter 4 will explore the relevance of this pathway 
in sites outside the lung and uncover an IL-33-dependent innate immune mechanism of 
intestinal tissue repair dependent on AREG-EGFR interactions. Collectively, the data 
presented in this thesis reveal a conserved innate mechanism of barrier repair by which 
the mammalian immune system responds to damage cues from the local 
microenvironment to promote restoration of tissue homeostasis.  
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Figure 1: The type 2 immune response at barrier surfaces 
 
 
Figure 1: The type 2 immune response at barrier surfaces 
At mucosal surfaces, a single layer of epithelial cells serves as a critical barrier between 
the host immune system and outside envrionmental stimuli. Upon exposure to 
pathogens or allergens, epithelial cells release cytokine signals such as Interleukin (IL)-
25, IL-33 and thymic stromal lymphopoietin (TSLP) to elicit and activate the innate and 
adaptive immune cells of the type 2 inflammatory response. While activation of these 
cells is essential for host protective immunity and tissue repair to restore homeostasis, 
dysregulation of the type 2 immune response can result in development of pathologic 
chronic inflammation and tissue fibrosis. 
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Figure 2: The ILC family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The ILC family 
The innate lymphoid cell (ILC) family is composed of three main groups that all derive 
from Id2+ ILC precursors. Group 1 ILCs (orange) require T-bet, IL-7 and IL-15 for 
development and respond to IL-12 to produce IFNγ. Group 2 ILCs (green) are comprised 
of Nuocytes (Nuo), Natural Helper (NH) cells, Innate Type 2 Helper (Ih2) cells and lung-
resident ILCs that express GATA3 and depend upon RORα, TCF-1 and Gfi1 for 
development. Upon IL-25, IL-33 and/or TSLP stimulation, Group 2 ILCs can produce IL-
5, IL-13, IL-9 and amphiregulin (Areg). Group 3 ILCs (blue) consist of a heterogeneous 
population of RORγt-dependent ILCs that respond to IL-23, IL-1β and AhR ligands to 
express IL-22 and/or IL-17A.   
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Figure 3: ILC2s regulate immunity, inflammation and tissue homeostasis in the 
lung 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: ILC2s regulate immunity, inflammation and tissue homeostasis in the 
lung 
Contact with allergens, viruses or parasitic helminth worms causes inflammation of the 
airway epithelium, resulting in production of IL-33, IL-25 and/or TSLP (red arrow) that 
activates Group 2 ILCs to express a variety of effector cytokines that can drive either 
pathologic airway hyper-reactivity (AHR) responses (blue arrow) or can promote 
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beneficial tissue-protective responses to repair the damaged epithelium (green arrow). 
IL-5-mediated recruitment of eosinophils and IL-13-mediated epithelial cell/goblet cell 
proliferation can coordinately drive AHR responses. IL-9 acts in an autocrine manner to 
promote optimal IL-5/IL-13 expression in ILC2s. ILC2-derived IL-13 also influences 
differentiation of alternatively-activated macrophages and polarization of Th2 CD4 T 
cells (via DCs).  Additionally, data presented in Chapters 2 and 3 of this thesis 
demonstrate that ILC2 expression of amphiregulin (Areg) can promote epithelial cell 
proliferation to repair injured airway epithelia that has been damaged by virus infection 
(green arrow). 
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Chapter 2 
Innate lymphoid cells promote lung tissue homeostasis  
after influenza virus infection 
 
2.1 Abstract 
Innate lymphoid cells (ILCs), an emerging family of heterogeneous innate immune cells, 
reside at barrier surfaces and appear to represent the innate counterpart to the CD4 
helper T cell lineage. Previous studies have demonstrated a critical role for these cells in 
orchestrating immunity and inflammation in the intestine but whether ILCs can influence 
immune responses or tissue homeostasis at other mucosal sites remains poorly 
characterized. Data presented in this Chapter identify a population of lung-resident ILCs 
in mice and human airways that expressed CD90, CD25, CD127 and T1/ST2. 
Development of lung ILCs was critically dependent on the transcriptional factor Id2 but 
independent of commensal microbial-derived signals. Lung ILCs produced IL-5 and IL-
13 in response to the predominantly epithelial cell-derived cytokine IL-33, thereby 
demonstrating a functional profile reminiscent of recently identified natural helper cells 
and nuocytes (Group 2 ILCs “ILC2s”) that reside in the intestine and fat-associated 
lymphoid clusters. Strikingly, murine ILCs accumulated in the lung following influenza 
virus infection and depletion of ILCs or blockade of IL-33-IL-33R signaling resulted in 
loss of airway epithelial barrier integrity, decreased lung function and impaired airway 
tissue remodeling. Collectively, these results demonstrate a novel role for lung ILCs and 
the IL-33-IL-33R pathway in restoring airway epithelial integrity and tissue homeostasis 
following influenza virus-induced tissue damage. 
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2.2 Introduction 
Maintenance of epithelial barrier function at mucosal sites such as the intestine 
and respiratory tract is critical to limit exposure to environmental stimuli, commensal 
bacteria and invading pathogens (Artis, 2008; Sonnenberg et al., 2010; Turner, 2009). 
Recent studies have highlighted multiple roles for innate lymphoid cells (ILCs) in 
regulating immunity and/or inflammation at the intestinal barrier (Saenz et al., 2010a; 
Spits and Di Santo, 2011).  
ILCs are an emerging, diverse family of immune cells that are heterogeneous in 
their tissue location, cytokine production and effector functions (Saenz et al., 2010a; 
Spits and Di Santo, 2011). Although the lineage relationships between these 
heterogeneous ILC populations are still being fully elucidated and is an area under 
intense investigation, they are hypothesized to originate from a common Id2-dependent 
progenitor cell (Rankin and Belz, 2011; Spits and Di Santo, 2011). Based on their 
differential expression of the transcription factors T-bet, GATA3 and RORγt, mouse ILCs 
can be functionally divided into three main populations. Group 1 ILCs (ILC1) express the 
transcription factor T-bet and produce IFNγ (Bernink et al., 2013; Klose et al., 2014). 
GATA3+ Group 2 ILCs (ILC2) express the TH2 cell-associated cytokines IL-4, IL-5 and 
IL-13, and are composed of nuocytes, natural helper cells (NHCs) and innate helper type 
2 cells (Ih2). These cells are activated in response to the epithelial cell-derived cytokines 
IL-25 and/or IL-33 and can promote TH2 cytokine-dependent protective immunity against 
intestinal helminth parasites (Moro et al., 2010; Neill et al., 2010; Price et al., 2010; 
Saenz et al., 2010b).  Lastly, RORγt+ Group 3 ILCs (ILC3) include CD4+ lymphoid tissue 
inducer (LTi) cells, NKp46+ ILCs and a population of CD4- NKp46- ILCs, all of which 
express interleukin 17A (IL-17A) and/or IL-22 and can promote intestinal immunity 
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and/or inflammation (Buonocore et al., 2010; Satoh-Takayama et al., 2008; Sonnenberg 
et al., 2011; Spits and Di Santo, 2011; Takatori et al., 2009). Although these 
phenotypically distinct ILC populations have been identified in intestinal and lymphoid 
tissue compartments of mice, whether ILCs are present at barrier surfaces in humans 
and whether they influence immune responses or tissue homeostasis in the respiratory 
tract is unclear.  
Respiratory infections, such as influenza virus, cause significant damage to the 
lung epithelium as a consequence of direct virus-mediated cell death and indirect 
immunopathology caused by immune cell activation (Gorski et al., 2012; Peiris et al., 
2010). It is now well appreciated that successful recovery from respiratory viral infections 
involves not only virus clearance, but also appropriate remodeling of the injured tissue to 
restore airway barrier integrity and lung function. Repair and remodeling of damaged or 
inflamed tissue is a complex process involving many factors, including cytokines, 
chemokines, growth factors and extracellular matrix proteins that restore tissue 
homeostasis after injury (Crosby and Waters, 2010; Rock and Hogan, 2011). Failure to 
either appropriately initiate or resolve these repair responses can have detrimental 
effects, including loss of tissue integrity or function and promotion of chronic 
inflammation or tissue fibrosis (Crosby and Waters, 2010; Rock and Hogan, 2011). 
However, the cellular and molecular regulators of tissue remodeling following injury or 
infection at mucosal tissues such as the lung are poorly understood. 
Here in Chapter 2, we employ infection with the H1N1 PR8 strain of influenza 
virus and identify a previously unrecognized role for ILCs in promoting restoration of 
tissue homeostasis in the lung. In mice, lung-resident ILCs were Lin- and expressed cell 
surface markers associated with nuocyte and NHC populations (ILC2s), including CD90, 
CD25, CD127 and T1/ST2 and produced IL-5 and IL-13 in response to IL-33 stimulation. 
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An analogous population of Lin- lung ILC2s was also present in bronchoalveolar lavage 
fluid and lung parenchyma of humans. ILC2s accumulated in the lung of wild-type (WT) 
or Rag1-/- mice following experimental influenza virus infection and depletion of CD90+ 
ILCs or blockade of IL-33-IL-33R signaling in influenza virus-infected mice resulted in 
severely decreased lung function, loss of airway epithelial integrity and impaired 
respiratory tissue remodeling. Collectively, these data identify the presence of ILC2s in 
the lung of both humans and mice and demonstrate a crucial role for murine lung ILC2s 
in regulating airway epithelial integrity and orchestrating pulmonary tissue homeostasis 
following experimental influenza virus infection.   
 
2.3 Methods 
2.3.1 Mice 
C57BL/6 wild-type (WT) mice and Rag1-/- were purchased from the Jackson Laboratory. 
All mice were maintained in specific pathogen-free facilities at the University of 
Pennsylvania. All protocols were approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee (IACUC), and all experiments were performed 
according to the guidelines of the University of Pennsylvania IACUC. Germ-free mice 
were maintained in plastic isolator units, fed autoclaved feed and water, and routinely 
monitored to ensure absence of microbial contamination.	   Generation of Id2-deficient 
mice and fetal liver chimeras have been described previously (Cannarile et al., 2006; 
Monticelli et al., 2009). 	  For generation of Id2-deficient bone marrow chimeras, 10-20 x 
106 bone marrow cells from Id2+/+ or Id2-/- fetal liver chimeras were transferred i.v. into 
irradiated hosts (900 RAD) of a different congenic marker. All chimeras were placed on 
antibiotic drinking water (Sulfamethoxazole and Trimethoprim, Hi-Tech Pharmacal Co.) 
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for two weeks following irradiation and were allowed to reconstitute for 10 weeks prior to 
analysis.  
 
2.3.2 Flow cytometry 
Single cell suspensions were stained with a combination of the following monoclonal 
fluorescently conjugated antibodies: FITC-conjugated T1/ST2 (DJ8; MD Bioproducts). 
PE-conjugated ICOS (7E.17G9), Sca-1 (D7), c-kit (2B8), NKp46 (29AI.4), Siglec F (E50-
2440; BD Pharmigen). PerCP-Cy5.5-conjugated CD3 (17A2), CD5 (53-73), CD27 
(LG.7F9), NK1.1 (PK136), TCRβ (H57-597), CD11b (MI/70), CD11c (N418), B220 (RA3-
6B2). APC-conjugated CD44 (IM7), c-kit (2B8), CD90.1 (HIS51). eFluor-450-conjugated 
CD127 (A7R34), CD45.1 (A20). PE-Cy7-conjugated CD25 (PC61.5). Alexa 700-
conjugated CD90.2 (30-H12) and Ly6G (1A8; Biolegend). e-Fluor-780-conjugated 
CD11b (MI/70), CD11c (N418), TCRβ (H57-597), B220 (RA3-6B2), CD45.2 (104). PE-
Texas Red-conjugated CD4 (GK1.5; Abcam). All antibodies were purchased from 
eBioscience unless specified otherwise. For measurement of intracellular cytokine 
expression, stimulated cells were surface stained with a combination of the antibodies 
listed above, fixed and permeabilized using a commercially available kit (eBioscience), 
and stained with IL-5 APC (TRFK5; BD Pharmigen), IL-13-PE (eBio13A; eBioscience), 
IL-17A PE (TC11-18H10; BD Pharmigen), or IL22-02 (from Pfizer Inc.) conjugated to 
Alexa Fluor 647 according to manufacturer's instructions (Molecular Probes). For 
measurement of intracellular RORγt, cells were fixed, permeabilized and stained with 
RORγt PE (AFKJS-9; eBioscience)  For all stains, dead cells were excluded from 
analysis by means of an Aqua viability stain (Invitrogen LIVE/DEAD). Samples were 
acquired on a BD LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo 
software (v9.2, Tree Star). 
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2.3.3 Isolation of cells from mouse lung tissue 
Lungs were perfused with 10 ml PBS through the right ventricle of the heart prior to 
removal. Lungs were then cut into small pieces using scissors and digested with 1 mg/ml 
Collagenase D (Roche) in PBS for 30-45 min at 37 °C with vortexing every 10 min. 
Samples were mashed through 70 µm cell strainers, washed with DMEM media 
(supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin 
(GIBCO)), and any remaining red blood cells were lysed. Single cell suspensions were 
used for subsequent flow cytometry staining.  
 
2.3.4 Analysis of human BAL fluid and lung 
Human bronchoalveolar lavage samples were obtained as residual material from clinical 
procedures from nine patients undergoing routine surveillance bronchoscopies during 
the first year following lung transplant.	  Patients were on a regimen of immunomodulatory 
drugs following lung transplant, including tacrolimus and prednisone in addition to either 
mycophenolate or azathioprine. Use of human BAL samples for research purposes was 
approved by the University of Pennsylvania IRB and carried out in accordance with 
protocols for use of residual clinical material with waiver of consent. 
Human lung tissue was obtained from cadaver organ donors in collaboration with 
the New York Organ donor network (NYODN, New York, NY).  Consent was obtained for 
use of lung tissue from human cadavers for research purposes. Lung tissue was cut into 
small pieces with a curved scissor and subsequently incubated at 37 °C with shaking for 
1 h in collagenase solution (1 mg/ml Collagenase D, 1 mg/ml Trypsin Inhibitor and 25 
µg/ml DNAse I). The tissue was then mechanically dissociated using a gentleMACS 
Dissociator (Miltenyi Biotech) and strained with a wire mesh tissue sieve. Remaining 
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connective tissue was then removed by passing the cell suspension through a syringe 
column fitted with glass wool.  Lymphocytes were subsequently separated by 
centrifugation through Ficoll (LSM, Invitrogen).    
For analysis of ILC populations, single cell suspensions of BAL fluid and lung 
parenchyma were stained with the following monoclonal antibodies for flow cytometric 
analysis: ST2 FITC (B4E6; MD Bioproducts), CD3 PerCP-Cy5.5 (SK7; BD Pharmigen, 
intracellular staining), CD11b APC (MI/70; eBioscience), CD19 eFluor 450 (HIB19; 
eBioscience), CD25 PE-Cy7 (M-A251) BD Pharmigen), CD56 Alexa Fluor 700 (CMSSB; 
BD Pharmigen), CD127 eFluor 780 (eBioRDR5; eBioscience), CD11c PE-Cy5 (B-ly6) 
BD Pharmigen) and TCRαβ PE-Cy5 (IP26; eBioscience), live/dead aqua stain 
(Invitrogen). Samples were acquired on a BD LSRII flow cytometer (BD Biosciences) 
and analyzed using FlowJo software (v9.2, Tree Star).  
 
2.3.5 RNA isolation and Real-Time Quantitative PCR 
RNA was isolated from purified populations of CD90+ CD25+ lung ILCs, CD90+ CD4+ 
splenic LTi cells or B220+ splenic B cells, sorted using a BD FACSAria (BD Biosciences) 
cell sorter. RNA was isolated using RNeasy mini kit according to manufacturer’s 
instructions (QIAGEN).  cDNA was generated using Superscript reverse transcription 
(Invitrogen).  Real-time quantitative PCR (qRT-PCR) was performed on cDNA using 
SYBR green master mix (Applied Biosystems) and commercially available primer sets 
(QIAGEN).  Reactions were run on a real-time PCR system (ABI7500; Applied 
Biosystems).  Samples were normalized to β-actin and displayed as a fold induction 
relative to expression seen in purified B cells (Id2 and Rorc) or naïve lung tissue (Areg, 
Il5 and Il13). 
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2.3.6 Cytokine ELISA 
CD90+ CD25+ T1/ST2+ lung ILCs were sort-purified from the lungs of C57BL/6 mice 
using a BD FACSAria cell sorter. 2 x 104 lung ILCs were cultured in DMEM complete 
media in the presence of 10 ng/ml rmIL-7, 10 ng/ml rIL-2, and/or 30 ng/ml rmIL-33 (for 
measurement of IL-5, IL-13 and amphiregulin) or 50 ng/ml rmIL-23 (for measurement of 
IL-17A) for four days (all recombinant cytokines obtained from R&D Systems). 
Supernatants were collected after 4 days of culture. For measurement of amphiregulin in 
whole tissue, lung tissues from naïve or PR8 influenza-infected mice were homogenized 
in sterile PBS and centrifuged to remove cell debris. Measurement of IL-5, IL-13 and IL-
17A were performed using commercially available ELISA kits (eBioscience). 
Amphiregulin was measured using DuoSet ELISA Kit (R&D Systems).  
 
2.3.7 Influenza infection, antibody treatments and cytokine administration 
For infections with PR8 influenza virus, C57BL/6 or Rag1-/- mice were anaesthetized with 
2.5% Avertin i.p. and infected with 0.5 LD50 PR8-GP33 virus (recombinant virus 
expressing the LCMV epitope GP33) in 25µl volume administered intransally. PR8-GP33 
influenza virus was grown and titered as previously described(Decman	   et	   al.,	   2010).	  
The replication and pathogenicity of this recombinant PR8 strain was not substantially 
different from nonrecombinant virus39.	  	  
For monoclonal antibody treatments, anti-CD90.2 mAb (30H12) and anti-NK1.1 
mAb (PK136) were purchased from BioXCell (West Lebanon, NH). Anti-IL-33R mAb 
(anti-ST2 clone 245707) was purchased from R&D Systems. All mAb treatments were 
administered i.p. every 3 days at a dose of 200 µg/mouse starting on the day prior to 
infection. 
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For cytokine treatments, recombinant murine IL-13 or amphiregulin (R&D 
Systems) was administered i.p. every 2 days at a dose of 5-10 µg starting on the day of 
infection. 
 
2.3.8 ILC adoptive transfer 
1x105 Lin- CD90+ CD25+ T1-ST2+ ILCs were sort-purified from the lungs of naïve CD90.1 
wild-type mice and transferred intravenously into anti-CD90.2 mAb-treated Rag1-/- mice 
at day 0 and day 5 post influenza virus infection (0.5 LD50 PR8).  
 
2.3.9 Lung histological sections 
Left lobes of lungs were perfused and fixed with 4% paraformaldehyde, embedded in 
paraffin, and 5 µm sections were used for staining with H&E. 
 
2.3.10 Measurement of Pulse Oximetry 
The MouseOxTM Pulse-oximeter (Starr Life Sciences) was used to measure blood SpO2 
in PR8-infected mice during the course of infection. A depilatory agent (Nair, Church & 
Dwight Co.) was applied to the neck of anesthetized mice 2 days prior to influenza 
infection to remove hair and delay future hair growth. For readings, the oximeter clip was 
placed on the neck and percent SpO2 was measured each second over several minutes, 
data shown is average of SpO2 readings recorded over 3-5 min per mouse. 
 
2.3.11 Measurement of BAL fluid protein concentration 
Bronchoalveolar lavage fluid was collected from naïve or PR8-infected mice using the 
following method. A small cut was made in the trachea and a thin tube was inserted. 
Lungs were lavaged using 500 µl PBS and fluid was immediately placed on ice. BAL 
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fluid was spun down to pellet cells and cell-free supernatant was collected. 
Measurement of total protein was performed using a Micro BCA protein assay (Pierce 
Thermo Scientific) according to manufacturer’s instructions.   
 
2.3.12 Influenza virus quantification 
Lung tissue was homogenized and RNA was isolated using RNeasy mini kit according to 
manufacturer’s instructions (QIAGEN).  cDNA was generated using MultiScribe reverse 
transcription (Invitrogen).  Real-time quantitative PCR (qRT-PCR) was performed on 
cDNA using FAM/TAM system (Applied Biosystems). Primers and Taqman probe were 
generated that were specific for M1 protein of PR8-GP33 influenza virus. Reactions 
were run on a real-time PCR system (ABI7500; Applied Biosystems).  Viral RNA 
concentration (ng per gram of lung tissue) in each sample was determined by 
comparison to a standard curve of PR8-GP33 virus RNA concentrations and converted 
to µl of virus per gram of lung tissue. The TCID50 of PR8-GP33 per µl of virus was 
determined with a plaque assay on Madin-Darby canine kidney (MDCK) cell monolayers 
as previously described39. The TCID50 per µl of virus was then multiplied by the µl of 
virus present in the lung tissue to determine the TCID50 equivalence. 
 
2.3.12 Statistical analysis 
Results represent the mean ± SEM unless indicated otherwise.  Statistical significance 
was determined by unpaired Student’s t test. Statistical analyses were performed using 
Prism GraphPad software v5.0.  (*,P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
 
 
	   46	  
2.4 Results 
2.4.1 Lung-resident ILCs phenotypically resemble natural helper cells and 
nuocytes 
To examine whether ILCs are present at extra-intestinal mucosal sites, we performed 
flow cytometric analysis of cells isolated from the lung tissues of naive wild-type 
C57BL/6 or Rag1-/- mice. We identified a population of lineage negative (Lin-) cells that 
lacked expression of lineage markers associated with T cells (CD3, CD5, TCRβ, CD27), 
B cells (B220), macrophages (CD11b), dendritic cells (CD11c) or NK cells (NK1.1).  
These Lin- cells expressed CD90 (Thy1), CD25 (IL-2Rα) and CD127 (IL-7Rα) (Fig. 4A), 
a pattern of surface marker expression consistent with ILCs (Saenz et al., 2010a; Spits 
and Di Santo, 2011). Further examination of these Lin- CD90+ CD25+ lung ILCs revealed 
a lack of expression of either CD4 or NKp46 (Fig. 4B), thus distinguishing lung-resident 
ILCs from conventional ILC3 subsets (CD4+ LTi cells or NKp46+ ILCs (Spits and Di 
Santo, 2011)). However, lung ILCs did express the activation markers CD44 and ICOS 
as well as Sca-1 and c-kit (Fig. 4B), similar to the phenotype of nuocytes and 
NHCs(Moro et al., 2010; Neill et al., 2010). Furthermore, CD90+ CD25+ lung ILCs 
expressed the IL-33R subunit T1/ST2 (Fig. 4B). This Lin- population of ILCs was a 
relatively rare population, totaling 2-3 x104 cells in naïve mice, representing 0.4-1% of 
total live cells in the lung (Fig. 4C). Collectively, these data indicate that lung-resident 
ILCs most closely resemble nuocytes and NHCs, which were originally reported to be 
present in secondary lymphoid tissue and fat-associated lymphoid clusters (FALCs) 
(Moro et al., 2010; Neill et al., 2010). Collectively, these cell populations are now 
referred to as Group 2 ILCs (ILC2s). 
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2.4.2 ILCs are present in human lung and airways 
Recent studies have described heterogeneous populations of ILC3 LTi-like cells and 
NKp46+ cells that express IL-17A and/or IL-22 located in human lymphoid tonsil and 
Peyer’s patch tissues (Cella et al., 2009; Cella et al., 2010; Crellin et al., 2010b; Cupedo 
et al., 2009; Hughes et al., 2010). However, whether human ILC populations exist at 
other barrier surfaces such as the respiratory tract and what surface markers they 
express had not yet been examined. Similar to findings in mice, we identified a Lin- 
population of cells in previously healthy human lung parenchymal tissue from organ 
donors that lacked expression of markers for T cells (CD3, TCRαβ), dendritic cells 
(CD11c), NK cells (CD56), macrophages (CD11b) or B cells (CD19), but that expressed 
CD127 (IL-7Rα) (Fig. 5A). The Lin- CD127+ ILC population in the lung parenchyma 
expressed CD25 (IL-2Rα) and the IL-33R subunit ST2 (Fig. 5B), consistent with the cell 
surface phenotype of the lung-resident ILC population found in mouse lung (Fig. 5A,B) 
and previously identified members of the ILC2 subset including murine nuocytes and 
NHCs (Moro et al., 2010; Neill et al., 2010). To determine if an analogous ILC2 
population exists in the airway, we examined bronchoalveolar lavage (BAL) fluid from 
lung transplant recipients. Similar to the population of ILC2s found in lung parenchyma, 
we identified a Lin- CD127+ ILC population that also expressed CD25 and ST2 in BAL 
fluid from 7 of 9 lung transplant recipients examined (Fig. 5C,D). Thus, these data 
provide evidence of NHC/nuocyte-like ILC2 populations in human respiratory tissue.  
 
2.4.3 Lung-resident ILCs produce IL-5 and IL-13 but not IL-22  
Recent studies demonstrated that nuocytes and NHCs can be activated by IL-33 alone 
or in combination with IL-7 to produce IL-5 and IL-13 (Moro et al., 2010; Neill et al., 
2010).  While stimulation of sort-purified CD90+ CD25+ T1/ST2+ lung ILCs with IL-2 and 
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IL-7 had no apparent effect on IL-5 or IL-13 cytokine secretion, the addition of IL-33 
resulted in elevated production of both IL-5 and IL-13 (Fig. 6A,B). Unlike CD4+ splenic 
LTi (ILC3) cells (Fig 6C) or NKp46+ ILC3s (Satoh-Takayama et al., 2008; Sonnenberg et 
al., 2011; Takatori et al., 2009), CD90+ CD25+ lung ILCs expressed minimal IL-22 or IL-
17A in response to IL-23 stimulation (Fig. 6C,D). Consistent with in vitro IL-33 
stimulation, administration of recombinant (r)IL-33 in vivo resulted in an elevated 
frequency of lung-resident ILCs that produced the TH2 cell-associated cytokines IL-5 and 
IL-13, but not the TH1 cell-associated cytokine interferon-γ (IFN-γ) (Fig. 6E). Taken 
together, these results indicate that ILCs in the respiratory tract share a cell surface 
phenotype and cytokine profile that most closely resembles nuocytes and NHCs (ILC2s). 
 
2.4.4 Lung ILC development requires Id2 but not commensal microbial-derived 
signals 
Members of the ILC family including LTi cells, NKp46+ ILCs and NHCs share a 
developmental requirement for the transcriptional regulator Id2 (Boos et al., 2007; Moro 
et al., 2010; Satoh-Takayama et al., 2010; Yokota et al., 1999). To examine the 
influence of Id2 on the development of lung-resident ILCs, expression of Id2 was 
examined in sort-purified lung CD90+ CD25+ ILCs. Quantitative analysis of Id2 mRNA 
expression revealed comparable abundance of Id2 mRNA in lung-resident ILCs and 
conventional splenic CD4+ LTi (ILC3) cells (Fig. 7A), a population known to be Id2-
dependent (Boos et al., 2007; Satoh-Takayama et al., 2010; Yokota et al., 1999). 
Consistent with a developmental requirement for Id2, lung resident CD90+ CD25+ ILCs 
were not detectable in chimeric mice deficient in Id2 (Fig. 7B), thereby developmentally 
linking this cell population to the Id2-dependent ILC family. 
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  Based on their expression of the transcription factor RORγt, GATA3 and T-bet, 
ILCs can be divided into multiple populations, one of which is critically dependent on 
RORγt for development (LTi cells, NKp46+ ILCs) and the others that are RORγt-
independent (including nuocytes and NHCs) (Spits and Di Santo, 2011). Compared to 
splenic LTi cells, lung ILCs did not express abundant RORγt (Rorc) mRNA  (Fig. 7C) or 
protein (Fig. 7D, providing further evidence that lung ILCs are more closely related to 
nuocytes and NHCs (ILC2s) than LTi or NKp46+ ILC populations (ILC3s).  
Signals derived from commensal bacterial communities have also been 
implicated in the development and/or activation of several ILC subsets (Sanos et al., 
2009; Satoh-Takayama et al., 2008; Sawa et al., 2011). To test whether live commensal 
bacterial-derived signals influenced the development of lung-resident ILCs, we examined 
ILCs in the lungs of conventional (CNV) or germ-free (GF) C57BL/6 mice. CNV and GF 
mice had similar frequencies (Fig. 8A-B), total numbers (Fig 8C), and surface phenotype 
of lung ILCs (Fig. 8D), indicating that development of lung ILCs is dependent on Id2 but 
independent of signals derived from live commensal bacteria. 
 
2.4.5 Influenza virus induces ILC responses in the lung 
ILCs have been shown to mediate anti-bacterial or anti-helminth immunity in the 
intestine (Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2010b; 
Satoh-Takayama et al., 2008; Sonnenberg et al., 2011); however, the functional 
significance of ILCs in regulating immunity and/or inflammation in the lung is not well 
understood. To investigate whether lung ILCs can influence immunity, inflammation or 
tissue homeostasis in the lung, we utilized a model of respiratory infection with mouse-
adapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8). Wild-type mice control viral 
replication and recover following infection with this dose of PR8 (0.5 LD50 or ~300 
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TCID50) and although Rag1-/- mice are unable to clear infection and eventually succumb 
within 12-14 days, the early ILC response and pathologic consequences of infection, 
including the decline in lung function and lung immunopathology, were similar in 
immunocompetent and immunodeficient hosts (Fig 9A-C). In response to intranasal PR8 
infection, CD90+ CD25+ ILCs accumulated in the lung parenchyma in both wild-type 
C57BL/6 and Rag1-/- mice (Fig. 9D-F). Taken together, these data demonstrate that 
ILCs respond to influenza virus infection in the lung in the presence or absence of the 
adaptive immune system, suggesting a potential role for lung ILCs in regulating innate 
immunity, inflammation and/or tissue homeostasis in the lung. 
 
2.4.6 ILC depletion impairs lung function and tissue repair 
While both cellular and humoral arms of the adaptive immune system have been shown 
to be crucial for immunity to respiratory viruses, the influence of innate cell populations 
on anti-viral immunity in the lung remains poorly understood (Kohlmeier and Woodland, 
2009). To examine the influence of lung ILCs on innate immunity to influenza virus, 
isotype or anti-CD90.2 depleting monoclonal antibodies (mAb) were administered in vivo 
to PR8-infected Rag1-/- mice (Fig 10A). As some NK cells can also express CD90.2 
upon activation, an additional group of mice was treated with anti-NK1.1 mAb to allow 
direct comparison of anti-CD90.2-mediated depletion of ILCs versus anti-NK1.1-
mediated depletion of NK cells.  Administration of anti-CD90.2 antibody effectively 
depleted the CD90+ CD25+ population of ILCs in the lung (Fig. 10B). Depletion of 
CD90.2+ ILCs or NK1.1+ NK cells did not affect viral loads in the lung compared to 
isotype treated mice (Fig. 10C), suggesting that neither NK cells nor ILCs directly 
contribute to innate control of viral replication. However, mice that received anti-CD90.2 
mAb exhibited a substantially lower mean body temperature at day 10 post infection 
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(p.i.) (Fig. 10D), indicating exaggerated thermo-dysregulation and morbidity in the 
absence of CD90.2+ ILCs. Strikingly, depletion of CD90.2+ ILCs resulted in significantly 
decreased lung function as measured by pulse oximetry (Pulse Ox), reaching average 
blood oxygen saturation levels below 54% in anti-CD90.2 treated mice at day 9 p.i. 
compared to 76% in isotype-treated controls (Fig. 10E). Furthermore, depletion of 
CD90.2+ ILCs significantly impaired epithelial integrity, as measured by increased total 
protein concentration in the BAL fluid compared to isotype or anti-NK1.1 treated mice 
(Fig. 10F).  
Influenza is a cytopathic virus that replicates preferentially in airway epithelial 
cells and causes severe acute injury to the respiratory epithelium (Kohlmeier and 
Woodland, 2009). Although isotype-treated or NK cell-depleted Rag1-/- mice eventually 
succumb to infection between day 13-14 due to the absence of an adaptive immune 
response (data not shown), they generated hyperplastic epithelial and goblet cell 
responses essential for repair of the damaged airway epithelial barrier (Fig. 11A-B). In 
contrast to isotype or anti-NK1.1 mAb treatment, depletion of CD90.2+ ILCs resulted in 
an impaired ability to generate hyperplastic epithelial cell responses (Fig. 11C) and led 
to substantial epithelial degeneration and necrosis (black arrows), including in many 
cases the complete sloughing of the bronchiolar epithelial lining (Fig. 11C-D). This 
epithelial necrosis was unlikely to be due to anti-CD90.2 mAb treatment affecting the 
epithelia directly, as bronchioles in anti-CD90.2 mAb-treated naïve mice had normal 
epithelial cell lining (Fig. 11E) similar to untreated naïve mice (Fig. 11F).  Collectively, 
these observations indicate a critical role for CD90.2+ ILCs in promoting airway epithelial 
integrity and restoring tissue homeostasis in the lung following acute viral infection.  
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2.4.7 Lung ILCs are sufficient to restore airway integrity 
CD90 is expressed on a number of hematopoietic and non-hematopoietic cell lineages 
(Bradley et al., 2009). To directly test whether lung-resident ILCs were the cell 
population responsible for promoting tissue remodeling following influenza virus 
infection, we performed adoptive transfer experiments of congenically disparate CD90.1+ 
lung ILCs into PR8-infected, anti-CD90.2-depleted Rag1-/- mice. This system allowed for 
the selective depletion of endogenous CD90.2+ ILCs while leaving the transferred 
population of CD90.1+ lung ILCs unaffected. Analysis of lung tissue by flow cytometry at 
10 days p.i. indicated that while anti-CD90.2 mAb effectively abolished host CD90.2+ ILC 
responses in treated mice (Fig. 12A), a population of donor CD90.1+ ILCs could be 
detected (Fig. 12B). CD90.2-depleted mice receiving transferred CD90.1+ ILCs exhibited 
higher mean body temperature at day 10 p.i. compared to mice receiving anti-CD90.2 
mAb alone, suggesting that adoptively transferred ILCs can ameliorate influenza-virus 
induced morbidity (Fig. 12C). Additionally, analysis of blood oxygen saturation levels 
revealed that delivery of CD90.1+ lung ILCs effectively restored lung function to levels 
equivalent to isotype-treated mice (Fig. 12D). Similar to isotype-treated controls (Fig 
12E), anti-CD90.2 treated mice receiving CD90.1+ ILCs exhibited regions of epithelial 
proliferation within the bronchioles (Fig. 12G, black arrows) indicative of a beneficial 
tissue remodeling response, which was largely absent in mice receiving anti-CD90.2 
treatment alone (Fig. 12F, gray arrows). Collectively, these data provide evidence that 
the lung ILC population, not another CD90-expressing cell type, was critical for 
promoting respiratory tissue remodeling following influenza virus infection. 
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2.4.8 ILC-mediated repair is independent of IL-13  
 
Previous studies demonstrated that IL-13 can promote epithelial cell and goblet 
cell proliferation as well as epithelial mucin production in the context of airway 
inflammation and fibrosis (Crosby and Waters, 2010; Doherty and Broide, 2007; Wilson 
and Wynn, 2009). To test the hypothesis that ILC-derived IL-13 may be required to 
promote tissue homeostasis following influenza virus infection, rIL-13 was administered 
to anti-CD90.2-treated Rag1-/- mice. Although IL-13 protein could be detected in BAL 
fluid (Fig. 13A) and goblet cell hyperplasia was observed in the bronchioles of rIL-13-
treated animals confirming biological activity of the rIL-13 cytokine in the lung (Fig. 13B, 
black arrows), anti-CD90.2-depleted mice receiving rIL-13 had severely decreased blood 
oxygen saturation levels similar to mice receiving anti-CD90.2 mAb alone (59% 
compared to 62%, respectively) (Fig 13C). Furthermore, mice receiving anti-CD90.2 
alone or in combination with rIL-13 suffered severe influenza-induced morbidity, 
succumbing to infection four days earlier than isotype-treated mice (day 9 vs. day 13 p.i.) 
(data not shown). Taken together, these results indicate that rIL-13 is not sufficient to 
restore lung function in ILC-depleted mice, suggesting that lung ILCs may employ IL-13-
independent mechanisms to promote lung tissue homeostasis.   
 
2.4.9 IL-33-IL-33R signaling is critical for lung ILC responses 
Given the ability of lung ILCs to respond to IL-33 stimulation (Fig. 6B,E) and previous 
studies demonstrating that IL-33 is upregulated in the lung during influenza virus 
infection (Chang et al., 2011; Le Goffic et al., 2011b), we next sought to test whether IL-
33–IL-33R signaling was required for ILC-dependent maintenance of airway epithelial 
integrity. Anti-IL-33R (anti-T1/ST2) mAb or PBS was administered to wild-type mice 
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following influenza virus infection. Blockade of IL-33–IL-33R signaling resulted in a 
significant decrease in both frequency and total cell number of CD90+ CD25+ ILCs in the 
lungs of anti-IL-33R treated mice compared to PBS treated controls (Fig. 14A-C). 
Additionally, lung function was severely impaired, with blood oxygen saturation levels 
reaching 68% in anti-IL-33R treated mice compared to 79% in PBS treated controls (Fig. 
14D). Histological examination of lung parenchyma revealed regions of epithelial cell 
necrosis and bronchial degeneration within the airways of anti-IL-33R treated mice at 
day 10 p.i. (Fig. 14E-F) indicative of severe damage to the airway epithelial barrier 
similar to the results observed when ILCs were depleted with anti-CD90.2 mAb (Fig. 
12C). Taken together, these results confirm the ILC depletion studies and further 
demonstrate that a treatment that severely impairs lung ILC responses can compromise 
tissue repair and lung function in wild-type mice.   
 
2.5 Discussion 
A number of studies have identified heterogeneous ILC populations in the murine and 
human intestine and implicated a role for these cell populations in regulating immunity 
and inflammation in the gut (Saenz et al., 2010a; Spits and Di Santo, 2011). The data 
presented in this Chapter identify a population of ILCs constitutively present in the 
respiratory tract of humans and mice and demonstrate a novel function for murine lung 
ILCs in regulating airway epithelial barrier integrity and tissue homeostasis following 
influenza virus-induced pulmonary damage.   
 The ILC family in mice is remarkably heterogeneous and includes at least three 
main cell subsets found in lymphoid and intestinal tissues that exhibit distinct 
developmental requirements and patterns of effector cytokine expression (Saenz et al., 
2010a; Spits and Di Santo, 2011). While the nomenclature of ILC family members has 
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been greatly complicated by the simultaneous discovery of similar cell types across 
multiple laboratories, the current dogma classifies ILCs into three main subsets, ILC1, 
ILC2 and ILC3 (Spits et al., 2013). In this Chapter, we show that the development of 
lung-resident ILCs in mice is Id2-dependent and that these cells express a panel of cell 
surface markers characteristic of the Group 2 ILC subset (ILC2s), including CD90, 
CD25, CD127 and the IL-33R T1/ST2. Furthermore, lung-resident ILCs produced IL-5 
and IL-13 in response to IL-33 stimulation, but notably did not make high amounts of IL-
22 or IL-17A following culture with IL-23. The cell surface phenotype and cytokine profile 
of these lung-resident ILCs indicate that they most closely resemble NHCs or nuocytes, 
cell types originally identified within the gut-associated lymphoid tissue and fat-
associated lymphoid clusters and now referred to as ILC2s (Moro et al., 2010; Neill et 
al., 2010; Saenz et al., 2010a; Spits and Di Santo, 2011). Since the completion of 
studies outlined in this Chapter, new reports have emerged demonstrating the existence 
of phenotypically similar ILC2 populations throughout multiple anatomical sites, including 
skin and adipose tissue (Hams et al., 2013; Kim et al., 2013a; Roediger et al., 2013; 
Salimi et al., 2013). While these cells share common phenotypic and developmental 
requirements, the extent to which each population may possess distinct activation and 
functional characteristics unique to each tissue microenvironment remains incompletely 
understood. 
 In humans, previous studies identified RORγt+ ILC3 populations in the tonsils and 
Peyer’s patches that share a phenotype and cytokine profile similar to murine LTi cells 
and NKp46+ ILC3s (Cella et al., 2009; Cella et al., 2010; Crellin et al., 2010b; Cupedo et 
al., 2009; Hughes et al., 2010). In this report, we provide the first identification of an ILC 
population in the human respiratory tract and lung parenchyma. Human lung ILCs 
expressed CD25, CD127 and ST2 (IL-33R), indicating they are a nuocyte/NHC-like ILC2 
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population. Therefore, like murine ILCs, the human ILC family exhibits heterogeneity in 
tissue distribution, phenotype and functional capacity across different tissue sites. 
Examining other lymphoid and mucosal-associated tissues may lead to the identification 
of additional ILC-like cells and provide critical insight into the regulation of human ILC 
populations. Since the publication of the data in this Chapter 2, there has been a 
multitude of studies identifying ILC2s in BAL from patients with Idiopathic Pulmonary 
Fibrosis (IPF) (Hams et al., 2014), polyps from patients with allergic rhinosinusitis 
(Mjosberg et al., 2012), skin from patients with atopic dermatitis (Kim et al., 2013a), and 
blood from asthmatic patients (Bartemes et al., 2014). Importantly, however, the tissue 
distribution, phenotype and function of ILC2s in non-diseased human tissue remains 
largely unexplored and would provide critical ‘baseline’ information for understanding 
how these cells become dysregulated during disease. 
While previous studies have implicated murine ILC2s in promoting TH2 cytokine-
dependent anti-helminth immunity (Moro et al., 2010; Neill et al., 2010; Saenz et al., 
2010a; Spits and Di Santo, 2011), in this Chapter we identify a role for ILCs in repairing 
airway epithelial integrity and maintaining lung tissue homeostasis. While this study 
utilizes influenza virus as a model of severe lung injury, it is important to note that lung 
injury is a key feature of many diseases besides viral infections, for example COPD, 
ARDS, Sarcoidosis, asthma, allergy and others (Crosby and Waters, 2010; Rock and 
Hogan, 2011). Despite the high incidence of lung damage occurring in these diseases, 
the cellular and molecular mechanisms involved in effective versus ineffective lung 
repair and tissue remodeling remain poorly understood. The identification of lung ILCs 
as an important cell type regulating tissue homeostasis not only implicates a new 
hematopoietic cell type in orchestration of non-hematopoietic cell repair/regeneration, 
but also reveals previously unappreciated functions for the ILC2 lineage. Whether ILC2 
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act directly on airway epithelial cells to direct cellular proliferation and differentiation or 
whether they require interactions with other immune cells to orchestrate tissue repair will 
be addressed in Chapter 3. 
The TH2 cell cytokines IL-5 and IL-13 have also been shown to mediate epithelial 
cell and goblet cell hyperplasia in the lung (Broide, 2008; Doherty and Broide, 2007; 
Wilson and Wynn, 2009).  Although lung-resident ILCs were capable of producing high 
amounts of IL-5 and IL-13 in response to IL-33 stimulation and IL-33-IL-33R signaling 
was required for repair from influenza virus-induced lung damage, the administration of 
IL-13 failed to restore lung function or promote respiratory tissue remodeling in influenza 
virus-infected ILC-depleted mice. These data indicate a critical distinction between the 
tissue repair functions of lung ILCs and the previously described roles other ILC2 
populations (nuocyte and NHC) that are reported to act primarily through IL-13-
dependent mechanisms (Chang et al., 2011; Moro et al., 2010; Neill et al., 2010; Price et 
al., 2010).  It is currently unclear whether this difference indicates a minor role for IL-13 
in the disease context examined here or additional heterogeneity in the functional 
diversity of ILC populations in the lungs.  It is important to note that ILC-derived IL-13 
might play a more prominent role in other airway disease contexts. For example, a 
recent report found a role for ILC2-derived IL-13 using a different H3N1 influenza virus 
infection model that causes airway hyperreactivity early during infection (Chang et al., 
2011). In those studies, however, the ILC2-produced IL-13 contributed to airway 
hyperreactivity suggesting that in some settings the type 2 cytokines produced by lung 
ILC populations might have detrimental effects. Supporting this, the importance of ILC2-
derived IL-13 has also recently been demonstrated in multiple allergic, non-viral models 
of airway inflammation (Barlow et al., 2012; Barlow et al., 2013; Bartemes et al., 2012; 
Halim et al., 2012; Wilhelm et al., 2011). 
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The impact of lung ILC-derived cytokines and tissue remodeling proteins might 
depend on the pattern of lung injury (i.e. different pathogenesis of infectious or 
inflammatory disease) or other environmental factors. Nonetheless, the identification of a 
major pathway of tissue repair coordinated by lung ILCs suggests that these cells, and 
their products, could be targets for therapeutic manipulation in settings of lung infection, 
injury and chronic inflammation. Future studies are needed to define the mechanisms by 
which ILCs regulate tissue repair and to examine whether functionally distinct subtypes 
of ILCs exist in the respiratory tract; this question will be the focus of Chapter 3. It is 
interesting to note that IL-33, as a key alarmin cytokine made by epithelial and immune 
cell lineages, can activate lung ILCs and IL-33-IL-33R signaling was essential for 
recovery from influenza virus infection, indicating that a degree of crosstalk exists 
between the damaged tissue and the ILC population that initiates the repair process. 
Chapter 3 will explore the extent of this crosstalk between epithelial cells and ILCs and 
elucidate the molecular mechanisms employed by ILCs to promote tissue restoration. 
 In summary, the results presented in this report identify a previously 
unrecognized role for lung ILCs in promoting airway epithelial integrity and lung tissue 
homeostasis. In light of these new findings, targeting ILC responses in the airway and 
other tissues may offer new therapeutic potential in the clinical management of tissue 
damage or chronic inflammation. 
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Figure 4: ILCs in the lung phenotypically resemble nuocytes and NHCs 
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Figure 4: ILCs in the lung phenotypically resemble nuocytes and NHCs 
(A) Identification of lung ILCs in C57BL/6 wild-type (WT) and Rag1-/- mice by flow 
cytometry as CD90+ CD25+ CD127+ lineage (Lin) negative cells lacking expression of the 
follow markers: (CD3, CD5, NK1.1, CD27, TCRβ antibodies on the y-axis, B220, CD11b, 
CD11c antibodies on the x-axis). (B) Expression of cell surface markers on Lin- CD90+ 
CD25+ lung ILCs in C57BL/6 WT (blue line) and Rag1-/- mice (red line) compared to 
isotype controls (gray shaded). (C) Absolute number of CD90+ CD25+ ILCs in naïve WT 
or Rag1-/- lung. Data is representative of more than three experiments, n = at least 4 WT 
or Rag1-/- mice. 
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Figure 5: Lin- CD127+ CD25+ ST2+ ILCs in human lung and airways  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Lin- CD127+ CD25+ ST2+ ILCs in human lung and airways 
(A,C) Flow cytometric gating strategy for identifying CD127+ Lin- ILCs (CD3- TCRαβ- 
CD11c- CD11b- CD19- CD56-) in human lung parenchyma tissue (lower lobe) (A) or 
bronchoalveolar lavage (BAL) fluid (C), plots gated on live cells. (B,D) Expression of 
CD25 and ST2 on lineage negative CD127+ human lung parenchyma cells (B) and BAL 
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cells (D) (black line) compared to FMO controls (gray shaded). FMO = fluorescence 
minus one. For examination of human BAL, data shown is representative of 7 of 9 lung 
transplant recipient patients examined. Data from lung parenchyma is representative of 
more than four cadaver tissue donors. 
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Figure 6: Lung ILCs resemble nuocytes/natural helper cells in cytokine profile 
 
 
 
Figure 6: Lung ILCs resemble nuocytes/natural helper cells in cytokine profile 
(A) Flow cytometry plots of pre-sort and post-sort purity of CD90+ CD25+ T1-ST2+ WT 
lung ILCs, gated on live, lineage negative cells. (B) IL-5 and IL-13 cytokine secretion 
from flow sorted CD90+ CD25+ T1-ST2+ lung ILCs cultured with IL-2 + IL-7 alone or in 
combination with IL-33 for four days, measured by ELISA. (A-B) Data is representative 
of three independent experiments, n = 3 replicates, each replicate consisting of ILCs 
sorted from 5 pooled lungs. (C) Intracellular cytokine staining for IL-22 and IL-17A in Lin- 
CD90+ CD25+ lung ILCs or spleen CD90+ CD4+ LTi cells from WT mice, stimulated with 
50 ng/ml rIL-23 (12 h) + PMA and Ionomycin (4 h). (D) IL-17A cytokine secretion from 
flow sorted CD90+ CD25+ T1-ST2+ lung ILCs or spleen CD90+ CD4+ LTi cells cultured 
A B 
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with IL-2 + IL-7 alone or in combination with IL-23 for four days, measured by ELISA. 
Data is representative of two independent experiments, n = 3 replicates, each replicate 
consisting of ILCs sorted from 3 pooled lungs or spleens.  (E) Intracellular cytokine 
staining in Lin- CD90+ CD25+ lung ILCs from WT mice treated with 500 ng rIL-33 for 7 
days in vivo and stimulated with PMA + Ionomycin (4 hours) ex vivo. (C,E) Data is 
representative of 2 or more experiments, n = 3-4 mice.  
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Figure 7: Lung ILCs require Id2 for development but do not express RORγt  
 
 
 
 
 
 
 
 
 
 
Figure 7: Lung ILCs require Id2 for development but do not express RORγt  
(A,C) mRNA expression of Id2 (A) or RORc (C) in sort purified Lin- CD90+ CD25+ lung 
ILCs and Lin- CD90+ CD4+ splenic LTi cells, normalized to β-actin and shown relative to 
expression levels in purified B220+ B cells. n = 3 replicates, each replicate consisting of 
spleens (LTi cells) or lungs (ILCs) pooled from 5 C57BL/6 WT mice. (B) Flow cytometry 
plots of CD90+ CD25+ lung ILCs in WT or Id2-deficient bone marrow chimeras sacrificed 
10 weeks post reconstitution, gated on live Lin- donor cells. Data is representative of 3 
experiments, n = 2-4 Id2+/+ or Id2-/- chimeras. (D) Flow cytometry plot of RORγt 
expression in CD90+ CD25+ lung ILCs (dashed black line) or CD90+ CD4+ LTi cells (solid 
black line) compared to isotype antibody control (gray shaded). Data is representative of 
at least 3 experiments with n = 2-4 mice. 
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Figure 8: Lung ILCs develop independently of commensal microbial signals 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Lung ILCs develop independently of commensal microbial signals 
(A) Representative flow cytometry plots, total frequency, and absolute cell number of 
lung Lin- CD90+ CD25+ ILCs in conventional C57BL/6 (CNV) or germ-free (GF) mice. (B) 
Cell surface expression of c-kit, CD127, and T1-ST2 on Lin- CD90+ CD25+ lung ILCs in 
CNV (blue line) or GF (red line) mice compared to isotype controls (gray shaded). Data 
is representative of 2 independent experiments. Data shown are the mean ± SEM, n = 3-
5 CNV or GF mice.   
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Figure 9: Induction of lung ILC responses in influenza virus-infected wildtype and  
Rag1-/- mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Induction of lung ILC responses in influenza virus-infected wildtype and  
Rag1-/- mice 
(A-C) WT C57BL/6 or Rag1-/- were infected 0.5 LD50 PR8 i.n. and assessed for weight 
loss (A) and lung function by pulse oximetry (B). (C) Lung histological sections from 
naïve, WT or Rag1-/- mice at day 10 p.i., stained with H&E. Representative flow 
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cytometry plots (D) and frequency (E-F) of Lin- CD90+ CD25+ ILCs in the lung 
parenchyma of naïve or intranasally infected (0.5 LD50 PR8) C57BL/6 WT mice (day 16 
p.i.) (E) and Rag1-/- mice (day 10 p.i.) (F). Data shown is combination of 5 experiments, n 
= 3-5 mice per experiment. Scale bar = 100 µm. Data shown are the mean ± SEM. ** 
P < 0.01. 
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Figure 10: Depletion of CD90+ ILCs during influenza infection results in reduced 
lung function and compromised epithelial integrity  
 
 
 
Figure 10: Depletion of CD90+ ILCs during influenza infection results in reduced 
lung function and compromised epithelial integrity  
(A) Experimental schematic of Rag1-/- mice infected with 0.5 LD50 PR8 i.n. on D0 and 
treated with 200 µg of isotype, anti-NK1.1, or anti-CD90.2 mAb i.p. on D-1, D2, D5 and 
D8 p.i. and sacrificed day 10 p.i. (B) Representative flow cytometry plots of Lin- CD90+ 
CD25+ ILCs in the lungs of antibody-treated Rag1-/- at day 10 p.i. (C) PR8 viral copies 
per gram of lung tissue at day 10 p.i. from infected, untreated WT mice or from infected, 
antibody-treated Rag1-/- mice, measured by quantitative PCR and expressed as TCID50 
per gram, dashed line = limit of detection. (D) Body temperature measured in naïve mice 
and infected Rag1-/- at day 10 p.i. (E) Percentage blood oxygen saturation (SpO2) over 
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the course of PR8 infection. (F) Quantification of total protein present in the 
bronchoalveolar lavage (BAL) fluid at day 10 p.i., Data is representative of 3 or more 
independent experiments n = 3-4 mice per group. Data shown are the mean ± SEM. * 
P < 0.05, ** P < 0.01, *** P < 0.001.  
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Figure 11: Lung ILC depletion impairs airway epithelial repair after influenza virus 
infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Lung ILC depletion impairs airway epithelial repair after influenza virus 
infection 
(A-F) H&E staining of lung tissue from PR8-infected isotype (A), anti-NK1.1 (B), or anti-
CD90.2 (C) treated Rag1-/- mice, day 10 p.i. Scale bar, 50 µm. (A,B) Black arrows 
indicate goblet cell hyperplasia and white arrows indicate epithelial cell hyperplasia. (C) 
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Black arrows denote regions of epithelial shedding/necrosis within the bronchioles. (D) 
Histological score of respiratory epithelial degeneration. H&E stained lung sections from 
day 10 p.i. PR8-infected antibody-treated Rag1-/- mice were blindly graded on a scale of 
0-10 for degree of bronchial/bronchiolar epithelial degeneration and necrosis. (E-F) H&E 
staining of lung tissue from anti-CD90.2 treated naive mice (E) and untreated naive mice 
(F). Scale bar = 50 µm. Data is representative of 3 or more independent experiments n = 
3-4 mice per group. Data shown are the mean ± SEM. *** P < 0.001.  
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Figure 12: Adoptive transfer of lung-resident ILCs promotes tissue remodeling in 
anti-CD90.2-depleted mice 
  
 
Figure 12: Adoptive transfer of lung-resident ILCs promotes tissue remodeling in 
anti-CD90.2-depleted mice  
(A-G) Rag1-/- mice were infected with 0.5 LD50 PR8 i.n. on D0 and treated with 200 µg of 
isotype or anti-CD90.2 mAb i.p. on D-1, D2, D5, and D8 p.i. and sacrificed day 10 p.i. 
One group of anti-CD90.2-treated mice also received 1 x 105 FACS-sorted Lin- CD90.1+ 
CD25+ T1/ST2+ lung ILCs i.v. at D0 and D5 p.i. (A-B) Flow cytometry plots of 
endogenous Lin- CD90.2+ CD25+ ILCs (A) and donor Lin- CD90.1+ T1/ST2+ ILCs (B) in 
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the lungs of antibody-treated Rag1-/- at day 10 p.i.. (C) Body temperature measured in 
naïve mice and infected Rag1-/- at day 10 p.i. (D) Percentage blood oxygen saturation 
(SpO2) over the course of PR8 infection. (E-G) H&E staining of lung tissue from PR8-
infected isotype (E), anti-CD90.2 (F), or anti-CD90.2 + CD90.1 lung ILCs (G) treated 
Rag1-/- mice, day 10 p.i. Scale bar, 50 µm. Black arrows indicate epithelial cell 
hyperplasia and gray arrows denote regions of epithelial shedding/necrosis within the 
bronchioles. Scale bar = 50 µm. (A-G) Data is representative of 2 independent 
experiments n = 3-4 mice per group. Data shown are the mean ± SEM. * P < 0.05, ** P < 
0.01, *** P < 0.001.	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Figure 13: Administration of recombinant IL-13 fails to restore lung function in 
ILC-depleted mice 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 13: Administration of recombinant IL-13 fails to restore lung function in 
ILC-depleted mice 
(A-C) Rag1-/- mice were infected with 0.5 LD50 PR8 influenza virus and treated with 
isotype mAb, anti-CD90.2 mAb or anti-CD90.2 + rIL-13 (5-10 µg i.p. every 2 days 
A 
C 
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starting at D0). (A) Measurement of IL-13 protein in the BAL fluid, N.D. not detected. (B) 
Histological analysis of lung tissue from antibody-treated mice at 10 days p.i. Black 
arrows denote regions of goblet cell hyperplasia. Scale bar = 50 µm. (C) Measurement 
of blood oxygen saturation levels by pulse oximetry. Data is representative of 2 
independent experiments, n = 4 mice. Data shown are the mean ± SEM. * P < 0.05 
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Figure 14: Blockade of IL-33R signaling impairs lung function and airway repair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Blockade of IL-33R signaling impairs lung function and airway repair. 
(A-F) C57BL/6 WT mice received 200 µg anti-IL-33R (ST2) mAb or PBS every 3 days 
following infection with 0.5 LD50 PR8. Representative flow cytometry plots (A) and 
frequency and cell number (B,C) of CD90+ CD25+ ILCs in the lung of antibody-treated 
WT mice at 10 days p.i. (D) Pulse oximetry measurement of blood oxygen saturation 
levels. (E-F) H&E staining of lung tissue from PR8-infected PBS-treated mice (E) or anti-
IL-33R-treated mice (F) at day 10 p.i. Black arrows indicate epithelial cell hyperplasia 
and gray arrows denote regions of epithelial shedding/necrosis within the bronchioles. 
Scale bar = 100 µm. Data is representative of 3 independent experiments n = 3-4 mice 
per group. Data shown are the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.	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Chapter 3 
The amphiregulin-epidermal growth factor receptor pathway orchestrates  
repair of airway epithelial cells 
 
3.1 Abstract 
In Chapter 2 we demonstrated that ILC2s could promote tissue homeostasis following 
influenza virus-induced lung injury, although the mechanisms underlying ILC-dependent 
tissue repair remain undefined. In this Chapter we identify that lung ILC2s express 
multiple genes associated with tissue repair pathways, including the epidermal growth 
factor family member amphiregulin (AREG). AREG was increased during influenza virus-
induced lung injury and ILC depletion during infection resulted in decreased AREG 
expression, reduced lung function and impaired airway remodeling. IL-33, not IL-25, 
promoted expression of AREG in lung ILCs and administration of AREG effectively 
restored airway tissue remodeling in ILC-depleted mice, suggesting that ILC-intrinsic 
AREG is a central mediator of epithelial repair. Supporting this, chemical or genetic 
inhibition of the endogenous EGFR-AREG pathway during influenza virus infection 
resulted in severely impaired lung function and a failure to restore airway tissue 
homeostasis, leading to increased host mortality. Mechanistically, infection with 
influenza virus induced EGFR activation specifically in bronchiolar airway epithelial Clara 
cells in an ILC2-dependent manner, suggesting that ILC2s directly orchestrate repair of 
the airway epithelial barrier to promote host recovery. Taken together, these data 
uncover novel innate pathway critical for host recovery from influenza virus infection in 
which cytokine signals from the injured tissue instruct ILC2-mediated repair of the airway 
epithelial barrier via AREG-EGFR signaling. 
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3.2 Introduction 
 
The mammalian barrier surfaces of the skin, lung and intestinal tract are continually 
exposed to microbial, physical and environmental insults, which can lead to tissue injury 
and inflammation (Artis, 2008; Maloy and Powrie, 2011; Rescigno, 2011). The processes 
of tissue repair and remodeling that occur following acute injury or infection require a 
delicate balance between promoting beneficial regenerative responses that support 
epithelial cell proliferation while also acting to limit these responses once the tissue has 
been adequately repaired (Crosby and Waters, 2010; Rackley and Stripp, 2012; Turner, 
2009). The failure to initiate or resolve these repair responses can have detrimental 
effects on the host, resulting in either loss of tissue integrity and function or promotion of 
chronic inflammation and fibrosis, as observed in multiple inflammatory diseases of the 
respiratory tract including chronic obstructive pulmonary disease (COPD), idiopathic 
pulmonary fibrosis (IPF) and Sarcoidosis (Crosby and Waters, 2010; Kaser et al., 2010; 
Wilson and Wynn, 2009). Therefore, delineating the mechanisms that direct tissue repair 
and remodeling could identify new therapeutic targets to improve treatment of multiple 
chronic inflammatory diseases.  
A degree of crosstalk exists between the epithelial barrier and the mammalian 
immune system in which damaged epithelial cells release cytokine signals such as 
interleukin (IL)-25, IL-33 and thymic stromal lymphopoetin (TSLP) that activate sentinel 
immune cell populations (Oliphant et al., 2011; Saenz et al., 2010a; Ziegler and Artis, 
2010). Reciprocally, the immune system is integral to orchestrating epithelial repair and 
maintenance of tissue homeostasis at these barrier sites, providing key cytokines and 
growth factors that modulate epithelial cell function. For example, cytokines associated 
with type 2 inflammatory responses such as IL-13 can directly impact barrier function by 
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inducing epithelial cell proliferation, differentiation and survival (Akiho et al., 2005; Chiba 
et al., 2009; Shim et al., 2001). More broadly, the evolution of type 2 immune responses 
has been proposed to have originated as a host-protective response in mediating wound 
healing following tissue damage by parasites (Allen and Maizels, 2011; Gause et al., 
2013; Maizels et al., 2009), although the precise mechanisms underlying type 2 immune 
cell-driven tissue repair are not yet fully understood.  
It is now well appreciated that host recovery from cytopathic viruses like influenza 
A requires not only viral clearance mediated by the adaptive immune system, but also 
successful tissue repair of the damaged lung tissue in order to restore epithelial barrier 
integrity (Fukushi et al., 2011; Kohlmeier and Woodland, 2009; Peiris et al., 2010; 
Rackley and Stripp, 2012). However, the factors that regulate this process are poorly 
understood. In Chapter 2 we demonstrated a critical role for lung ILC2s in promoting 
tissue homeostasis following influenza virus-induced lung injury, although the precise 
mechanism underlying ILC-dependent tissue repair remained undefined. In this Chapter, 
we identify that lung ILC2s express multiple genes associated with tissue repair 
pathways, including the epidermal growth factor family member amphiregulin (AREG). 
AREG was increased during influenza virus-induced lung injury and ILC depletion during 
infection resulted in decreased AREG expression, reduced lung function and impaired 
airway remodeling while addition of recombinant AREG could restore these defects in 
ILC-depleted mice. Further, endogenous AREG-EGFR interactions were essential for 
epithelial repair and host recovery from influenza virus-induced lung damage, revealing 
a previously unrecognized role for EGFR signaling during respiratory viral infection. 
Remarkably, ILC2-intrinsic AREG expression alone was sufficient to restore tissue 
homeostasis, revealing a critical non-redundant role for these innate cells. Virus-induced 
lung damage resulted in activation of EGFR specifically in the bronchiolar airway 
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epithelial Clara cells, not in the alveolar epithelium, suggesting that ILC2-derived AREG 
may act directly on the airway barrier to orchestrate restoration of tissue homeostasis. 
Taken together, these data indicate a critical role for group 2 ILCs in mediating lung 
tissue homeostasis though an IL-33-AREG-EGFR axis and suggest that ILCs serve as a 
key link between the signaling pathways of Type 2 inflammation and tissue repair.  
 
3.3 Methods 
3.3.1 Mice 
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Rag1-/- 
and EGFRvel/+ mice were purchased from the Jackson Laboratory and bred in house. 
Areg-/- mice were provided by Dietmar Zaiss (University of Edinburgh, UK) and had been 
backcrossed to C57BL/6 for over 14 generations before arrival. All mice were maintained 
in specific pathogen-free facilities at the University of Pennsylvania. All protocols were 
approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee (IACUC), and all experiments were performed according to the guidelines of 
the University of Pennsylvania IACUC.  
 
3.3.2 Flow Cytometry 
Single cell suspensions were stained with a combination of the following monoclonal 
fluorescently conjugated antibodies: FITC-conjugated FceR1; PE-conjugated CD127; 
PerCP-Cy5.5-conjugated CD3, CD5, NK1.1, CD11b; biotinylated T1/ST2 (IL-33R) (MD 
Bioproducts); APC streptavidin; eFluor-450-conjugated CD127; PE-Cy7-conjugated 
CD25; Alexa 700-conjugated CD90.2 (Biolegend); e-Fluor-780-conjugated CD11c, 
TCRβ, B220; PE-Texas Red-conjugated CD4, CD11b (Invitrogen); eFluor 605NC CD45; 
eFluor 650NC CD45, CD4. All antibodies were purchased from eBioscience unless 
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specified otherwise. For measurement of intracellular cytokine expression, cells were 
isolated ex vivo and stimulated with PMA and ionomycin for four hours in the presence 
of brefeldin A. Cells were subsequently surface stained with a combination of the 
antibodies listed above, fixed and permeabilized using a commercially available kit (BD 
Cytofix/Cytoperm, BD Biosciences), and stained with IL-13 FITC (eBioscience), IL-5 PE 
(eBioscience) and AREG Alexa Fluor 647 (AREG rat anti-mouse monoclonal mAb (clone 
206220, R&D Systems) conjugated to Alexa Fluor 647 according to manufacturer's 
instructions (Molecular Probes)). For measurement of intracellular transcription factor 
expression, cells were isolated directly ex vivo, stained with antibodies against surface 
antigens, fixed and permeabilized according to manufacturer’s instructions 
(Foxp3/Transcription Factor Staining Buffer Set, eBioscience) and stained with GATA3 
PE (eBioscience) and Foxp3 eFluor 450 (eBioscience). For all stains, dead cells were 
excluded from analysis by means of a viability stain (Live/Dead Fixable Aqua stain, 
Invitrogen). Samples were acquired on a BD LSRII flow cytometer (BD Biosciences) and 
analyzed using FlowJo software (v9.2, Tree Star). 
 
3.3.3 Isolation of cells from mouse lung tissue 
Lungs were perfused with 10 ml PBS through the right ventricle of the heart prior to 
removal. Lungs were then cut into small pieces using scissors and digested with 1 mg/ml 
Collagenase D (Roche) in PBS for 30-45 min at 37 °C with vortexing every 10 min. 
Samples were mashed through 70 µm cell strainers, washed with DMEM media 
(supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin 
(GIBCO)), and any remaining red blood cells were lysed. Single cell suspensions were 
used for subsequent flow cytometry staining.  
 
	   83	  
3.3.4 RNA isolation and Real-Time Quantitative PCR 
RNA was isolated from purified populations of CD90+ CD25+ lung ILCs, CD90+ CD4+ 
splenic LTi cells or B220+ splenic B cells, sorted using a BD FACSAria (BD Biosciences) 
cell sorter. RNA was isolated using RNeasy mini kit according to manufacturer’s 
instructions (QIAGEN).  cDNA was generated using Superscript reverse transcription 
(Invitrogen).  Real-time quantitative PCR (qRT-PCR) was performed on cDNA using 
SYBR green master mix (Applied Biosystems) and commercially available primer sets 
(QIAGEN).  Reactions were run on a real-time PCR system (ABI7500; Applied 
Biosystems).  Samples were normalized to β-actin and displayed as a fold induction 
relative to expression seen in naïve lung tissue (Areg, Il5 and Il13). 
 
3.3.5 ELISA 
CD90+ CD25+ T1/ST2+ lung ILCs were sort-purified from the lungs of C57BL/6 mice 
using a BD FACSAria cell sorter. 2 x 104 lung ILCs were cultured in DMEM complete 
media in the presence of 10 ng/ml rmIL-7, 10 ng/ml rIL-2, and/or 30 ng/ml rmIL-33 (for 
measurement of IL-5, IL-13 and amphiregulin) or 50 ng/ml rmIL-23 (for measurement of 
IL-17A) for four days (all recombinant cytokines obtained from R&D Systems). 
Supernatants were collected after 4 days of culture. For measurement of amphiregulin in 
whole tissue, lung tissues from naïve or PR8 influenza-infected mice were homogenized 
in sterile PBS and centrifuged to remove cell debris. Amphiregulin protein levels were 
measured using DuoSet ELISA Kit (R&D Systems) and normalized to tissue weight.  
 
3.3.6 Influenza virus infection, antibody treatments and EGFR inhibitor 
administration 
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For infections with PR8 influenza virus, C57BL/6 wildtype, EGFRvel/+, EGFR+/+ or Areg-/- 
mice were anaesthetized with Avertin i.p. and infected with 0.5 LD50 PR8-GP33 virus 
(recombinant virus expressing the LCMV epitope GP33) in 25µl volume administered 
intransally. PR8-GP33 influenza virus was grown and titered as previously described 
(Decman et al., 2010). The replication and pathogenicity of this recombinant PR8 strain 
was not substantially different from nonrecombinant virus (Decman et al., 2010).	   For 
monoclonal antibody treatments, anti-CD90.2 mAb (30H12) was purchased from 
BioXCell (West Lebanon, NH) and administered i.p. every 3 days at a dose of 200 
µg/mouse starting on the day prior to infection. Anti-AREG mAb (clone 206220, R&D 
Systems) was administered in sterile PBS intraperitoneally (i.p.) every 2 days at a dose 
of 300 µg/mouse starting on the day of infection. For chemical inhibition of EGFR 
signaling, AG1478 (Calbiochem) was reconstituted in 100% DMSO to aid in 
solubilization and further diluted in 1 ml sterile PBS for injection. 10 mg/kg of AG1478 or 
vehicle control was administered i.p. every 2 days starting at the time of PR8 infection.  
 
3.3.7 In vivo cytokine treatments 
For examination of intracellular cytokine production, 300 ng of recombinant murine IL-25 
or IL-33 (carrier-free, R&D Systems) in sterile PBS was administered intraperitoneally 
(i.p.) into C57BL/6 wildtype mice daily for six days and cytokine expression was 
assessed on day seven. For cytokine treatments during influenza infection, recombinant 
murine IL-13 or amphiregulin (R&D Systems) was administered i.p. every 2 days at a 
dose of 5-10 µg starting on the day of infection. 
 
3.3.8 ILC2 adoptive transfer 
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C57BL/6 wild-type mice were treated i.p. with IL-7 complexes (2 µg rIL-7 + 15 µg anti-IL-
7 M25 antibody) every 2 days for 1 week. Recombinant murine IL-7 (carrier-free) was 
purchased from R&D Systems, and anti-human IL-7 M25 antibody was kindly provided 
by Amgen Inc. Lin- CD45+ CD90+ CD25+ T1/ST2+ ILC were sort-purified from the lungs 
of IL-7 complex-treated mice using a BD FACSAria and 1 x 105 ILC2 were transferred 
intravenously into Areg-/- mice on days 0, 4 and 7 after PR8 infection.   
 
3.3.9 Tissue histological sections 
For PR8 influenza experiments, left lobes of lungs were inflated and fixed with 4% 
paraformaldehyde, embedded in paraffin, and 5 µm sections were used for staining with 
hematoxylin and eosin or were used for immunohistochemical staining of 
phosphorylated EGFR (p-EGFR, Tyr1068). In brief, slides were deparaffinized with 
xylene and changes of 100%, 95%, 80%, 70% ethanol followed by water. Endogenous 
peroxidase activity was removed using 180 ml methanol with 3 ml of 30% hydrogen 
peroxide. Antigen retrieval was performed in 1 mM EDTA buffer pH 8 in a microwave 
oven. Blocking of non-specific binding was achieved with Avidin D-Biotin blocking 
reagent kit (Vector Elite Laboratories) and incubation in 5% goat serum. Primary 
antibody (phospho-EGFR Tyr1068 XP rabbit mAb (Cell Signaling)) was diluted 1:800 in 
diluent (SignalStain Antibody Diluent, Cell Signaling). Isotype control rabbit IgG XP mAB 
(Cell Signaling) was used at an equivalent concentration. Slides were then incubated 
with rabbit anti-biotin secondary antibody diluted in goat serum block solution. Slides 
were incubated with HRP-conjugated Avidin Biotin Complex reagent (Vector Elite 
Laboratories) and signal was developed using DAB Substrate Kit for Peroxidases. Slides 
were counter-stained with hematoxylin, rehydrated with ethanol and mounted with a 
coverslip for imaging.  
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3.3.10 Measurement of Pulse Oximetry 
As previously described (Monticelli et al., 2011), the MouseOxTM Pulse-oximeter (Starr 
Life Sciences, Oakmont PA) was used to measure blood SpO2 in PR8-infected mice 
during the course of infection. A depilatory agent (Nair, Church & Dwight Co.) was 
applied to the neck of anesthetized mice 2 days prior to influenza infection to remove 
hair and delay future hair growth. For readings, the oximeter clip was placed on the neck 
and percent SpO2 was measured each second over several minutes. Data shown are 
the average of steady SpO2 readings recorded over 3-5 minutes per mouse. 
 
3.3.11 Measurement of protein in BAL fluid 
Bronchoalveolar lavage fluid was collected from naïve or PR8-infected mice using the 
following method: a small cut was made in the trachea, a thin tube was inserted, the 
lungs were lavaged using 500 µl PBS, and fluid was immediately placed on ice. BAL 
fluid was spun down to pellet cells and cell-free supernatants were collected. 
Measurement of total protein was performed using a Micro BCA protein assay (Pierce 
Thermo Scientific) according to manufacturer’s instructions. 
 
3.3.12 Microarray gene expression profiling 
 Lin- CD90+ CD25+ ILCs and Lin- CD90+ CD4+ LTi cells were sorted from the lungs 
(ILC2) and spleens (LTi cell) of naïve C57BL/6 wild-type mice. Four biological replicates 
were collected, each consisting of 15,000-20,000 cells sorted from 6 pooled lungs (ILCs) 
or 10 pooled spleens (LTi cells) to >97% purity.  Cells were sorted directly into TRIzol LS 
(Invitrogen). mRNA was isolated, amplified, and hybridized to Affymetrix GeneChips 
(Mouse Gene 1.0ST). 
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3.3.13 Data Normalization and Differential Gene Expression Profiling 
Affymetrix Power Tools software was used to process and quantile normalize fluorescent 
hybridizaiton signals using the Robust Multichip Averaging (RMA) method (Irizarry et al., 
2003). Transcripts were log2 normalized and technical replicates were averaged for fold-
change analysis. Using the ClassNeighbors module of GenePattern, genes were ranked 
by the signal-to-noise ratio and class-biased genes were identified by permutation 
testing (Reich et al., 2006). Genes were considered differentially expressed if the fold-
change was > 2, P < 0.05.  
 
3.3.14 GO Enrichment Analysis 
Differentially expressed genes (fold-change >2) in both the naïve lung ILC2 and naïve 
splenic ILC3 (LTi) transcriptional profiles were uploaded to the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) (Huang da 
et al., 2009), and Fischer’s exact test was used to identify significantly enriched Gene 
Ontology (GO, http://www.geneontology.org) terms (Huang da et al., 2009). (Full list of 
enriched genes for specific GO terms listed in available in Table 1).  
 
3.3.15 Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (GSEA) was performed using the Broad Institute program 
(http://www.broadinstitute.org/gea/index.jsp) as described previously (Subramanian et 
al., 2005). Published gene expression arrays of whole lungs divided into either “control” 
or “LPS-treated” groups were downloaded from Gene Expression Omnibus (GEO, 
www.ncbi.nlm.nih.gov/geo/)_ENREF_34	   (Altemeier et al., 2005). The normalized 
enrichment score (NES) and q-value were calculated for enrichment of the top 100 
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differentially expressed genes from the ILC naïve data sets (as previously defined using 
the ClassNeighbors signal-to-noise ratio) between the publically accessible gene arrays 
(described above). (Leading-edge genes listed in Table 2.) 
 
3.3.16 Statistical analysis 
Results represent the mean ± SEM unless indicated otherwise.  Statistical significance 
was determined by unpaired Student’s t test. Statistical analyses were performed using 
Prism GraphPad software v5.0.  (*,P < 0.05; **, P < 0.01; ***, P < 0.001). 
 
3.4 Results 
3.4.1 Wound healing genes are enriched in ILCs 
To investigate potential mechanisms by which lung ILC2s influence maintenance of 
airway epithelial integrity or restoration of lung tissue homeostasis, we performed 
genome-wide transcriptional profiling of lung-resident ILC2s. CD90+ CD25+ lung ILC2s 
and CD90+ CD25+ CD4+ splenic ILC3s (also referred to as adult lymphoid tissue inducer 
(LTi) cells) were sort-purified from the lungs or spleens of naïve C57BL/6 mice and 
mRNA isolated from these populations was then hybridized to Affymetrix GeneChips for 
genome-wide transcriptional profiling. Examination of the top 100 genes differentially 
expressed in lung ILC2s compared to spleen ILC3s illustrated substantial differences 
between these two ILC populations (Fig. 15A). Splenic ILC3 cells were characterized by 
high expression of CD4, CCR6, IL-23R and RORγt, in agreement with previous studies 
(Sonnenberg et al., 2011; Takatori et al., 2009), while the top transcripts in the lung ILCs 
included the ST2 receptor IL1Rl1, IL-25 receptor IL-17Rb, and the cytokines IL-2 and IL-
5 (Fig. 15B).  In addition, within the top 100 genes expressed in lung ILC2s, there was 
striking expression of multiple genes associated with tissue remodeling, including genes 
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encoding the extracellular matrix proteins decorin, asporin and dermatopontin as well as 
epidermal growth factor family members like amphiregulin (Fig. 15B).  Analysis of the 
differentially expressed genes between lung ILC2 versus splenic ILC3 populations using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) revealed a 
transcriptional signature of lung ILC2s that was significantly enriched in pathways 
regulating wound healing, immune defense responses, inflammatory responses and cell 
proliferation (Fig. 15C and Table 1). In contrast, splenic ILC3s were significantly 
enriched in processes associated with hematopoietic and lymphoid organ development, 
immune responses, and cell activation (Fig. 15C and Table 1). 
Gene Set Enrichment Analysis (GSEA) was then employed to compare the gene 
expression signature of lung ILC2s with previously reported models of lung damage or 
inflammation.  Direct comparison of the lung ILC2 gene set with a previously published 
data set examining the effects of lipopolysaccharide (LPS)-induced acute lung injury 
(Altemeier et al., 2005) revealed enrichment of the transcriptional signatures of lung 
ILC2s in the LPS-treated group compared to PBS-treated controls, consistent with a 
signature of tissue damage and wound repair (Fig. 15D). Further analysis of the 
transcripts which most contributed to the bias toward the LPS-treated group (denoted by 
the ‘leading edge’) revealed the presence of the gene amphiregulin (Areg). Thus, this 
epidermal growth factor, which was highly expressed in the lung ILC2 gene expression 
profile, is one of the strong “driver genes” in this enrichment pattern (Fig. 15D and Table 
2). Collectively, these results represent the first genome-wide transcriptional profiling of 
lung ILC2s and demonstrate clear gene signatures of wound healing in the lung ILC2 
population. 
 
 
	   90	  
3.4.2 IL-33, but not IL-25, stimulates ILC2-intrinsic amphiregulin expression 
Amphiregulin is a member of the EGF family of growth factors that has been implicated 
in regulating tissue remodeling and repair in the context of acute epithelial injury and 
asthma (Dolinay et al., 2006; Enomoto et al., 2009; Fukumoto et al., 2010).  Quantitative 
qPCR analysis confirmed the microarray results demonstrating high expression of 
amphiregulin mRNA by lung ILC2s compared to splenic ILC3s (Fig. 16A). Further, 
stimulation of sort-purified CD90+ CD25+ T1-ST2+ lung ILC2s with IL-2 and IL-7 in 
combination with IL-33 resulted in elevated production of amphiregulin protein compared 
to culture with IL-2 and IL-7 alone (Fig. 16B). In addition to IL-33, previous studies have 
also demonstrated that IL-25 can activated ILC2s to produce IL-5 and IL-13 (Monticelli et 
al., 2012; Spits and Cupedo, 2011). However, the differential role of these two cytokines 
in eliciting AREG expression in ILC2s is unknown. To address this question, we 
developed a new staining protocol to allow the first single cell analysis of intracellular 
expression of AREG in ILCs. Wildtype (WT) mice were treated in vivo with PBS, 
recombinant (r)IL-25 or rIL-33 and lung cells were assessed for expression of AREG, IL-
5 and IL-13 by intracellular cytokine staining. Flow cytometric analysis of gated lineage 
negative (Lin-) CD45+ CD90+ T1/ST2+ lung ILC2s revealed minimal expression of AREG, 
IL-5 or IL-13 in PBS-treated mice (Fig. 16C). Although administration of rIL-25 resulted 
in increased IL-5 and IL-13 expression in lung ILC2s consistent with previous reports 
(Barlow et al., 2013; Bartemes et al., 2012), there was no detectable effect on the 
frequency of AREG-expressing ILC2s (Fig. 16C). In striking contrast to PBS or rIL-25 
treatment, rIL-33 elicited robust lung ILC2 responses that consisted of distinct 
heterogeneous populations of ILC2s expressing AREG, IL-5 and/or IL-13 (Fig. 16C). 
Furthermore, multivariate analysis of the composition of cytokine producers within the 
lung ILC population revealed that rIL-33 treatment induced a greater proportion of single- 
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(green pie slice), double- (yellow slice) and triple- (red slice) cytokine-expressing cells 
compared to PBS or rIL-25 treatment (Fig. 16D). Further examination of the cytokine 
distribution among these single, double and triple cytokine producers revealed that the 
majority of IL-33-elicited ILC2s expressed AREG (black arc surrounding the pie graph) 
compared to IL-5 (gray arc) or IL-13 (brown arc) (Fig. 16D).  Collectively, these data 
reveal remarkable heterogeneity in the cytokine profile of lung ILC2s and demonstrate a 
dominant role for the cytokine IL-33, but not IL-25, in eliciting robust AREG expression 
from lung ILC2 in vivo. 
 
3.4.3 Recombinant AREG restores lung function in ILC-depleted mice 
Analysis of lung parenchyma tissue in Rag1-/- mice at 10 days post-influenza virus 
infection revealed a significant increase in amphiregulin mRNA (Fig. 17A) and protein 
expression (Fig. 17B) compared to naïve controls, indicating that AREG expression is 
upregulated in the lung following influenza virus infection and airway damage. Analysis 
of lung tissue from anti-CD90.2 treated mice revealed reduced amphiregulin mRNA in 
the absence of CD90.2+ ILCs (Fig. 17C), indicating that lung ILC2s are a major source 
of AREG in vivo and that secretion of this protein may be one mechanism by which ILCs 
promote airway epithelial integrity and restore lung function.  
To directly test whether delivery of AREG could promote airway epithelial 
integrity and restore lung function following influenza virus-induced damage, 
recombinant AREG was administered to anti-CD90.2 treated PR8-infected Rag1-/- mice 
(Fig. 17D). Mice receiving recombinant AREG exhibited substantially higher mean body 
temperatures (Fig. 17E) and significantly improved lung function compared to anti-
CD90.2 treated controls, reaching blood oxygen saturation levels comparable to isotype-
treated mice at day 9 p.i. (78% vs 80%, respectively) (Fig. 17F). Additionally, mice 
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treated with recombinant amphiregulin exhibited diminished amounts of total protein 
present in the BAL fluid compared to anti-CD90.2-treated controls (Fig. 17G) and 
histologic analysis of lungs from anti-CD90.2-depleted mice receiving recombinant 
AREG revealed regions of epithelial cell hyperplasia and goblet cell proliferation (black 
arrows) within the bronchial airways indicating that recombinant AREG treatment 
promoted restoration of airway epithelial integrity and lung tissue homeostasis (Fig. 17H-
J). Collectively, these data provide both in vitro and in vivo evidence implicating 
amphiregulin as one mechanism by which ILCs can promote tissue homeostasis 
following influenza virus infection. 
 
3.4.4 Endogenous AREG is required for recovery from influenza virus-induced 
lung damage 
IL-33 acts as an alarmin when released upon epithelial cell damage during inflammation 
and infection, as occurs with pathogens like Influenza A virus (Le Goffic et al., 2011a; 
Monticelli et al., 2011). While treatment with exogenous AREG in influenza-infected 
Rag1-/- mice following depletion of ILCs could restore lung epithelial repair (Fig 17) 
whether physiologic levels of endogenous AREG are important for lung tissue repair and 
host recovery in the presence of functional adaptive immune responses remains 
unknown. To test this, we employed a monoclonal antibody (mAb)-mediated approach 
that neutralizes endogenous AREG in vivo. Wildtype mice were infected intranasally with 
0.5 LD50 H1N1 PR8 virus and 300 µg of anti-AREG mAb was administered every 2 days 
starting at the time of infection. Mice were monitored over the course of infection for 
parameters of influenza virus-induced morbidity. Strikingly, neutralization of AREG in 
mice infected with PR8 virus was associated with impaired lung function as measured by 
decreased blood oxygen saturation levels (PulseOX) (Fig. 18A) as well as increased 
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protein levels in the bronchoalveolar lavage (BAL) fluid (Fig. 18B) indicative of impaired 
airway epithelial integrity.  
Additionally, histological examination of lung sections from mice treated with 
isotype antibodies revealed regions of epithelial hyperplasia within the bronchiolar 
airways indicative of mounting a beneficial tissue remodeling response (Fig. 18C). 
However, upon AREG neutralization, there was a failure to efficiently mount this tissue 
reparative response, and many airway bronchioles exhibited complete sloughing of the 
bronchial epithelial lining (Fig. 18C). The failure to promote restoration of the airway 
epithelial barrier correlated with increased host mortality, as anti-AREG mAb-treated 
mice succumbed to infection within 2 weeks while isotype-treated controls survived (Fig. 
198D). Collectively these results demonstrate an essential physiologic role for 
endogenous AREG in regulating lung tissue homeostasis and indicate that a single 
growth factor is a critical component of host survival from influenza virus-induced lung 
damage. 
 
3.4.5 ILC2-intrinsic AREG is sufficient to restore airway epithelial repair in the 
presence of adaptive immunity  
While ILC2s are the predominant innate source of AREG in the lung during influenza 
virus infection (Fig. 17), amphiregulin expression is not exclusively restricted to innate 
cells (Burzyn et al., 2013; Zaiss et al., 2006). Therefore, we next sought to test whether 
ILC2-intrinsic AREG expression alone was sufficient to restore airway epithelial repair 
and tissue homeostasis in a lymphocyte-sufficient setting. To generate sufficient 
numbers of ILC2s to perform adoptive transfers, we expanded the cells in vivo using 
immune complexes consisting of anti-IL-7 and recombinant IL-7, a strategy previously 
used to expand Group 3 ILCs (Schmutz et al., 2009).  Administration of anti-IL-7-rIL-7 
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complexes to wildtype mice resulted in robust expansion of ILC2s in the lung by both 
frequency (Fig. 19A) and cell number (Fig. 19B). Sort-purified lung ILC2s were then 
transferred into AREG-deficient (Areg-/-) hosts during influenza virus infection, and mice 
were examined for parameters of influenza virus-induced morbidity. Although there was 
no intrinsic impairment in lung ILC2 accumulation in Areg-/- mice following influenza virus 
infection (Fig. 20A), consistent with our anti-AREG neutralization studies, mice deficient 
in AREG exhibited severely reduced lung function compared to their WT counterparts 
(Fig. 20B). Strikingly, adoptive transfer of AREG-sufficient ILC2s into Areg-/- mice was 
sufficient to restore blood oxygen saturation levels equivalent to levels observed in WT 
mice (Fig. 20B). Additionally, Areg-/- mice receiving AREG-sufficient ILC2 cells had 
reduced protein in the BAL fluid (Fig. 20C) and exhibited regions of epithelial cell 
hyperplasia in the bronchiolar airways similar to wildtype mice that were largely absent in 
Areg-/- mice (Fig. 20D).  Taken together, these results indicate that ILC2-intrinsic AREG 
is sufficient to promote airway epithelial remodeling and maintenance of tissue 
homeostasis in the presence of adaptive immunity. 
 
3.4.6 Influenza virus-induced lung damage is associated with bronchiolar airway 
epithelial cell-intrinsic EGFR activation in vivo 
Amphiregulin binds to EGFR, inducing a signaling cascade that can lead to the 
proliferation and differentiation of epithelial cells (Burgel and Nadel, 2004; Nadel, 2001). 
However, the in vivo cellular targets of EGFR activity in response to cytopathic 
respiratory pathogens such as influenza virus are unknown. In order to interrogate which 
epithelial cell lineages may be responsive to ILC2-derived AREG in the context of lung 
injury, we performed immunohistochemical staining for phosphorylated EGFR (p-EGFR) 
tyrosine kinase activity (Fig. 21A-C). Naïve mouse lungs exhibited little to no p-EGFR 
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activity in the bronchiolar (BR) airway epithelial cells (Fig. 21D,E), in the endothelial cells 
lining the blood vessels (BV) (Fig. 21D), or the alveolar type 2 pneumocytes in the lung 
parenchyma (Fig. 21D,F). However, upon infection with influenza virus, EGFR activity 
was strongly enhanced, as illustrated by bright p-EGFR staining in the non-ciliated Clara 
cells that comprise the bronchiolar airway epithelial lining (Figure 21G,I). Furthermore, 
the cellular pattern of EGFR activity appeared to be largely restricted to the bronchiolar 
epithelial cells, with only very minor levels of p-EGFR detected on cells within the lung 
parenchyma alveolar spaces (Fig. 21H). Collectively, these results demonstrate that 
EGFR activity is strongly upregulated in vivo following influenza-virus induced lung 
damage and suggest that the primary cellular targets of virus-induced EGFR activation 
are bronchiolar airway, not alveolar, epithelial cells. 
 
3.4.7 ILC depletion abolishes EGFR activity in lung airway epithelial cells 
To test whether ILC2s can influence EGFR activation in the airways during influenza 
virus infection, we utilized the antibody-mediated ILC depletion approach in Rag1-/- mice 
that was introduced in Chapter 3. Consistent with the results observed in wildtype 
C57BL/6 mice (Fig. 21), there was no detectable EGFR phosphorylation in the lungs of 
naïve Rag1-/- mice although EGFR activity was strongly induced upon influenza virus 
infection primarily in the bronchiolar airway epithelium (Fig. 22A-B). Remarkably, 
antibody-mediated depletion of CD90.2+ ILC2s completely abolished EGFR activity in 
the airways of influenza virus-infected Rag1-/- mice at day 10 post infection, as indicated 
by the absence of phosphorylated EGFR staining in the airway epithelium of anti-
CD90.2-treated mice compared to their isotype-treated counterparts (Fig. 22B-C). These 
results reveal a critical, non-redundant role for ILC2s in regulating EGFR activity in the 
bronchiolar airway epithelium following influenza virus-induced lung damage. 
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3.4.8 Constitutive or temporal disruption in EGFR signaling during influenza virus 
infection results in reduced lung function, impaired airway epithelial remodeling 
and increased host mortality 
While the data above provide insight into the cellular targets of the ILC2-AREG-EGFR 
pathway, the in vivo functional significance of EGFR signaling during respiratory viral 
infection has never been examined. To test whether the EGFR signaling pathway is 
critical for recovery from influenza virus-induced lung damage in vivo, we utilized mice 
with a dominant negative mutation in the EGFR tyrosine kinase domain (called velvet) 
that have reduced EGFR activity (Du et al., 2004). Although mice heterozygous for the 
velvet mutation (EGFRvel/+) had no intrinsic defect in ILC2 accumulation in the lung (Fig. 
23A), EGFRvel/+ exhibited severe influenza virus-induced morbidity, including 
exacerbated weight loss (Fig. 23B), reduced blood oxygen saturation levels (Fig. 24C) 
and elevated BAL fluid protein (Fig. 23D) compared to their littermate controls.  
 Furthermore, although naïve EGFRvel/+ mice had a normal bronchiolar airway 
epithelial lining under steady-state conditions (Fig. 23E), upon exposure to influenza 
virus-induced damage EGFRvel/+ mice exhibited sloughing of the epithelial lining and 
failure to initiate proliferative epithelial remodeling responses (Fig. 23F), suggesting that 
EGFR signaling is critical for generating a hyperplastic epithelial response to restore the 
damaged airway barrier. Similar to mice deficient in AREG, EGFRvel/+ exhibited 
increased host mortality, succumbing to infection within 2 weeks (Fig. 23G). Notably, 
temporal disruption of EGFR signaling during the course of infection using the selective 
EGFR tyrosine kinase inhibitor AG1478 (Hartmann et al., 2009) resulted in a similar 
phenotype to that observed in the genetic EGFRvel/+ model, whereby wildtype mice 
treated with AG1478 had impaired lung function (Fig. 24A) and a failure to generate 
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epithelial remodeling responses in the airways (Fig. 24B), resulting in eventual host 
mortality (Fig. 24C).  Collectively, these data reveal that EGFR signaling is an essential 
component of the epithelial remodeling response that restores tissue homeostasis 
following virus-induced injury.  
 
3.5 Discussion 
It is now well appreciated that host recovery from cytopathic viruses like influenza 
A requires not only viral clearance, but also successful tissue repair of the damaged lung 
tissue in order to restore epithelial barrier integrity (Fukushi et al., 2011; Kohlmeier and 
Woodland, 2009; Peiris et al., 2010; Rackley and Stripp, 2012). However, the factors 
that regulate this process are poorly understood.	   In the previous Chapter 2, we 
demonstrated that ILC2s were critical for epithelial repair during influenza infection. Here 
we identify that lung ILC2s express a transcriptional gene signature associated with 
wound healing pathways, including the epidermal growth factor family member AREG, 
and that exogenous AREG could promote lung tissue homeostasis in a lymphocyte-
deficient setting. These data illustrate a novel innate pathway of lung tissue repair but 
also provoke fundamental questions regarding the relevance of the endogenous ILC2-
AREG pathway in the presence of a functional adaptive immune system. The second 
part of this Chapter demonstrates that physiologic levels of a single growth factor, 
AREG, are essential for promoting tissue homeostasis and ultimately influencing host 
morbidity and mortality. Additionally, we provide the first in vivo evidence for EGFR 
signaling regulating lung epithelial repair and host recovery from a respiratory viral 
infection. Remarkably, ILC2-intrinsic AREG expression alone was sufficient to restore 
airway epithelial reparative responses in AREG-deficient mice, highlighting an essential 
role for an innate immune cell-derived growth factor in regulating epithelial cell function.  
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IL-33 acts a cytokine ‘alarmin’ that is released rapidly upon epithelial cell damage 
to activate resident immune cell populations of the lung and intestine (Garcia-Miguel et 
al., 2013; Le et al., 2013; Ohno et al., 2012). Our data demonstrate that IL-33 is a potent 
in vivo stimulus for inducing AREG expression in ILC2s compared to another epithelial 
cell-derived cytokine IL-25. Intriguingly, single cell analysis revealed that IL-33 elicited 
distinct populations of polyfunctional ILC2s that expressed IL-5, IL-13 and/or AREG 
simultaneously, identifying a previously unrecognized degree of potential functional 
heterogeneity in ILC2s that may reflect their differential roles in regulating pro-
inflammatory versus tissue-protective responses at barrier surfaces.  
EGFR is widely expressed in epithelial cell lineages across multiple tissues sites 
although the cellular pattern of EGFR activity depends upon the nature of the 
inflammatory stimulus (Burgel and Nadel, 2004, 2008; Nadel and Burgel, 2001). 
Therefore, in this study we sought to examine the cellular sources of EGFR activity to 
provide insight into the mechanism by which the IL-33-ILC2-AREG pathway influences 
tissue repair. In the case of the lung airways, respiratory viruses can influence EGFR 
activity on stromal cells in vitro (Eierhoff et al., 2010; Ueki et al., 2013), but the in vivo 
cellular targets of EGFR signaling during influenza virus infection have never been 
examined. In this Chapter we demonstrate that EGFR activity is strongly and selectively 
upregulated in the Clara cells lining the bronchiolar airway epithelium, with little to no 
activity in the parenchyma alveolar epithelial cells. Combined with the in vivo 
requirement for EGFR signaling to promote airway epithelial remodeling responses, 
these data are consistent with a model in which ILC2-derived AREG acts on bronchiolar 
airway epithelial Clara cells or on a facultative airway progenitor stem cell population to 
promote cellular proliferation to restore the airway epithelial barrier, although further 
studies are needed to test this directly. Strikingly, data in this Chapter demonstrated that 
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depletion of ILCs was sufficient to completely abolish EGFR phosphorylation in the 
airways of influenza virus-infected mice, thereby revealing an essential and non-
redundant role for ILC2s in regulating EGFR activity in the airways. Collectively, these 
data shed new light on the cellular and molecular mechanisms that regulate lung tissue 
remodeling and repair during infection-induced injury. The question of whether this 
pathway may be conserved in settings of non-infectious tissue damage at extra-
pulmonary barrier surfaces will be the focus of Chapter 4. 
Taken together, these data highlight a mechanism by which the innate immune 
system responds to cytokine cues from damaged epithelia at mucosal surfaces to 
orchestrate repair and restoration of tissue homeostasis through the AREG-EGFR 
pathway. These findings could have important implications for clinical treatment of 
inflammatory diseases of the respiratory tract. For example, pharmaceutical grade 
EGFR inhibitors are a widely used therapeutic treatment for multiple diseases, including 
cancers of the lung and intestine (Busser et al., 2011a; Hartmann et al., 2009; Iyer and 
Bharthuar, 2010). Notably, there have been reports of fatal interstitial lung disease of 
unknown etiology occurring in lung cancer patients treated with EGFR inhibitors (Chou 
et al., 2010; Makris et al., 2007; Wang et al., 2013). Given the role of endogenous EGFR 
signaling in regulating lung tissue repair in murine models, it is possible that the 
inhibition of EGFR signaling may disrupt lung tissue regenerative responses in these 
patients and potentially contribute to development of disease, provoking the need for 
caution in utilizing these therapies. In contrast, in some circumstances such infection 
with cytopathic pathogens, the targeted promotion of the ILC2-AREG-EGFR pathway to 
promote epithelial repair may have therapeutic benefit in improving clinical outcomes in 
multiple chronic infectious and inflammatory diseases of the respiratory tract.    
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Figure 15: Global gene expression profiling of lung-resident ILC2s reveals strong 
enrichment for genes regulating wound healing pathways 	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Figure 15: Global gene expression profiling of lung-resident ILC2s reveals strong 
enrichment for genes regulating wound healing pathways 	  
(A-D) CD90+ CD25+ ILC2s and CD90+ CD4+ ILC3s cells were FACS-sorted from the 
lung (ILC2s) or spleen (ILC3s) of naïve C57BL/6 WT mice. mRNA was isolated, 
amplified, and hybridized to Affymetrix gene chips for microarray analysis. (A) Heat map 
representing gene expression profiles of the top 100 differentially expressed genes in 
lung ILC2s versus spleen ILC3s. Red = high expression, blue = low expression. (B) Heat 
map of key genes highly expressed in lung ILC2s or spleen ILC3s. Red = high 
expression, blue = low expression (C) Gene expression signatures of ILC2s and ILC3 
(genes differentially expressed by two-fold or greater) were examined using Database 
for Annotation, Visualization and Integrated Discovery (DAVID) to identify enriched Gene 
Ontology terms describing biological processes. Shaded boxes represent significant 
enrichment (light gray P > 0.05, black P < 0.0004). (D) Gene Set Enrichment Analysis 
comparing the lung ILC2 gene expression signature with a previously published data set 
examining the effects of LPS-induced acute lung injury. Analysis of the top transcripts in 
the LPS-treated group shows presence of amphiregulin (Areg) (highlighted by arrow). 
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Table 1: GO term gene list enriched in lung ILC2 and splenic ILC3 gene expression 
signatures 
 
        
Lung ILC2 Enriched     Spleen ILC3 Enriched   
regulation of 
cell 
proliferation 
defense 
response 
response 
to 
wounding 
inflammatory 
response 
immune 
response 
hematopoetic 
or lymphoid 
organ 
development 
cell 
activation 
CSF2 CXCL1     CXCL1 CXCL1 IL1F9  STAP1 FYB 
CAV1 RARRES2 NFKBID NFKBID IL1R1 TGFBR1 KLRK1 
FOSL2 NFKBID C3 C3 SUSD2 G6PDX MYO1F 
FGF7 C3 CXCL3 CXCL3 PGLYRP1 RORC RORC 
PTGS2 CXCL3 PPARG CXCL2 CD74 VAV1 SKAP2 
CSF1 PPARG TLR1 TLR1 TMEM173 CD74 VAV1 
PPARG TLR1 CXCL2 PPARG FCER1G HBA-A1 CD74 
NFKBIA CXCL2 GJA1 C1S CD4 ZFP826 CXCR5 
CD24A C1S C1S CD24A BCL6 HBA-A2 VAMP7 
SCGB1A1 PRDX1 TIMP3 TGFB1 CLEC4D CXCR5 PLCG2 
TGFB1 CD24A CD24A CALCA MPA2L MFSD7B FCER1G 
ADA TGFB1 TGFB1 CFH LTB PLCG2 CD4 
CDH5 CALCA CALCA THBS1 LTA, CD4 BCL6 
LIF SH2D1A ARG1 NFKBIZ CD7 BCL6  H2-DMA 
SPRY2 CFH CFH IL6 RAB27A HBB-B1 HDAC9 
GPC3 THBS1 THBS1 IL5 IGH H2-DMA RAB27A 
GATA3 NFKBIZ NFKBIZ CCL21A IL18R1 HDAC9 LTB 
BCL11B IL6 IL6 SERPING1 IRGM1 LTB LTA 
CALCRL IL5 IL5 CCL11 IL23R LTA HELLS 
MYC IL1RL1 CCL21A HIF1A LY96 HELLS  
DPT CCL21A SERPING1 CCR5 IGJ   
KLF5 SERPING1 PLAUR CCR4 MYO1F   
IRS2 COTL1 CCL11 CXCL15 H2-AB1   
AR CCL11 THBD CCR2 VAV1   
IL6 HIF1A HIF1A ALOX5 H2-DMB2   
SPARC PENK CCR5 KDM6B TNFSF8   
PROX1 CCR5 CCR4  PSMB9   
HES1 CCR4 CXCL15  BTLA,   
PRKCQ CXCL15 CCR2  VAMP7   
ADRB2 CCR2 ALOX5   H2-EB1   
CDKN1A ALOX5 PROS  PLCG2   
RBPJ RBPJ KDM6B  H2-AA   
KLF4 KDM6B   GBP4   
BMPR1A    H2-DMA   
NFIB        
IL2        
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Table 2: Top gene transcripts (“leading edge”) in LPS-treated lung GSEA data set 
 
 
GSEA leading edge genes 
Cxcl2 
Tnfaip3 
Myc 
Csf2 
Tiparp 
Fgl2 
Gadd45b 
Cdkn1a 
Chd7 
Ctla2b 
Aim1 
Areg 
Nr4a1 
Ccr2 
Ptgir 
Skil 
Tlr1 
Calca 
Fosl2 
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Figure 16: IL-33 elicits AREG in lung ILC2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: IL-33 elicits AREG in lung ILC2 
(A) mRNA expression of amphiregulin (Areg) in sort-purified CD90+ CD25+ T1/ST2+ lung 
ILC2s compared to CD90+ CD4+ splenic ILC3s. (B) Production of AREG protein by sort-
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purified lung ILC2s stimulated with IL-2, IL-7, +/- IL-33 for four days, as measured by 
ELISA.  (C-D) C57BL/6 wildtype (WT) mice were treated i.p. with PBS, 300 ng rIL-25 or 
300 ng rIL-33 daily for 6 days. (C) Lung cells were stimulated ex vivo with PMA and 
Ionomycin plus brefeldin A for 4 hours and then examined for intracellular cytokine 
expression of IL-5, IL-13 and AREG via flow cytometry. Plots gated on Lin- CD45+ CD90+ 
CD25+ T1/ST2+ lung ILC2. (D) Multivariate analysis of flow cytometric data from (C) 
using SPICE Software. Pie slice color indicates number of cytokines (IL-5, IL-13 or 
AREG) produced by lung ILC2s (blue = 0, green = 1, yellow = 2, red = 3). Pie arcs 
illustrate the distribution of IL-5-, IL-13- and/or AREG-expressing cells within each 
population of single (green pie slice), double (yellow pie slice) or triple (red pie slice) 
cytokine-producing ILC2s. IL-5 (gray arc), IL-13 (brown arc) and AREG (black arc). Data 
is representative of at least 3 independent experiments n = 3-4 mice per group. Data 
shown are the mean ± SEM. ** P < 0.01, *** P < 0.001. 
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Figure 17: AREG restores lung function, barrier integrity and respiratory tissue 
remodeling following influenza virus-induced damage.  
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Figure 17: AREG restores lung function, barrier integrity and respiratory tissue 
remodeling following influenza virus-induced damage 
(A-B) mRNA (A) and protein (B) expression of ammphiregulin in the lung of naïve or 
PR8-infected Rag1-/- mice at day 10 p.i. (C) mRNA expression of Areg in the lung of 
naïve or PR8-infected Rag1-/- mice receiving isotype or anti-CD90.2 mAb (day 10 p.i.). 
(D-J) Rag1-/- mice were infected i.n. with 0.5 LD50 PR8 and treated with isotype, anti-
CD90.2 mAb, or anti-CD90.2 mAb + 5-10 µg recombinant murine AREG i.p. every 2 
days. (D) Representative flow cytometry plots of lung ILC2s in antibody-treated mice. (E) 
Body temperature of antibody-treated mice at day 10 p.i. (F) Percentage blood oxygen 
saturation in antibody-treated mice. (G) Total protein concentration in BAL fluid at day 10 
p.i. (H-J) H&E staining of lung tissue in isotype (H), anti-CD90.2 (I) and anti-CD90.2 + 
AREG (J) treated mice at day 10 p.i. Black arrows indicate epithelial cell hyperplasia and 
gray arrows denote regions of epithelial shedding/necrosis within the bronchioles. Scale 
bar = 50 µm. Data is representative of 2 independent experiments n = 3-4 mice per 
group. Data shown are the mean ± SEM. *P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 18: Endogenous AREG is required for recovery from influenza virus-
induced lung damage   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Endogenous AREG is required for recovery from influenza virus-
induced lung damage     
 (A-D) C57BL/6 WT mice were infected with 0.5 LD50 PR8 i.n. and treated with 300 mg 
of isotype or anti-AREG mAb i.p.every 2 days starting the day of infection. (A) 
Percentage blood oxygen saturation (SpO2) over the course of PR8 infection, as 
measured by pulse oximetry. (B) Quantification of total protein present in the 
bronchoalveolar lavage (BAL) fluid at day 10 post-infection (p.i.), as determined by BCA 
Inf + isotype Inf + !-AREG 
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protein assay. (C) H&E staining of lung tissue from PR8-infected isotype or anti-AREG 
treated mice, day 10 p.i. Scale bar, 50 µm or 100 µm (for enlarged images). (D) Percent 
survival over the course of infection. Data is representative of 2 independent 
experiments n = 3-4 mice per group. Data shown are the mean ± SEM. ** P < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   110	  
Figure 19: anti-IL-7-rIL-7 complexes elicit ILC2s in vivo 
 
 
 
 
 
 
 
 
 
 
Figure 19: anti-IL-7-rIL-7 complexes elicit ILC2s in vivo 
C57BL/6 wild-type mice were treated i.p. with PBS or IL-7 complexes (2 mg rIL-7 + 15 
mg anti-IL-7 M25 antibody) every 2 days for 1 week and assessed for lung ILC2 (A) 
frequency and (B) cell number. Frequency of ILC2 gated as percentage of Lin- CD45+ 
cells. Data are representative of at least 3 independent experiments n = 3-4 mice per 
group. Data shown are the mean ± SEM. ***p < 0.001. 
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Figure 20: ILC2s are sufficient to restore lung function and tissue repair in AREG-
deficient mice following influenza virus-induced lung damage 
 
 
 
Figure 20: ILC2s are sufficient to restore lung function and tissue repair in AREG-
deficient mice following influenza virus-induced lung damage 
(A-D) Areg-/- or WT C57BL/6 mice were infected with 0.5 LD50 PR8 i.n. and 1 x 105 sort-
purified ILC2s from IL-7 complex-treated mice were transferred i.v. into Areg-/- mice at 
day 0, day 4 and day 7 p.i. (A) Frequency of T1/ST2+ CD127+ ILC2 in the lungs of naïve 
and PR8-infected WT and Areg-/- mice at day 10 p.i., gated on Lin- CD45+ cells. (B) 
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Percentage blood oxygen saturation over the course of PR8 infection. (C) Quantification 
of total protein present in the BAL fluid at day 10 p.i. (D) H&E staining of lung tissue from 
PR8-infected WT, Areg-/- or Areg-/- + ILC2, day 10 p.i. Scale bar, 50 µm or 100 µm (for 
enlarged images). Data are representative of 2-3 independent experiments n = 3-4 mice 
per group. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01. 
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Figure 21: EGFR is selectively activated in the airway bronchiolar epithelial cells 
following influenza virus infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: EGFR is selectively activated in the airway bronchiolar epithelial cells 
following influenza virus infection 
(A-I) C57BL/6 WT mice were infected with 0.5 LD50 PR8 i.n. and sacrificed at day 10 p.i. 
(A-C) Validation of p-EGFR staining in influenza virus-infected lung tissue. Lung sections 
from PR8-infected wildtype mice at day 10 post infection and stained without primary 
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antibody (A), or with rabbit IgG isotype control antibody (B) or with phosphorylated 
EGFR (p-EGFR) antibody (Tyr1068). (D-I) Immunohistochemistry staining of 
phosphorylated EGFR (p-EGFR, Tyr1068) in different anatomical lung sections from 
naïve WT mice (D-F) or PR8-infected mice (G-I). BV = blood vessel, BR = bronchiolar 
airway. Scale bar, 50 µm or 100 µm (for enlarged images). Data are representative of 
more than 3 experiments with n = 3 mice. 
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Figure 22: ILC depletion abolishes EGFR activity in lung airway epithelial cells  
 
 
 
 
 
 
 
 
 
 
Figure 22: ILC depletion abolishes EGFR activity in lung airway epithelial cells  
(A-C) Rag1-/- mice were infected with 0.5 LD50 PR8 i.n. and treated with 200 mg of 
isotype or anti-CD90.2 mAb i.p. every 2 days starting the day prior to infection. Mice 
receiving anti-CD90.2 treatment were also given either sort-purified ILC2 cells (day 0 
and day 5 p.i.). Immunohistochemistry staining for phosphorylated EGFR (p-EGFR, 
Tyr1068) in paraffin-embedded lung sections from naïve (A), isotype (B), anti-CD90.2 
(C), anti-CD90.2 + ILC2 treated mice at day 9 p.i. Data are representative of 2-3 
experiments, n = 3-4 mice per group. 
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Figure 23: Constitutive disruption in EGFR signaling during influenza virus 
infection results in reduced lung function, impaired airway epithelial remodeling 
and increased host mortality 
 
 
 
Figure 23: Constitutive disruption in EGFR signaling during influenza virus 
infection results in reduced lung function, impaired airway epithelial remodeling 
and increased host mortality 
 (A-G) EGFRvel/+ and EGFR+/+ littermates were infected with 0.5 LD50 PR8 i.n. (A) 
Frequency of T1/ST2+ CD127+ ILC2 in the lungs at day 10 p.i., gated on Lin- cells. (B) 
Weight loss over the course of infection. (I) Percentage blood oxygen saturation over the 
course of infection. (C) Quantification of total protein present in the BAL fluid at day 10 
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p.i. (E-F) H&E staining of lung tissue from naïve (E) or from PR8-infected infected (F) 
EGFR+/+ and EGFRvel/+ mice at day 10 p.i. Scale bar, 50 µm or 100 µm (for enlarged 
images). (G) Percent survival over the course of infection. Data are representative of at 
least 3 independent experiments n = 3-4 mice per group. Data shown are the mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 24: Temporal disruption in EGFR signaling impairs lung function and 
airway epithelial repair following influenza virus infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Temporal disruption in EGFR signaling impairs lung function and 
airway epithelial repair following influenza virus infection 
 (A-C) C57BL/6 WT mice were infected with 0.5 LD50 PR8 and treated with 10 mg/kg 
EGFR inhibitor AG1478 or vehicle control starting on the day on infection. (A) 
Percentage blood oxygen saturation over the course of infection. (B) H&E staining of 
lung tissue from PR8-infected WT mice treated with vehicle or AG1478, at day 9 p.i. 
Inf + vehicle Inf + AG1478 
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Scale bar, 50 µm or 100 µm (for enlarged images) (C) Percent survival over the course 
of infection. Data are representative of at least 3 independent experiments n = 3-4 mice 
per group. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.  
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Chapter 4 
IL-33 promotes an innate pathway of intestinal tissue repair dependent on 
amphiregulin-epidermal growth factor receptor interactions 
 
4.1 Abstract 
The barrier surfaces of the skin, lung and intestine are constantly exposed to 
environmental stimuli that can result in inflammation and tissue damage, as observed in 
multiple human chronic inflammatory diseases at these tissue sites. IL-33-dependent 
group 2 innate lymphoid cells (ILC2s) are enriched at barrier surfaces and have been 
implicated in promoting inflammation, however the mechanisms underlying the tissue-
protective roles of IL-33 or ILC2s at surfaces such as the intestine remain poorly defined. 
In this Chapter we demonstrate that following activation with IL-33, expression of a 
growth factor amphiregulin (AREG) is a dominant functional signature of gut-associated 
ILC2s. Utilizing a murine model of intestinal damage and inflammation, we demonstrate 
that the numbers of AREG-expressing ILC2s are increased following intestinal injury and 
that genetic disruption of the endogenous AREG-epidermal growth factor receptor 
(EGFR) pathway results in defective repair of the epithelial barrier and exacerbated 
disease. Conversely, therapeutic administration of exogenous AREG was associated 
with reduced intestinal inflammation, less severe disease and enhanced tissue repair. 
Notably, exogenous AREG could ameliorate disease even in the absence of the 
adaptive immune system, revealing a previously unrecognized innate immune 
mechanism of intestinal tissue repair. Further, therapeutic treatment with IL-33 
preferentially elicited ILC2s and ameliorated intestinal disease severity in an AREG-
dependent manner, identifying a critical feedback loop in which cytokine cues from 
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damaged epithelia activate innate immune cells to express growth factors essential for 
the restoration of epithelial barrier function and maintenance of tissue homeostasis.  
 
4.2 Introduction 
A single layer of epithelial cells serves to separate the skin, lung and intestinal tracts 
from exposure to microbial, physical and environmental insults, which can lead to tissue 
injury and inflammation (Artis, 2008; Maloy and Powrie, 2011; Peterson and Artis, 2014; 
Rescigno, 2011). Following host infection or injury, a tissue remodeling response is 
initiated that serves to repair the damaged cells and restore homeostasis. (Crosby and 
Waters, 2010; Rackley and Stripp, 2012; Turner, 2009). In the context of chronic 
diseases like inflammatory bowel disease (IBD), the failure to initiate or resolve these 
repair responses can have detrimental effects on the host, resulting in loss of tissue 
function and promotion of chronic inflammation and fibrosis (Crosby and Waters, 2010; 
Kaser et al., 2010; Wilson and Wynn, 2009). Therefore, delineating the cellular and 
molecular mechanisms that direct tissue repair and remodeling could identify new 
therapeutic targets to improve treatment of multiple chronic inflammatory diseases. 
Crosstalk exists between the epithelial barrier and the mammalian immune 
system in which damaged epithelial cells release cytokine signals such as interleukin 
(IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP) that recruit and activate diverse 
immune cell populations (Oliphant et al., 2011; Peterson and Artis, 2014; Saenz et al., 
2010a; Ziegler and Artis, 2010). In particular, elevated expression of IL-33 and its 
receptor ST2 has been reported in IBD patients (Kobori et al., 2010; Lopetuso et al., 
2012; Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a 
pathologic or tissue-protective role during intestinal injury remains controversial (Duan et 
al., 2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso 
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et al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013; Sedhom et al., 2013), and the 
cellular and molecular mechanisms which act downstream of IL-33 to regulate disease 
severity are unknown. Additionally, the immune system is essential to orchestrating 
epithelial repair and restoration of tissue homeostasis at these barrier sites, producing 
cytokines and growth factors that can directly modulate epithelial turnover and/or 
differentiation. Recently, amphiregulin (AREG), a ligand of the epidermal growth factor 
receptor (EGFR), has emerged as a component of the type 2 inflammatory response in 
the context of intestinal helminth infection (Zaiss et al., 2006), influenza virus-induced 
lung damage (Jamieson et al., 2013; Monticelli et al., 2011) and muscle injury (Burzyn et 
al., 2013). In the context of IBD, dysregulated expression of EGFR family members and 
associated ligands has been reported in patients (Sipos et al., 2005; Sipos et al., 2010) 
and in murine models of intestinal inflammation (Brandl et al., 2010; Yan et al., 2011). 
Despite these advances, however, the cellular sources and functional significance of 
specific EGFR ligands during disease remain poorly understood. 
In Chapter 2 and 3, we demonstrated that a subset of the innate lymphoid cell 
(ILC) family (called group 2 ILCs or ‘ILC2’) were a previously unrecognized cellular 
source of AREG in the respiratory tract and that lung ILC2s were critical for restoration of 
airway epithelial reparative responses following influenza virus-induced damage 
(Monticelli et al., 2011). However, the majority of studies have implicated classical type 2 
cytokines IL-5 and IL-13 in ILC2 function in the lung (Barlow et al., 2012; Barlow et al., 
2013; Bartemes et al., 2012; Chang et al., 2011; Halim et al., 2012; Halim et al., 2014; 
Kim et al., 2012), skin (Kim et al., 2013a; Kim et al., 2013b; Roediger et al., 2013; Salimi 
et al., 2013) and intestine (Camelo et al., 2012; Moro et al., 2010; Neill et al., 2010; Price 
et al., 2010) while a role for ILC2-derived growth factors such as AREG has only been 
described within the lung. Whether ILC2s at other barrier sites such as the intestine can 
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express AREG and what functional significance this may have in regulating intestinal 
inflammation and tissue homeostasis remains unknown.  
In this Chapter, we demonstrate that AREG production is a dominant functional 
signature of gut-associated ILC2s in response to the epithelial cell-derived cytokine IL-
33. Utilizing the dextran sodium sulfate (DSS) model of intestinal damage and 
inflammation where IL-33 is induced, we demonstrate for the first time that AREG-
expressing ILC2s are increased in response to intestinal injury. Genetic disruption of the 
endogenous AREG-EGFR pathway was associated with impaired epithelial barrier repair 
and exacerbated disease while therapeutic administration of AREG limited intestinal 
inflammation and decreased disease severity in both lymphocyte-sufficient and 
lymphocyte-deficient mice, revealing a previously unrecognized innate immune 
mechanism of intestinal repair. Further, therapeutic treatment with IL-33 preferentially 
elicited ILC2s and ameliorated intestinal disease severity in an AREG-dependent 
manner, revealing one mechanism through which cytokine cues from damaged epithelia 
orchestrate immune cells to express growth factors essential for tissue repair and the 
restoration of intestinal homeostasis. 
 
4.3 Methods 
4.3.1 Mice 
C57BL/6 WT mice were purchased from the Jackson Laboratory (Bar Harbor, ME). 
Rag1-/- and EGFRvel/+ mice were purchased from the Jackson Laboratory and bred in 
house at the University of Pennsylvania. Areg-/- mice were provided by Dietmar Zaiss 
(University of Edinburgh, UK) and were backcrossed to C57BL/6 for 14 generations. For 
all DSS experiments, mice were either co-housed littermates or had shared soiled 
bedding for at least two weeks prior to start of DSS exposure. All mice were maintained 
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in specific pathogen-free facilities at the University of Pennsylvania. All protocols were 
approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee (IACUC), and all experiments were performed according to the guidelines of 
the University of Pennsylvania IACUC.  
 
4.3.2 Flow cytometry 
Single cell suspensions were stained with a combination of the following monoclonal 
fluorescently conjugated antibodies: FITC-conjugated anti-FceR1; PE-conjugated anti-
CD127; PerCP-Cy5.5-conjugated anti-CD3, anti-CD5, anti-NK1.1, anti-CD11b; 
biotinylated T1/ST2 (IL-33R) (MD Bioproducts); APC streptavidin; eFluor-450-conjugated 
anti-CD127; PE-Cy7-conjugated anti-CD25; Alexa 700-conjugated anti-CD90.2 
(Biolegend); e-Fluor-780-conjugated anti-CD11c, anti-TCRβ, anti-B220; PE-Texas Red-
conjugated anti-CD4, anti-CD11b (Invitrogen); eFluor 605NC anti-CD45; eFluor 650NC 
anti-CD45, anti-CD4. All antibodies were purchased from eBioscience unless specified 
otherwise. For measurement of intracellular cytokine expression, cells were isolated ex 
vivo and stimulated with PMA and ionomycin for four hours in the presence of brefeldin 
A. Cells were subsequently surface stained with a combination of the antibodies listed 
above, fixed and permeabilized using a commercially available kit (BD Cytofix/Cytoperm, 
BD Biosciences), and stained with anti-IL-13 FITC (eBioscience), anti-IL-5 PE 
(eBioscience) and anti-AREG Alexa Fluor 647 (AREG rat anti-mouse monoclonal mAb 
(clone 206220, R&D Systems) conjugated to Alexa Fluor 647 according to 
manufacturer's instructions (Molecular Probes)). For measurement of intracellular 
transcription factor expression, cells were isolated directly ex vivo, stained with 
antibodies against surface antigens, fixed and permeabilized according to 
manufacturer’s instructions (Foxp3/Transcription Factor Staining Buffer Set, 
	   125	  
eBioscience) and stained with anti-GATA3 PE (eBioscience) and anti-Foxp3 eFluor 450 
(eBioscience). For all stains, dead cells were excluded from analysis by means of a 
viability stain (Live/Dead Fixable Aqua stain, Invitrogen). Samples were acquired on a 
BD LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (v9.2, 
Tree Star) 
  
4.3.3 Isolation of cells from mouse tissue 
For isolation of cells from lymphoid tissues, tissues were pressed through 70 µm cell 
strainers using the plunger of a 3 ml syringe, washed with DMEM Wash Media (DMEM 
supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin 
(GIBCO)), and any remaining red blood cells were lysed (ACK Lysis Buffer, GIBCO). For 
isolation of cells from lung tissue, lungs were perfused with 10 ml PBS through the right 
ventricle of the heart prior to removal. Right lobes of lungs were then cut into small 
pieces using scissors and digested with 2 mg/ml Collagenase D (Roche) in PBS for 30-
45 minutes at 37 degrees with vortexing every 10 minutes. Samples were pressed 
through 70 µm cell strainers, washed with DMEM Wash Media, and any remaining red 
blood cells were lysed. Single cell suspensions were used for subsequent flow cytometry 
staining.  
 
4.3.4 RNA isolation and Real-Time Quantitative PCR 
1 cm length of colon tissue distal to the cecum was flushed out with PBS and placed in 
RNAlater (QIAGEN). Tissue was homogenized in RLT buffer and RNA was isolated 
using RNeasy mini kit according to manufacturer’s instructions (QIAGEN).  cDNA was 
generated using Superscript reverse transcription (Invitrogen).  Real-time quantitative 
PCR (qRT-PCR) was performed on cDNA using SYBR green master mix (Applied 
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Biosystems) and commercially available primer sets (QIAGEN).  Reactions were run on 
a real-time PCR system (ABI7500; Applied Biosystems).  Samples were normalized to β-
actin and displayed as a fold induction relative to expression levels in naïve tissue. 
 
4.3.5 DSS administration and pathological scoring 
Mice were given 3% (weight/volume) Dextran Sodium Sulfate (DSS) in the drinking 
water (molecular weight 36,000-50,000, MP Biomedicals). Mice were monitored daily for 
morbidity (piloerection, lethargy), weight loss, and rectal bleeding as previously 
described(Troy et al., 2009). Briefly, severity of disease was scored as follows: 1. weight 
loss (no change, 0; <5%, 1; 6–10%, 2; 11–20%, 3; >20%, 4); 2. Feces (normal, 0; pasty, 
semiformed, 1; sticky, 2; sticky with some blood, 3; completely liquid, bloody, or unable 
to defecate after ten minutes, 4); 3. rectal bleeding (no blood, 0; visible blood in rectum, 
1; visible blood on fur, 2); 4. general appearance (normal, 0; piloerect, 1; lethargic and 
piloerect, 2; lethargic and hunched, 3; motionless and sickly, 4). 
 
4.3.6 In vivo cytokine treatments 
For examination of intracellular cytokine production, 300 ng of recombinant murine IL-33 
(carrier-free, R&D Systems) in sterile PBS was administered intraperitoneally (i.p.) into 
C57BL/6 wildtype mice daily for six days and cytokine expression was assessed on day 
seven. For treatment during DSS-induced intestinal inflammation, 10 µg of recombinant 
murine AREG or 300-400 ng recombinant murine IL-33 (carrier-free, R&D Systems) was 
administered i.p. daily for the duration of the seven days on 3% DSS. Endotoxin levels 
were reported to be ≤ 0.00669 EU/µm. 
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4.3.7 Tissue histological sections 
1 cm of colon tissue distal to the cecum was removed and flushed out with PBS. Colon 
tissue was fixed in 4% paraformaldehyde, embedded in paraffin, and 5 µm sections were 
used for staining with hematoxylin and eosin (H&E). 
 
4.3.8 Statistical analysis 
Results represent the mean ± SEM unless indicated otherwise.  Statistical significance 
was determined by unpaired Student’s t test unless indicated otherwise. Statistical 
analyses were performed using Prism GraphPad software v5.0.  (*, p < 0.05; **, p < 
0.01; ***, p < 0.001). 
 
4.4 Results 
4.4.1 IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue 
Previous studies investigating the roles of ILC2s have implicated classical type 2 
cytokines IL-5 and IL-13 in ILC2 function, while the role of ILC2-derived growth factors 
such as AREG have only been described within the lung. Whether ILC2s that are found 
in tissues other than the respiratory tract can express AREG and what functional 
significance this may have in regulating tissue homeostasis of extra-pulmonary barrier 
sites such as the intestine is unknown. Further, it is unclear if AREG-producing ILC2s 
represent a distinct population of ILC2s from the classical IL-5- and IL-13-expressing 
cells. To address these questions, we performed single cell analysis of intracellular 
expression of AREG in ILC2s from multiple tissue sites. Wildtype (WT) mice were 
treated in vivo with recombinant (r)IL-33 to activate the ILC2s and assessed for 
production of AREG, IL-5, and IL-13 in the lung, mesenteric lymph node (mLN) and 
Peyer’s Patches (PP). Notably, in all tissue sites examined, IL-33 elicited distinct 
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populations of polyfunctional ILC2s that expressed IL-5, IL-13, and/or AREG, revealing a 
previously unrecognized degree of potential functional heterogeneity in ILC2s (Fig. 25A-
C).  
Examination of the patterns of effector molecule expression in ILC2s revealed 
that the majority of IL-33-elicited ILC2s expressed AREG (black arc surrounding the pie 
graph) compared to IL-5 (gray arc) or IL-13 (brown arc), suggesting that AREG 
production is a dominant functional signature of ILC2s following IL-33 stimulation. 
Notably, multivariate analysis revealed that a greater proportion of ILC2s in the GALT 
exhibited triple effector molecule producing-capacity compared to their lung counterparts 
(Fig. 25D, red pie slices). Specifically, the mLN contained a significantly higher 
proportion of ILC2s that expressed AREG alone and a higher percentage of triple 
cytokine-producing cells capable of expressing AREG, IL-5 and IL-13 simultaneously as 
compared to the lung (Fig. 25D, black arcs, and Fig. 25E). Collectively, these data 
reveal unexpected functional heterogeneity in IL-33-elicited ILC2s and demonstrate that 
gut-associated ILC2s express high levels of AREG, provoking the question of whether 
the IL-33-ILC2-AREG pathway may play a role in regulating tissue homeostasis or 
inflammation at the intestinal barrier. 
 
4.4.2 Enhanced ILC2 responses during DSS-induced intestinal injury and 
inflammation 
To test the potential contribution of the ILC2-AREG pathway to intestinal inflammation 
and repair, we utilized the dextran sodium sulfate (DSS)-induced model of intestinal 
damage and inflammation. Oral administration of DSS is toxic to colonic epithelial cells 
at the base of the crypts, leading to barrier leakage and subsequent exposure to 
commensal bacteria that results in immune cell infiltration and increased expression of 
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pro-inflammatory cytokines (Perse and Cerar, 2012). Additionally, progression of DSS-
induced intestinal inflammation does not require the adaptive immune response (Perse 
and Cerar, 2012), making it a useful model to assess the contribution of innate immune 
cells to intestinal inflammation and tissue repair. Consistent with previous reports (Duan 
et al., 2012; Grobeta et al., 2012; Pastorelli et al., 2010), IL-33 mRNA expression was 
increased in the colon of WT mice in response to DSS-induced intestinal damage (Fig. 
26A). The increase in IL-33 expression was associated with an elevation in the 
frequency and cell number of Lin- CD45+ CD90+ T1/ST2+ ILC2s in the mLN that drain the 
colon during DSS-induced inflammation (Fig. 26B-D). Additionally, the number of ILC2s 
expressing AREG was also elevated in response to DSS-induced intestinal damage 
(Fig. 26E) provoking the hypothesis that the ILC2-AREG pathway may influence 
inflammation or epithelial repair responses following intestinal damage. 
 
4.4.3 Epithelial repair and restoration of tissue homeostasis following DSS-
induced intestinal injury requires endogenous AREG-EGFR interactions 
To test how the AREG-EGFR pathway influences development of intestinal inflammation 
or epithelial cell remodeling, WT and Areg-/- mice were exposed to DSS in the drinking 
water for seven days and clinical disease scores (incorporating multiple disease 
parameters including weight loss, lethargy and rectal bleeding (Troy et al., 2009)) were 
monitored. In comparison to DSS-treated WT mice, Areg-/- mice exhibited increased 
weight loss (Fig. 27A), exacerbated colonic shortening (Fig. 27B) and a more severe 
disease pathology score (Fig. 27C). Furthermore, histological examination of the colon 
tissue revealed that Areg-/- mice exhibited more severe pathological changes within the 
intestinal mucosa compared to WT mice, including increased smooth muscle 
hyperplasia (red arrows) and greatly enhanced immune cell infiltration (green arrows) 
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that resulted in loss of crypt architecture throughout the colon (Fig. 27D).  Taken 
together, these data provide the first evidence that a single EGFR ligand AREG is a 
critical component of a host-protective tissue repair in response to DSS-induced 
intestinal damage. 
 To test the role of downstream EGFR signaling in limiting intestinal inflammation, 
we utilized the EGFRvel/+ mouse model that exhibits reduced EGFR tyrosine kinase 
activity (Du et al., 2004). Upon exposure to DSS, EGFRvel/+ mice exhibited increased 
weight loss (Fig. 28A), profound colonic shortening (Fig. 28B) and a more severe 
pathological disease score (Fig. 28C) compared to littermate controls. Strikingly, 
histological examination revealed that in comparison to littermate controls, EGFRvel/+ 
mice exhibited increased edema (black arrows) and greater immune cell infiltration 
(green arrows) that resulted in near complete loss of crypt architecture throughout the 
colon (Fig. 28D). Taken together, these results demonstrate a critical role for AREG-
EGFR signaling in limiting inflammation and regulating epithelial remodeling responses 
during DSS-induced intestinal injury.   
 
4.4.4 Exogenous AREG ameliorates DSS-induced intestinal inflammation and 
tissue damage  
Given the critical role of the endogenous AREG-EGFR signaling pathway in regulating 
inflammation and epithelial remodeling during DSS-induced intestinal damage, we 
sought to test whether therapeutic administration of recombinant AREG (rAREG) could 
limit or ameliorate DSS-induced intestinal inflammation. Wildtype mice were exposed to 
DSS in the drinking water and rAREG was administered in vivo daily while mice were 
monitored for clinical disease parameters. WT mice treated with rAREG exhibited 
reduced weight loss (Fig. 29A) and improved pathological disease score (Fig. 29B) 
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compared to PBS-treated controls. Furthermore, histological examination of colonic 
tissue revealed reduced inflammatory infiltrates (green arrows) and improved restoration 
of epithelial architecture with goblet cell responses (blue arrows) (Fig. 29C), suggesting 
a role for AREG in limiting disease severity in response to DSS-induced intestinal 
damage.             
 In the intestine, EGFR is primarily expressed on epithelial cells (Yan et al., 2011) 
although recent evidence suggests it can also be expressed on some hematopoietic 
cells, including T regulatory (Treg) cells (Zaiss et al., 2013). Amphiregulin enhances 
Treg function, raising the possibility that exogenous rAREG ameliorates intestinal 
inflammation through its actions on the adaptive immune system. To test this, Rag1-/- 
mice were exposed to DSS and treated daily with rAREG.  Similar to the results 
observed with wildtype mice (Fig. 29A-C), rAREG treatment of DSS-exposed Rag1-/- 
mice resulted in decreased weight loss (Fig. 30A), a significant improvement in colitis 
disease score (Fig. 30B), reduced inflammation in the colon and restoration of goblet 
cell responses in the crypts (blue arrows) (Fig. 30C). Taken together, these results 
demonstrate that administration of exogenous AREG can limit intestinal damage and 
ameliorate disease severity independently of the adaptive immune system. 
 
4.4.5 Therapeutic administration of recombinant IL-33 preferentially elicits ILC2 
responses during intestinal injury  
Expression of IL-33 and its receptor ST2 has been shown to be dysregulated in patients 
diagnosed with IBD (Kobori et al., 2010; Lopetuso et al., 2012; Pastorelli et al., 2011; 
Pastorelli et al., 2010). However, whether IL-33 plays a tissue-protective or pathologic 
role in the colonic intestinal mucosa during disease remains controversial (Duan et al., 
2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso et 
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al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013; Sedhom et al., 2013) and the 
cellular and molecular mechanisms which act downstream of IL-33 to regulate disease 
severity are poorly understood. Given the ability of IL-33 to elicit AREG production by 
ILC2s and the protective role of AREG in limiting DSS-induced intestinal inflammation, 
we sought to test whether therapeutic treatment with recombinant IL-33 (rIL-33) could 
ameliorate inflammation or promote tissue repair through induction of the ILC2-AREG 
pathway. WT or Areg-/- mice were exposed to DSS and treated with rIL-33 or PBS daily 
and monitored for ILC2 responses and clinical disease parameters. Flow cytometric 
analysis of the mLN revealed that treatment with rIL-33 elicited a robust 16-20 fold 
expansion of a lineage negative (Lin-) cell population in both WT and Areg-/- mice (Fig. 
31A-B). Further examination of this Lin- population revealed induction of CD90+ T1/ST2+ 
ILC2s at comparable frequencies in WT and Areg-/- mice (Fig. 31C-D).  
 CD4+ Th2 cells can also express IL-33R (Le et al., 2013) and can express AREG 
mRNA in the context of anti-helminth intestinal immunity (Zaiss et al., 2006), raising the 
possibility that IL-33 may induce Th2 cell responses during intestinal inflammation. 
However, total CD4+ T cell frequencies were unaffected by rIL-33 treatment (Fig. 31E). 
Additionally, comparative analysis of GATA3+ CD4- ILC2 and GATA3+ CD4+ Th2 cell 
induction during DSS revealed that rIL-33 preferentially induced ILC2s while having a 
minimal effect on Th2 cell responses (Fig. 31F). This preferential accumulation 
corresponded to an average 47-fold increase in the frequencies of ILC2s versus a 4-fold 
change in CD4+ Th2 cells (Fig. 31G). Furthermore, the IL-33-mediated induction of ILC2 
responses was associated with a significant increase in colonic AREG mRNA 
expression over levels observed in mice treated with PBS (Fig. 31H). Taken together, 
these data demonstrate that rIL-33 preferentially induces a robust ILC2 response and 
results in enhanced colonic expression of amphiregulin. 
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4.4.6 Therapeutic administration of recombinant IL-33 ameliorates intestinal 
disease severity in an AREG-dependent manner 
Strikingly, therapeutic administration of rIL-33 to WT mice resulted in decreased weight 
loss (Fig. 32A), reduced colonic shortening (Fig. 32B) and improved pathological 
disease score (Fig. 32C) compared to PBS-treated mice. In contrast, severe weight loss, 
profound colonic shortening and elevated disease score (Fig. 32A-C) was still evident in 
IL-33-treated Areg-/- mice, indicating that IL-33-mediated disease amelioration was 
dependent on AREG. Histological examination of the colon revealed that in contrast to 
PBS-treated animals (Fig. 32D), WT mice given rIL-33 exhibited enhanced goblet cell 
responses in the crypts (Fig. 32E, blue arrow) and restoration of normal colonic 
architecture without excessive immune cell infiltration. The restoration of crypt 
architecture and goblet cell responses were dependent upon AREG, as Areg-/- mice 
treated with rIL-33 exhibited severe disruption of colonic crypt architecture with poor 
goblet cell responses, robust immune cell infiltration (green arrow), edema (black arrow) 
and smooth muscle hyperplasia (red arrow) (Fig. 32G), similar to Areg-/- mice treated 
with PBS alone (Fig. 32F). Notably, amelioration of disease was not associated with an 
enhancement in Treg responses, as PBS- and rIL-33-treated WT and Areg-/- mice had 
equivalent frequencies of Tregs (Fig. 33A-B), supporting a role for IL-33 in eliciting an 
innate AREG-EGFR-dependent repair process in the intestine. 
 
4.5 Discussion 
Crosstalk between the epithelium and the immune system is essential for maintaining 
tissue homeostasis at barrier surfaces of the skin, lung and intestine (Artis, 2008; Maloy 
and Powrie, 2011; Peterson and Artis, 2014; Rescigno, 2011). ILC2s are enriched at 
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these barrier sites and previous studies have largely focused only on the role of the 
classical type 2 cytokines IL-5, IL-9 and IL-13 in regulating pro-inflammatory functions of 
ILC2s. Specifically in the intestine, ILC2s were originally described as critical innate 
sources of IL-13 that promoted immunity to helminth parasites (Moro et al., 2010; Neill et 
al., 2010; Price et al., 2010). However, the ability of gut-associated ILC2s to express 
growth factors such as AREG and whether these cells can serve a tissue-protective 
function during intestinal injury has never been tested.  
This Chapter provides new insight into the tissue-reparative functions of ILC2s in 
the intestinal tract and implicates the AREG-EGFR signaling pathway as a critical 
mechanism by which ILC2s may limit inflammation and promote epithelial repair during 
DSS-induced intestinal injury. Further, we identify that therapeutic IL-33 treatment 
preferentially elicits ILC2s and ameliorated intestinal disease severity in an AREG-
dependent manner, identifying a critical feedback loop in which cytokine signals from 
damaged epithelia orchestrate innate immune cell responses and promote expression of 
growth factors essential for restoration of epithelial barrier function and tissue 
homeostasis. Notably, a previous study utilizing an oxazolone-induced intestinal injury 
model where type 2 cytokines are known to be pathologic observed that IL-25 elicited IL-
13+ ILC2s correlated with disease severity (Camelo et al., 2012), suggesting that under 
some circumstances ILC2s can serve pro-inflammatory functions during intestinal injury. 
This potential dual function of ILC2s in intestinal injury parallels the role of gut RORγt+ 
group 3 ILCs, where their production of pro-inflammatory cytokines IFNγ and IL-17A can 
drive intestinal colitis disease in some settings (Buonocore et al., 2010; Geremia et al., 
2011), while conversely in other models their expression of IL-22 can serve to promote 
restoration of tissue integrity (Aujla et al., 2008; Mielke et al., 2013b; Sanos et al., 2011; 
Sonnenberg et al., 2010; Sonnenberg et al., 2011; Zheng et al., 2008). 
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IL-33 acts a cytokine ‘alarmin’ that is released rapidly upon epithelial cell damage 
to activate resident immune cell populations of the lung and intestine (Garcia-Miguel et 
al., 2013; Le et al., 2013; Ohno et al., 2012). Expression of IL-33 and its receptor ST2 
has been shown to be dysregulated in IBD patients (Kobori et al., 2010; Lopetuso et al., 
2012; Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a 
tissue-protective or pathologic role in the colonic intestinal mucosa during disease 
remains controversial (Duan et al., 2012; Garcia-Miguel et al., 2013; Grobeta et al., 
2012; Imaeda et al., 2011; Lopetuso et al., 2012; Pastorelli et al., 2011; Pushparaj et al., 
2013; Sedhom et al., 2013), and the cellular and molecular mechanisms which act 
downstream of IL-33 to regulate disease severity are unknown. We identify the ILC2-
AREG-EGFR axis as one mechanism by which IL-33 orchestrates tissue repair in the 
intestine. Importantly, this AREG-dependent protection was evident in lymphocyte-
sufficient and lymphocyte-deficient mice and was not associated with enhanced Treg 
frequencies, highlighting a previously unappreciated role for the innate immune system 
in regulating tissue repair in the intestine.  
Dysregulated expression of EGFR family members and associated ligands has 
been reported in patients diagnosed with IBD (Sipos et al., 2005; Sipos et al., 2010) and 
in murine models of intestinal inflammation (Brandl et al., 2010; Yan et al., 2011). 
Additionally, therapeutic administration of a single EGFR ligand reduced disease 
severity and inflammation in a clinical trial (Sinha et al., 2003). However, despite these 
advances, the cellular sources of specific EGFR ligands during disease and the 
functional significance of individual ligands in limiting intestinal inflammation or regulating 
mucosal tissue repair during disease remain poorly characterized. Our data identifying 
AREG as a single ligand that is both necessary and sufficient for limiting disease 
severity and promoting tissue repair provides a critical conceptual advance in our 
	   136	  
understanding of EGFR-mediated regulation of intestinal biology. Remarkably, in the 
steady-state AREG-deficient mice exhibit few physiological abnormalities besides 
impaired mammary development (Luetteke et al., 1999), suggesting that other EGFR 
ligands or alternative growth factors can compensate for the absence of AREG to 
maintain tissue homeostasis. In contrast, under inflammatory conditions when the 
epithelial barrier is damaged, the data presented in Chapters 3 and 4 indicate that innate 
immune cell-derived AREG becomes a critical factor in orchestrating restoration of 
epithelial barrier function and tissue homeostasis at multiple barrier surfaces. The 
identification of ILC2s as a previously unrecognized hematopoietic cellular source of 
AREG in the intestine indicates that manipulation of the AREG-EGFR pathway could 
provide therapeutic benefit in the treatment of intestinal inflammatory diseases. 
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Figure 25: IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
AREG 
IL
-5
 
!"#$% &!'% ((%
IL
-1
3 
)*+,% )-+.%
)*+/%
-0+.% 1)+-%
,2+*%
)3+,% 1,+1%
-.+.%
1-+3% 1)+3%
-1+/%
.+/% 10+)%
*0+-%
)*+*% 1-+-%
)1+/%
C 
CD90 
T1
/S
T2
 
,.+*% 12+*% 1-+0%
AREG 
!"#$% &!'% ((%D 
E 
1 
2 
3 
0 Pie Slice:  
Number of 
cytokines  
Pie Arc:  
Distribution  
of cytokines 
AREG+ 
IL-5+ 
IL-13+ 
+ 
- 
- 
+ 
+ 
+ 
AREG+ 
IL-5+ 
IL-13+ 
	   138	  
Figure 25: IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue 
(A-E) C57BL/6 WT mice were treated i.p. with 300 ng rIL-33 daily for 6 days. Cells were 
isolated from the lung, mesenteric lymph node (mLN) and Peyer’s Patches (PP) on day 
7, stimulated ex vivo with PMA and Ionomycin plus brefeldin A for 4 hours and then 
examined for intracellular cytokine expression of IL-5, IL-13 and AREG via flow 
cytometry. (A) Frequency of CD90+ T1/ST2+ ILC2 in the lung, mLN and PP after rIL-33 
treatment, gated on Lin- CD45+ cells. (B) Frequency of Lin- CD45+ CD90+ T1/ST2+ ILC2s 
expressing IL-5 and AREG in rIL-33-treated WT mice. (C) Frequency of Lin- CD45+ 
CD90+ T1/ST2+ ILC2s expressing IL-13 and AREG in rIL-33-treated WT mice. (D) 
Multivariate analysis of flow cytometric data from (B-C) using SPICE Software. Pie slice 
color indicates number of cytokines (IL-5, IL-13 or AREG) produced by lung ILC2s (blue 
= 0, green = 1, yellow = 2, red = 3). Pie arcs illustrate the distribution of IL-5-, IL-13- 
and/or AREG-expressing cells within each population of single (green pie slice), double 
(yellow pie slice) or triple (red pie slice) cytokine-producing ILC2s. IL-5 (gray arc), IL-13 
(brown arc) and AREG (black arc). (E) Frequency of total ILC2 in lung, mLN and PP 
expressing AREG alone or expressing AREG, IL-5 and IL-13 simultaneously. Data are 
representative of at least 3 independent experiments n = 3-4 mice per group per 
experiment. Data shown are the mean ± SEM. *p < 0.05 
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Figure 26: Epithelial remodeling during DSS-induced intestinal inflammation is 
associated with enhanced ILC2 responses 
 
 
 
 
 
 
 
 
 
 
Figure 26: Epithelial remodeling during DSS-induced intestinal inflammation is 
associated with enhanced ILC2 responses 
(A-E) C57BL/6 WT mice were exposed to 3% (weight/volume) dextran sodium sulfate 
salt (DSS) in the drinking water for 7 days. (A) mRNA expression levels of IL-33 in 
colonic tissue from mice on DSS or normal water, normalized to β-actin and shown 
relative to expression levels in mice on normal water. Frequency (B-C) and cell number 
(D) of CD90+ T1/ST2+ ILC2 in the colonic draining mesenteric lymph nodes (mLN), gated 
on Lin- CD45+ cells. (E) mLN cells from water or DSS-treated mice were briefly 
stimulated ex vivo with PMA and Ionomycin plus brefeldin A for 4 hours and assessed 
for total number of AREG-expressing ILC2s, as determined by intracellular cytokine 
staining. Data are representative of at least 3 independent experiments, n = 3-4 mice per 
group per experiment. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 
0.001. 
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Figure 27: Epithelial remodeling during DSS-induced intestinal inflammation 
requires endogenous AREG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Epithelial remodeling during DSS-induced intestinal inflammation 
requires endogenous AREG 
(A-D) WT or Areg-/- mice were administered 3% DSS in the drinking water and assessed 
on day 7 for weight loss (A), colon length (B) and pathological disease score (C). (D) 
H&E staining of colon sections from WT or Areg-/- mice after 7 days of DSS exposure. 
Green arrows denote regions of cellular infiltrate and red arrows denote thickening and 
hyperplasia of the smooth muscle lining. Scale bar, 100 µm. Data are representative of 
at least 3 independent experiments, n = 3-4 mice per group per experiment. Data shown 
are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
D 
W
at
er
 
D
SS
 
WT 
WT 
Areg-/- 
Areg-/- 
W
T 
Ar
eg
-/-
 
B 
C 
A 
	   141	  
Figure 28: EGFR signaling is critical for limiting inflammation and promoting 
epithelial remodeling during DSS-induced intestinal injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: EGFR signaling is critical for limiting inflammation and promoting 
epithelial remodeling during DSS-induced intestinal injury  
 (A-B) EGFRvel/+ and EGFR+/+ littermates were exposed to 3% DSS in the drinking water 
for 7 days and assessed for weight loss (A), colon length (B) and pathological disease 
score (C). (D) H&E staining of colon sections from EGFRvel/+ or EGFR+/+ mice after 7 
days of DSS exposure. Green arrows denote regions of cellular infiltrate and black 
arrows denote areas of edema. Scale bar, 100 µm. Data are representative of at least 3 
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independent experiments, n = 3-4 mice per group per experiment. Data shown are the 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 29: Therapeutic administration of AREG ameliorates DSS-induced 
intestinal inflammation and tissue damage  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Therapeutic administration of AREG ameliorates DSS-induced 
intestinal inflammation and tissue damage  
C57BL/6 WT mice were exposed to 3% DSS in the drinking water for 7 days and treated 
with PBS or 10 µg recombinant (r)AREG intraperitoneally (i.p.) daily starting on the initial 
day of DSS exposure. Mice were examined for weight loss (A) over the course of 
treatment and pathological disease score (B was assessed on day 7. (C) H&E staining 
of colon tissue from PBS or rAREG-treated mice on day 7. Blue arrows indicated goblet 
cell hyperplasia, green arrows denote regions of cellular infiltrate and black arrows 
denote areas of edema. Scale bar, 100 µm. Data are representative of 2-3 independent 
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experiments, n = 4 mice per group per experiment. Data shown are the mean ± SEM. *p 
< 0.05, ***p < 0.001. 
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Figure 30: AREG ameliorates DSS-induced intestinal inflammation and promotes 
tissue repair in the absence of adaptive immunity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: AREG ameliorates DSS-induced intestinal inflammation and promotes 
tissue repair in the absence of adaptive immunity 
Rag1-/- mice were exposed to 3% DSS in the drinking water for 7 days and treated with 
PBS or 10 µg recombinant (r)AREG intraperitoneally (i.p.) daily starting on the initial day 
of DSS exposure. Mice were examined for weight loss (A) over the course of treatment 
and pathological disease score (B) was assessed on day 7. (C) H&E staining of colon 
tissue from PBS or rAREG-treated mice on day 7. Blue arrows indicated goblet cell 
hyperplasia, green arrows denote regions of cellular infiltrate and black arrows denote 
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areas of edema. Scale bar, 100 µm. Data are representative of 2-3 independent 
experiments, n = 4 mice per group per experiment. Data shown are the mean ± SEM. *p 
< 0.05, **p < 0.01. 
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Figure 31: Therapeutic administration of recombinant IL-33 preferentially elicits 
ILC2 responses during intestinal injury  
 
 
Figure 31: Therapeutic administration of recombinant IL-33 preferentially elicits 
ILC2 responses during intestinal injury  
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days 
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of 
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initial DSS treatment. Frequency of CD45+ Lin- cells (A,B) and CD45+ Lin- CD90+ 
T1/ST2+ ILC2s (C,D) in the colonic draining mesenteric lymph nodes (mLN) of WT and 
Areg-/- mice at day 7 following PBS or rIL-33 treatment. Lineage antibodies include 
NK1.1, CD11b, CD11c, FcεR1, CD3, CD5, TCRβ, B220. (E) Frequency of total CD4+ T 
cells in the colonic draining mesenteric lymph node (mLN), gated on CD45+ cells. (F) 
Frequency of GATA3+ CD4- ILC2s and GATA3+ CD4+ Th2 cells in the mLN of WT mice 
on 3% DSS treated with PBS or rIL-33, plots are gated on CD45+ cells. (G) Fold 
increase in relative frequency of GATA3+ CD4- ILC2s and GATA3+ CD4- Th2 cells 
following rIL-33 treatment during DSS.  (H) mRNA expression levels of AREG in the 
colon tissue of PBS or rIL-33-treated WT and Areg-/- mice after 7 days of DSS exposure, 
normalized to β-actin and shown relative to expression levels in WT mice on normal 
water. Data are representative of 2 independent experiments, n = 4 mice per group per 
experiment. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 32: Therapeutic administration of recombinant IL-33 limits intestinal 
inflammation and promotes tissue repair in an AREG-dependent manner 
 
 
 
Figure 32: Therapeutic administration of recombinant IL-33 limits intestinal 
inflammation and promotes tissue repair in an AREG-dependent manner 
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days 
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of 
initial DSS treatment. Weight loss (A), colon length (B) and pathological disease score 
(C) of PBS and rIL-33-treated WT and Areg-/- mice on DSS. (D-G) H&E staining of colon 
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tissue after 7 days of DSS exposure. Blue arrows denote goblet cell hyperplasia, green 
arrows indicate regions of severe cellular infiltrate, red arrows indicate hyperplasia of the 
smooth muscle lining and black arrows denote areas of edema. Scale bar, 100 µm. Data 
are representative of 2 independent experiments, n = 4 mice per group per experiment. 
Data shown are the mean ± SEM. **p < 0.01, ***p < 0.001.  
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Figure 33: Regulatory T cell frequency is unaltered following rIL-33 treatment  
 
 
 
 
 
 
 
 
 
 
Figure 33: Regulatory T cell frequency is unaltered following rIL-33 treatment  
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days 
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of 
initial DSS treatment. Flow cytometry plots (A) and frequency (B) of CD45+ CD4+ CD25+ 
Foxp3+ regulatory T cells (Tregs) in the draining mesenteric lymph node (mLN). Data are 
representative of 2 independent experiments, n = 4 mice per group per experiment. Data 
shown are the mean ± SEM.  
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Chapter 5 
Summary, Discussion and Future Directions 
 
5.1 The expanding ILC family 
Recent work over the past several years has shed light on the development, regulation 
and effector function of this novel family of immune cells that play vital roles in balancing 
host-protective immunity and pathologic inflammation barrier surfaces. Data presented in 
Chapters 2 and 3 of this thesis identify a novel ILC population in the respiratory tract of 
humans and mice and implicate these cells as critical drivers of epithelial cell repair to 
restore tissue homeostasis following acute injury. Our studies suggest that lung ILCs 
phenotypically and functionally resemble members of the Group 2 ILC (ILC2) subset, 
previously indentified in the intestinal tract and fat-associated lymphoid clusters and 
referred to as natural helper (NH) cells, nuocytes or innate helper type 2 (Ih2) cells 
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010). While the biological distinctions 
between NH cells, nuocytes and Ih2 cells remain a point of controversy, the striking 
similarities in cell surface phenotype, developmental requirements and effector cytokine 
expression between the three populations strongly suggest that these cells are part of a 
single subset that exists in multiple anatomical locations and exhibits some degree of 
functional heterogeneity. Transient differences in reported cell surface expression of 
activation markers (such as c-Kit or Sca-1) between these three cell populations could 
be the result of varying degrees of maturation/differentiation governed by environmental 
cues in distinct tissue microenvironments. Furthermore, there is very little known about 
the trafficking patterns and chemokine receptor expression profiles of ILCs, raising the 
possibility that some ILCs (or their less differentiated progenitors) may circulate 
throughout the bloodstream or lymph, migrating into different anatomical sites in 
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response to infectious or inflammatory cues, while other ILCs may remain tissue-
resident sentinels at barrier sites. Since the completion of studies outlined in this thesis, 
new reports have emerged demonstrating the existence of phenotypically similar ILC2 
populations throughout multiple anatomical sites, including skin, liver and adipose tissue 
(Hams et al., 2013; Kim et al., 2013a; McHedlidze et al., 2013; Roediger et al., 2013; 
Salimi et al., 2013). While these cells appear to share common phenotypic and 
developmental requirements, the extent to which each population may possess distinct 
activation and functional specialization unique to each tissue microenvironment remains 
incompletely understood and merits further investigation.  
 
5.2 Identification of the AREG-EGFR pathway as a key component of immune cell-
mediated tissue repair 
Amphiregulin (AREG) was originally discovered as a growth factor associated with 
proliferation of mammary cancer cell lines (Berasain and Avila, 2014; Busser et al., 
2011b). Although AREG is just one of several ligands of the epidermal growth factor 
receptor (EGFR) family, it is now appreciated as a central regulator of cellular 
proliferation and differentiation for a diverse array of non-hematopoietic cell lineages 
including epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, keratinocytes 
and osteoclasts (Berasain and Avila, 2014; Busser et al., 2011b; Kataoka, 2009). 
However, it was only been the past several years that AREG has been recognized as a 
modulator of hematopoietic cell function. First reported as a new component of the type 
2 cytokine franchise produced by Th2 CD4 T cells to expel parasites from the intestine 
(Zaiss et al., 2006), AREG is now considered to be an effector molecule of multiple cells 
types associated with type 2 immunity, including basophils, eosinophils, mast cells and 
regulatory T cell (Tregs) (Burgel et al., 2001; Matsumoto et al., 2009; Meulenbroeks et 
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al., 2014; Qi et al., 2010; Zaiss et al., 2013). However, it would be short-sighted to 
assume that AREG is solely an effector molecule of the type 2 immune response. Due to 
the lack of a comprehensive assessment of AREG expression in innate and adaptive 
murine cells, it is unclear whether AREG could also be induced during type 1 or type 17 
immune responses. Notably, examination of human AREG expression in T cells 
indicates that AREG can be induced in both CD4 and CD8 cells irrespective of prior in 
vitro polarization (Qi et al., 2012). Taken together with our data in Chapters 3 and 4 
demonstrating a dominant role for the cytokine alarmin IL-33 in inducing ILC2-intrinsic 
AREG expression, these data suggest that regulation of AREG production is more likely 
dependent on instruction from local environmental cues rather than programmed early in 
lineage specification. 
It is surprising that under homeostatic conditions, mice lacking AREG are 
reported to exhibit few physiological abnormalities besides impaired mammary 
development while mice with genetic deletions in EGFR die in utero (Luetteke et al., 
1999). Furthermore, mice that are only heterozygous for mutations that reduce EGFR 
activity still exhibit profound abnormalities in skin and mammary tissues where EGFR 
expression is strongest (Berasain and Avila, 2014; Du et al., 2004; Luetteke et al., 1999), 
illustrating the essential role of EGFR signaling in prenatal development. These data 
suggest that the other EGFR ligand family members can compensate for the absence of 
AREG to maintain tissue homeostasis during early development and postnatal 
homeostatic conditions in the adult mouse. Supporting this, reports of growth retardation 
and spontaneous intestinal abnormalities have only been reported in mice that are 
genetically deficient in multiple EGFR ligands simultaneously (AREG, EGF, TGFα) 
(Troyer et al., 2001). 
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In contrast, under inflammatory conditions when the epithelial barrier is 
damaged, the data presented in Chapters 3 and 4 of this thesis indicate that innate 
immune cell-derived AREG becomes a critical factor in orchestrating restoration of 
epithelial barrier function and tissue homeostasis at multiple barrier surfaces (Fig. 34). 
Future studies are needed to investigate the possibility that additional EGFR ligand 
family members (or non-EGFR growth factors) may also contribute to ILC2-mediated 
tissue repair. Nonetheless, the data presented in this thesis identifying ILC2s as a 
previously unrecognized hematopoietic cellular source of AREG and demonstrating an 
essential role of the AREG-EGFR pathway during tissue repair suggest that 
manipulation of this innate axis could provide therapeutic benefit in the treatment of 
multiple inflammatory diseases of the respiratory and intestinal tracts. 
 
5.3 Heterogeneity in ILC2 functionality in response to epithelial cytokines 
In Chapter 2 we demonstrate that IL-33, but not another epithelial cell-derived cytokine 
IL-25, is a robust, in vivo signal for inducing AREG expression in ILC2s. Intriguingly, IL-
33 elicited distinct populations of polyfunctional ILC2s that expressed IL-5, IL-13 and/or 
AREG simultaneously, illustrating a previously unrecognized degree of functional 
heterogeneity in ILC2s. As IL-33 is upregulated in diverse inflammatory conditions of 
allergy, infection, or non-infectious tissue injury (Garcia-Miguel et al., 2013; Le Goffic et 
al., 2011a; Oboki et al., 2011; Ohno et al., 2012; Smith, 2011), it is tempting to speculate 
that this functional heterogeneity may reflect the differential roles that IL-33-elicited 
ILC2s play in the context of inflammation or tissue repair. For example, IL-5 and IL-13 
are critical for development of ILC2-mediated allergic and virus-induced airway 
inflammation (Barlow et al., 2013; Chang et al., 2011; Halim et al., 2012; Kim et al., 
2012) but data presented in Chapter 2 and elsewhere (Monticelli et al., 2011) indicate 
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that these cytokines are dispensable for ILC2-mediated tissue repair during influenza 
virus infection. Conversely, ILC2 single cytokine producers expressing AREG alone may 
be the critical ILC2 population regulating restoration of tissue homeostasis following 
influenza virus-induced tissue damage.  
Whether AREG-expressing ILC2s can also contribute to pathologic airway 
inflammation remains unknown. Patients undergoing acute asthma attacks have been 
reported to express high levels of AREG in their sputum (Enomoto et al., 2009), 
suggesting that ILC2-derived AREG could also be involved in airway remodeling in 
human disease. Furthermore, given the ability of AREG to promote epithelial cell and 
fibroblast proliferation and regulate mucus production (Broide, 2008; Crosby and Waters, 
2010), it is possible that ILC2-derived AREG may also be involved in the pathology 
associated with chronic inflammatory lung disorders such as Idiopathic Pulmonart 
Fibrosis (IPF) or Chronic Obstructive Pulmonary Disease (COPD) although this has yet 
to be formally explored. One recent study reported a critical role for ILC2-derived IL-13 in 
driving pathologic tissue fibrosis and collagen depositions in a murine model of IPF 
(Hams et al., 2014), however, the potential contribution of ILC2-intrinsic AREG to 
disease progression was not examined. Future studies utilizing transgenic cytokine 
reporter mice and mice with conditional deletions of multiple ILC2-derived cytokines will 
be needed to fully elucidate the relative contributions of these polyfunctional ILC2 
populations during settings of inflammation and tissue repair. 
 
5.4 Innate versus adaptive mechanisms of tissue repair 
At mucosal surfaces of the lung and gut, exposure to environmental insults such as 
allergens or infection with pathogens can cause varying degrees of injury to the host 
tissue that must be adequately repaired to avoid prolonged inflammation or loss of 
	   157	  
epithelial barrier function (Gorski et al., 2012; Keely et al., 2012; Morrisey and Hogan, 
2010; Neurath, 2014; Rock et al., 2010). While tissue damage often begins at the very 
onset of exposure, before adaptive immune responses are generated, it can later be 
amplified due to T cell-driven immunopathology, suggesting there may be a temporal 
regulation of tissue repair by the innate and adaptive immune systems. However, the 
relative contribution of innate versus adaptive immune cells to tissue repair and 
restoration of barrier integrity in different disease settings is poorly understood.  
In the context of the intestine, data in Chapter 4 indicates that exogenous 
rAREG or rIL-33 treatment resulted in reduced tissue damage and improved restoration 
of epithelial crypt architecture independently of any potential effects on the adaptive 
immune system. The pathologic versus tissue-protective role of IL-33-IL-33R signaling 
during intestinal inflammation is controversial and appears to depend upon the type of 
injury stimulus employed, the genetic background of the mouse strain and the duration 
of inflammation (Duan et al., 2012; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso 
et al., 2012; Pushparaj et al., 2013). Interestingly, a previous study identified a protective 
role for IL-33 during the recovery stage following chronic DSS inflammation (Duan et al., 
2012) and observed enhanced goblet cell metaplasia during rIL-33 treatment similar to 
what we observed during acute inflammation. Notably, in that study the protective effect 
of IL-33 was attributed to Tregs, a well-appreciated regulator of intestinal inflammatory 
disease. However, this interpretation is complicated by the fact that the authors 
employed anti-CD25 mAb to eliminate Tregs, a strategy that will also target ILC2s for 
depletion (Kobori et al., 2010). More recently, work from Powrie and colleagues has 
demonstrated that IL-33 can directly induce Tregs which can ameliorate inflammation in 
a model of T cell-driven colitis (Schiering et al., 2014). 
	   158	  
In contrast to those studies, the data presented in Chapter 4 of this thesis reveal 
an innate immune mechanism of intestinal tissue repair, illustrated by the therapeutic 
benefit of rAREG in the absence of the adaptive immune system and by the preferential 
accumulation of ILC2s following IL-33 treatment without detectable effects on Treg 
frequency. While the reasons for these differential cellular mechanisms are not yet clear, 
it may be reflect the nature of the damage stimulus (DSS-induced barrier disruption 
versus T cell transfer-driven colitis) or the duration of inflammation (acute versus 
chronic). However, as Tregs have been shown to be a source of AREG at sites outside 
the intestine (Burzyn et al., 2013). it remains possible that adaptive immune cell-derived 
AREG may play a more important role in other inflammatory conditions besides the 
acute injury model utilized in this thesis. Future studies utilizing lineage-specific deletion 
in AREG would be beneficial in determining the contribution of adaptive versus innate 
cell-derived AREG to IL-33-mediated tissue repair during different phases of intestinal 
injury and inflammation. 
 
5.5 Epithelial and hematopoietic targets of AREG-EGFR activity 
 
The lung contains a complex architecture of specialized epithelial cell lineages that are 
central to maintaining proper airway barrier integrity and gas exchange (Kumar et al., 
2004; Rackley and Stripp, 2012; Rock and Hogan, 2011). A similar paradigm exists in 
the intestine, where distinct epithelial lineages employ anti-microbial peptides, mucus 
secretions and tight junction proteins to maintain barrier integrity and prevent 
translocation of trillions of commensal bacteria (Garcia-Miguel et al., 2013; Hisamatsu et 
al., 2013; Neurath and Travis, 2012). Regeneration of these distinct epithelial 
populations after tissue injury can occur through local proliferation of terminally 
differentiated cells or can involve differentiation from progenitor stem cells (Chen et al., 
	   159	  
2009; Rackley and Stripp, 2012; Rawlins et al., 2009; Rock and Hogan, 2011; Teisanu et 
al., 2011).  
EGFR is widely expressed in epithelial cell lineages across multiple tissues sites 
although the cellular pattern of phosphorylated EGFR activity depends upon the nature 
of the inflammatory stimulus (Burgel and Nadel, 2004, 2008; Nadel and Burgel, 2001). 
While AREG-EGFR signaling can promote proliferation and survival of differentiated 
epithelial cells in vitro (Kim and Nadel, 2009; Kim et al., 2005; Kim et al., 2002; Koff et 
al., 2008; Wang et al., 2005), the in vivo cellular targets of this pathway during acute 
injury repair or progression of chronic inflammation are poorly understood. Therefore, in 
this thesis we sought to examine the cellular sources of EGFR activity to provide insight 
into the mechanism by which the IL-33-ILC2-AREG pathway influences tissue repair.  
In the lung in Chapter 3 we demonstrate that EGFR activity is selectively 
upregulated in the cells lining the bronchiolar airway epithelium (consisting almost 
entirely of Clara cells), with virtually no activity in the parenchyma alveolar epithelial 
cells. Given the in vivo requirement for EGFR signaling to promote airway epithelial 
remodeling responses, these data are consistent with a model in which ILC2-derived 
AREG acts on bronchiolar airway epithelial Clara cells (or on a facultative airway 
progenitor stem cell population) to promote cellular proliferation and/or differentiation to 
restore the airway epithelial barrier (Fig. 34). Further studies are needed to test this 
directly, however. In particular, conditional deletion of EGFR on different epithelial 
lineages (CC10 for Clara cells, SFPTC for alveolar parenchyma cells, Krt5 for basal 
cells) during influenza virus infection would aid in confirming the cellular target of ILC-
derived AREG in the respiratory tract. The apparent tropism of AREG-EGFR activity for 
the Clara cells of the airway epithelium, but not the Type I and Type II alveolar cells of 
the lung parenchyma, is surprising given that EGFR is expressed on all lung epithelial 
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lineages (Berasain and Avila, 2014; Burgel and Nadel, 2004, 2008; Nadel, 2001; Shim et 
al., 2001; Ueki et al., 2013) and influenza virus-induced injury is widespread throughout 
the lung (Fukushi et al., 2011; Iwasaki and Pillai, 2014; Peiris et al., 2010). The 
exclusivity of EGFR activation for bronchiolar airway epithelial cells suggests that airway 
versus alveolar epithelial repair are governed by distinct cellular and molecular cues. 
Indeed, a recent report demonstrates that Krt5+ basal cells of the lung parenchyma act 
as facultative stem cell progenitors for regenerating alveolar, but not bronchiolar airway, 
epithelial cells in response to influenza virus-induced cell damage (Kumar et al., 2011). 
 A similar mechanism may also apply to settings of intestinal injury and 
inflammation. EGFR activity is upregulated in colonic epithelial cells during DSS-induced 
injury (Yan et al., 2011) although it is unclear whether AREG-EGFR signaling acts solely 
on mature, fully differentiated epithelial lineages or may promote tissue restoration by 
modulating intestinal stem cell function. EGFR ligand EGF is commonly added to the 
growth factor medium required for generating three-dimensional epithelial organoid 
cultures from single Lgr5+ stem cells (Barker, 2014; Peterson and Artis, 2014) 
suggesting that intestinal stem cells (or their immediate progeny) express EGFR and 
could potentially be responsive to other ligands such as AREG. Future studies utilizing 
conditional deletion of EGFR on mature epithelial cells versus Lgr5+ stem cells will aid in 
determining the epithelial target of ILC2-mediated, AREG-dependent intestinal tissue 
repair.  
EGFR was previously thought to be primarily restricted to epithelial and stromal 
cell lineages (Burgel and Nadel, 2004, 2008; Nadel, 2001) and therefore any effects of 
EGFR signaling on immune cell function were presumed to be due to indirect regulation 
via epithelia. Recently, however, a few studies have challenged this dogma and revealed 
a direct functional role for EGFR on hematopoietic cells, where EGFR signaling can 
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enhance suppressive ability of regulatory T cells (Tregs) (Zaiss et al., 2013), promote 
survival of bone marrow hematopoietic stem cells (HSCs) (Doan et al., 2013) and 
regulate intestinal macrophage function (Lu et al., 2014). Therefore, future studies 
should address the possibility that in the context of DSS-induced colitis, AREG-EGFR 
signaling does not act directly upon the epithelium but instead could activate immune 
cells which in turn produce additional cytokines and growth factors to promote 
restoration of the epithelial barrier.  
 
5.6 The AREG-EGFR pathway in human health and disease 
In the clinic, EGFR inhibitors are a widely used therapeutic treatment for multiple human 
diseases, most commonly for cancers of the lung, intestine and pancreas (Busser et al., 
2011a; Hartmann et al., 2009; Iyer and Bharthuar, 2010). Unfortunately, fatal interstitial 
lung disease of unknown etiology has been reported to occur in lung cancer patients 
treated with several types of pharmacological EGFR inhibitors (Chou et al., 2010; Makris 
et al., 2007; Wang et al., 2013). Given the data presented here in Chapter 3 describing 
the role of endogenous EGFR signaling in regulating lung tissue repair in murine 
models, it is possible that the inhibition of EGFR signaling may disrupt lung tissue 
regenerative responses in these patients and potentially contribute to development of 
disease. These data provoke the need for caution in utilizing these therapies and 
suggest that screening patients for a history of recent viral or bacterial infections prior to 
initiation of treatment may help identify patients more susceptible to developing the 
interstitial lung disease. In contrast, in some circumstances such as infection with 
pathogens that cause lung injury, the targeted promotion of the AREG-EGFR pathway to 
promote epithelial repair may have therapeutic benefit in improving clinical outcomes.  
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Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the 
intestinal mucosa that results in impaired epithelial barrier integrity and a failure to 
regulate mucosal wound healing (Hisamatsu et al., 2013; Kaser et al., 2010; Neurath, 
2014; Neurath and Travis, 2012; Scharl and Rogler, 2012; Strober et al., 2007). The 
etiology of IBD is multi-factorial and has been linked to multiple growth factor pathways, 
including EGFR-associated family members (Hisamatsu et al., 2013; Kaser et al., 2010; 
Krishnan et al., 2011; Neurath, 2014; Strober et al., 2007). EGFR is normally expressed 
throughout the intestine and elevated receptor activity and expression of EGFR ligands 
including amphiregulin have been observed in human IBD patients (Sipos et al., 2005; 
Sipos et al., 2010) and murine models of intestinal inflammation (Brandl et al., 2010; Yan 
et al., 2011). Additionally, therapeutic administration of a single EGFR ligand EGF 
reduced inflammation and ameliorated disease severity in a clinical trial (Sinha et al., 
2003). However, despite these advances, the cellular sources and functional 
significance of specific EGFR ligands in limiting intestinal inflammation or regulating 
mucosal tissue repair during disease remained poorly understood. Given our data in 
Chapter 4 identifying AREG as a single ligand that is both necessary and sufficient for 
limiting disease severity and promoting tissue repair, it is possible that administration of 
exogenous AREG could be a potential future therapeutic treatment designed to speed 
recovery of intestinal barrier integrity.  
 
5.7 Concluding remarks 
The epithelium of the respiratory and intestinal tracts serves dual roles as a physical 
barrier to prevent host exposure to environmental insults, commensal microbes and 
pathogens while simultaneously integrating signals from these sources to instruct the 
function of sentinel immune cells. The members of the diverse family of innate lymphoid 
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cells are enriched at these barrier sites and have been shown to be novel regulators of 
host immunity, inflammation, and barrier maintenance. Collectively, the data presented 
in this thesis reveal a conserved innate mechanism of barrier repair by which ILCs 
responds to damage cues from the local microenvironment to promote restoration of 
tissue homeostasis through an IL-33-AREG-EGFR axis (Fig. 34). 
While advances in the ILC field have moved at an extraordinary pace the past 
several years since their formal discovery, the study of ILCs still remains in its infancy 
with fundamental questions about their development, activation and effector function 
remaining unclear. Furthermore, advancements in the ILC field are hindered by a lack of 
genetic and molecular tools to selectively target ILCs in the presence of adaptive 
immune cells. Understanding the extent of the crosstalk between ILC2s and the adaptive 
immune system is essential for assessing the utility of therapeutically targeting human 
ILC2s in the context of generating protective immune responses, limiting tissue 
inflammation and promoting barrier maintenance. Related to this, much of the recent 
work on murine ILC2 development (for example GATA3 and Gfi1) and effector function 
(IL-5, IL-9, IL-13) has been focused on their similarity to pathways already identified in 
Th2 CD4 helper T cell biology. Extensive microarray transcriptional analyses or use of 
next generation RNA-Seq technology will be an invaluable exploratory tool to uncover 
the unique factors regulating the development and functional potential of murine and 
human ILC2s.  
Their enrichment at barrier surfaces and their rapid response to damage signals 
make ILCs an attractive target for therapeutic manipulation in the clinical treatment of 
multiple human infectious or inflammatory diseases. However, the rarity of ILCs makes 
selective in vivo targeting challenging and therapeutic treatments aimed at modulating 
upstream regulators such as IL-33 are non-specific and will influence a multitude of 
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diverse immune cell subsets with contradictory pro-inflammatory versus tissue-protective 
functionality. Greater understanding of the environmental cues that dictate the 
heterogeneous downstream effector mechanisms employed by ILCs in inflammatory 
versus host protective immune responses will be key to designing effective therapeutic 
strategies to improve human health. 
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Figure 34: A conserved innate immune mechanism of tissue repair at barrier 
surfaces 
 
 
Figure 34: A conserved innate immune mechanism of tissue repair at barrier 
surfaces 
Upon injury to the epithelium of the lung and intestine, IL-33 is released to activate 
immune cell populations, including ILC2s. ILC2s produce the growth factor amphiregulin 
(AREG) that binds to the epidermal growth factor receptor (EGFR) on the epithelium, 
resulting in proliferation and/or differentiation of epithelial cells to restore barrier integrity 
and tissue homeostasis. Data presented in Chapter 3 and 4 suggests that in the lung, 
the primary targets of ILC2-derived AREG are EGFR+ airway Clara cells (blue cells) 
while in the intestinal crypts it is not yet clear whether mature epithelial cells or stem 
cells are affected. 
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